
<html lang="en"     class="pb-page"  data-request-id="2f5a62e4-f4fa-411c-a27d-99aff2cd8766"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-14;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.9b01953;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT2C Receptor-Positive Allosteric Modulators with Enhanced Drug-like Properties" /></meta><meta name="dc.Creator" content="Eric A.  Wold" /></meta><meta name="dc.Creator" content="Erik J.  Garcia" /></meta><meta name="dc.Creator" content="Christopher T.  Wild" /></meta><meta name="dc.Creator" content="Joanna M.  Miszkiel" /></meta><meta name="dc.Creator" content="Claudia A.  Soto" /></meta><meta name="dc.Creator" content="Jianping  Chen" /></meta><meta name="dc.Creator" content="Konrad  Pazdrak" /></meta><meta name="dc.Creator" content="Robert G.  Fox" /></meta><meta name="dc.Creator" content="Noelle C.  Anastasio" /></meta><meta name="dc.Creator" content="Kathryn A.  Cunningham" /></meta><meta name="dc.Creator" content="Jia  Zhou" /></meta><meta name="dc.Description" content="Targeting the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) allosteric site to potentiate endogenous 5-HT tone may provide novel therapeutics to alleviate the impact of costly, chronic diseases such a..." /></meta><meta name="Description" content="Targeting the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) allosteric site to potentiate endogenous 5-HT tone may provide novel therapeutics to alleviate the impact of costly, chronic diseases such a..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 22, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01953" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01953" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01953" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01953" /></link>
        
    
    

<title>Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT2C Receptor-Positive Allosteric Modulators with Enhanced Drug-like Properties | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01953" /></meta><meta property="og:title" content="Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT2C Receptor-Positive Allosteric Modulators with Enhanced Drug-like Properties" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0015.jpeg" /></meta><meta property="og:description" content="Targeting the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) allosteric site to potentiate endogenous 5-HT tone may provide novel therapeutics to alleviate the impact of costly, chronic diseases such as obesity and substance use disorders. Expanding upon our recently described 5-HT2CR-positive allosteric modulators (PAMs) based on the 4-alkylpiperidine-2-carboxamide scaffold, we optimized the undecyl moiety at the 4-position with variations of cyclohexyl- or phenyl-containing fragments to reduce rotatable bonds and lipophilicity. Compound 12 (CTW0415) was discovered as a 5-HT2CR PAM with improved pharmacokinetics and reduced off-target interactions relative to our previous series of molecules. The in vivo efficacy of compound 12 to potentiate the effects of a selective 5-HT2CR agonist was established in a drug discrimination assay. Thus, 12 is reported as a 5-HT2CR PAM with characteristics suitable for in vivo pharmacological studies to further probe the biological and behavioral mechanisms of allosteric modulation of a receptor important in several chronic diseases." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01953"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01953">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01953&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01953&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01953&amp;href=/doi/10.1021/acs.jmedchem.9b01953" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 7529-7544</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00471" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00143" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT<sub>2C</sub> Receptor-Positive Allosteric Modulators with Enhanced Drug-like Properties</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Eric A. Wold</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric A. Wold</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div><div class="loa-info-affiliations-info">Chemical Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric+A.++Wold">Eric A. Wold</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6434-7562" title="Orcid link">http://orcid.org/0000-0001-6434-7562</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Erik J. Garcia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erik J. Garcia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erik+J.++Garcia">Erik J. Garcia</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Christopher T. Wild</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher T. Wild</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div><div class="loa-info-affiliations-info">Chemical Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+T.++Wild">Christopher T. Wild</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Joanna M. Miszkiel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joanna M. Miszkiel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joanna+M.++Miszkiel">Joanna M. Miszkiel</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Claudia A. Soto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claudia A. Soto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claudia+A.++Soto">Claudia A. Soto</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5214-9136" title="Orcid link">http://orcid.org/0000-0002-5214-9136</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jianping Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianping Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div><div class="loa-info-affiliations-info">Chemical Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianping++Chen">Jianping Chen</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Konrad Pazdrak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Konrad Pazdrak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Konrad++Pazdrak">Konrad Pazdrak</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Robert G. Fox</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert G. Fox</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+G.++Fox">Robert G. Fox</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Noelle C. Anastasio</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Noelle C. Anastasio</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div><div class="loa-info-affiliations-info">Chemical Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#b0ded3d1ded1c3c4d1f0c5c4ddd29ed5d4c5"><span class="__cf_email__" data-cfemail="640a07050a0517100524111009064a010011">[emailÂ protected]</span></a>. Phone: (409)-772-9656. Fax: (409)-772-7050.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Noelle+C.++Anastasio">Noelle C. Anastasio</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5579-4213" title="Orcid link">http://orcid.org/0000-0001-5579-4213</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Kathryn A. Cunningham</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kathryn A. Cunningham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div><div class="loa-info-affiliations-info">Chemical Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#96fdf5e3f8f8fff8f1d6e3e2fbf4b8f3f2e3"><span class="__cf_email__" data-cfemail="6d060e18030304030a2d1819000f43080918">[emailÂ protected]</span></a>. Phone: (409)-772-9629. Fax: (409)-772-7050.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kathryn+A.++Cunningham">Kathryn A. Cunningham</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4257-1739" title="Orcid link">http://orcid.org/0000-0002-4257-1739</a></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Jia Zhou</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jia Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div><div class="loa-info-affiliations-info">Chemical Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#157f7c6f7d7a6055606178773b707160"><span class="__cf_email__" data-cfemail="aec4c7d4c6c1dbeedbdac3cc80cbcadb">[emailÂ protected]</span></a>. Phone: (409) 772-9748. Fax: (409) 772-9648.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Zhou">Jia Zhou</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2811-1090" title="Orcid link">http://orcid.org/0000-0002-2811-1090</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01953&amp;href=/doi/10.1021%2Facs.jmedchem.9b01953" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 7529â7544</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 22, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 December 2019</li><li><span class="item_label"><b>Published</b> online</span>22 June 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 July 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01953" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01953</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7529%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DEric%2BA.%2BWold%252C%2BErik%2BJ.%2BGarcia%252C%2BChristopher%2BT.%2BWild%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D14%26contentID%3Dacs.jmedchem.9b01953%26title%3DDiscovery%2Bof%2B4-Phenylpiperidine-2-Carboxamide%2BAnalogues%2Bas%2BSerotonin%2B5-HT2C%2BReceptor-Positive%2BAllosteric%2BModulators%2Bwith%2BEnhanced%2BDrug-like%2BProperties%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7544%26publicationDate%3DJuly%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01953"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1186</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01953" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT2C Receptor-Positive Allosteric Modulators with Enhanced Drug-like Properties&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;A. Wold&quot;},{&quot;first_name&quot;:&quot;Erik&quot;,&quot;last_name&quot;:&quot;J. Garcia&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;T. Wild&quot;},{&quot;first_name&quot;:&quot;Joanna&quot;,&quot;last_name&quot;:&quot;M. Miszkiel&quot;},{&quot;first_name&quot;:&quot;Claudia&quot;,&quot;last_name&quot;:&quot;A. Soto&quot;},{&quot;first_name&quot;:&quot;Jianping&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Konrad&quot;,&quot;last_name&quot;:&quot;Pazdrak&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;G. Fox&quot;},{&quot;first_name&quot;:&quot;Noelle&quot;,&quot;last_name&quot;:&quot;C. Anastasio&quot;},{&quot;first_name&quot;:&quot;Kathryn&quot;,&quot;last_name&quot;:&quot;A. Cunningham&quot;},{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Zhou&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;7529-7544&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01953&quot;},&quot;abstract&quot;:&quot;Targeting the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) allosteric site to potentiate endogenous 5-HT tone may provide novel therapeutics to alleviate the impact of costly, chronic diseases such as obesity and substance use disorders. Expanding upon our recently described 5-HT2CR-positive allosteric modulators (PAMs) based on the 4-alkylpiperidine-2-carboxamide scaffold, we optimized the undecyl moiety at the 4-position with variations of cyclohexyl- or phenyl-containing fragments to reduce rotatable bonds and lipophilicity. Compound 12 (CTW0415) was discovered as a 5-HT2CR PAM with improved pharmacokinetics and reduced off-target interactions relative to our previous series of molecules. The in vivo efficacy of compound 12 to potentiate the effects of a selective 5-HT2CR agonist was established in a drug discrimination assay. Thus, 12 is reported as a 5-HT2CR PAM with characteristics suitable for in vivo pharmacological studies to further probe the biological and behavioral mechanisms of allosteric modulati&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01953&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01953" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01953&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01953" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01953&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01953" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01953&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01953&amp;href=/doi/10.1021/acs.jmedchem.9b01953" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01953" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01953" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01953%26sid%3Dliteratum%253Aachs%26pmid%3D32567857%26genre%3Darticle%26aulast%3DWold%26date%3D2020%26atitle%3DDiscovery%2Bof%2B4-Phenylpiperidine-2-Carboxamide%2BAnalogues%2Bas%2BSerotonin%2B5-HT2C%2BReceptor-Positive%2BAllosteric%2BModulators%2Bwith%2BEnhanced%2BDrug-like%2BProperties%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D14%26spage%3D7529%26epage%3D7544%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291713" title="Polyacrylamide">Polyacrylamide</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/jmcmar.2020.63.issue-14/20200723/jmcmar.2020.63.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Targeting the serotonin (5-HT) 5-HT<sub>2C</sub> receptor (5-HT<sub>2C</sub>R) allosteric site to potentiate endogenous 5-HT tone may provide novel therapeutics to alleviate the impact of costly, chronic diseases such as obesity and substance use disorders. Expanding upon our recently described 5-HT<sub>2C</sub>R-positive allosteric modulators (PAMs) based on the 4-alkylpiperidine-2-carboxamide scaffold, we optimized the undecyl moiety at the 4-position with variations of cyclohexyl- or phenyl-containing fragments to reduce rotatable bonds and lipophilicity. Compound <b>12</b> (CTW0415) was discovered as a 5-HT<sub>2C</sub>R PAM with improved pharmacokinetics and reduced off-target interactions relative to our previous series of molecules. The in vivo efficacy of compound <b>12</b> to potentiate the effects of a selective 5-HT<sub>2C</sub>R agonist was established in a drug discrimination assay. Thus, <b>12</b> is reported as a 5-HT<sub>2C</sub>R PAM with characteristics suitable for in vivo pharmacological studies to further probe the biological and behavioral mechanisms of allosteric modulation of a receptor important in several chronic diseases.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Neuropsychiatric and metabolic disorders currently encompass exceedingly costly and intractable diseases both in the United States and worldwide. Indeed, obesity and substance use disorders (SUDs) can manifest as chronic conditions that dramatically reduce life expectancy. The serotonin (5-HT) 5-HT<sub>2C</sub> receptor (5-HT<sub>2C</sub>R) is predominately a central nervous system (CNS) G protein-coupled receptor (GPCR) that modulates key disease-related neurological pathways and behaviors.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> For example, 5-HT<sub>2C</sub>R agonists suppress food intake and increase satiety in humans and animals,<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6">(2â6)</a> and preclinical studies indicate a major role for 5-HT<sub>2C</sub>R in modulating the rewarding and incentive salience value of psychostimulants (e.g., cocaine), opioids, and ethanol, as well as behavioral factors predictive of relapse during SUD recovery.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10 ref11">(7â11)</a> In human studies, the 5-HT<sub>2C</sub>R agonist lorcaserin increased the rate of cessation from tobacco smoking and decreased corticolimbic activation evoked by presentation of palatable food cues, thus implicating 5-HT<sub>2C</sub>R as a target mechanism for disorders characterized by reward and cue-associated events.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Therefore, 5-HT<sub>2C</sub>R is a favorable therapeutic target at the intersection of disinhibited behaviors that promote obesity and SUDs, and a pharmacotherapy that could aid in the successful treatment of SUDs would be a first-in-class medication.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a></div><div class="NLM_p">Selective targeting of 5-HT<sub>2C</sub>R remains challenging because each of the 13 5-HT GPCR subtypes shares a conserved orthosteric binding site for the endogenous agonist 5-HT. Among the 5-HT<sub>2</sub>R subtypes (5-HT<sub>2A</sub>R, 5-HT<sub>2B</sub>R, and 5-HT<sub>2C</sub>R), 5-HT<sub>2C</sub>R selectivity is necessary to avoid the potential for hallucinations or cardiac valvulopathy that may result as a consequence of 5-HT<sub>2A</sub>R or 5-HT<sub>2B</sub>R stimulation, respectively.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> One possible strategy to achieve selective 5-HT<sub>2C</sub>R modulation is the rational design of positive allosteric modulators (PAMs).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> By targeting a binding site that is spatially distinct from the conserved 5-HT orthosteric site, divergent residues or topological surfaces may be exploited to achieve 5-HT<sub>2C</sub>R selectivity while enhancing the functional response to 5-HT.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> This strategy has been employed for numerous class A GPCRs<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and specifically for the discovery of 5-HT<sub>2C</sub>R PAMs by our group and others (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24 ref25">(21â25)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Highlighted compounds resulting from the search for synthetic small-molecule 5-HT<sub>2C</sub>R PAMs. Highlighted here are lead compounds from the published 5-HT<sub>2C</sub>R PAM drug discovery campaigns. The <i>C</i> log <i>P</i>, calculated in ChemDraw 18.0, for each compound displays a trend in high lipophilicity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our previously described 5-HT<sub>2C</sub>R PAMs were obtained by an iterative exploration and optimization process beginning with the initial 5-HT<sub>2C</sub>R PAM small-molecule PNU-69176E (<b>1</b>). The first priority in this process was the simplification of the Î±-<span class="smallcaps smallerCapital">d</span>-galactopyranoside fragment, termed the polar head (PH), to provide a more drug-like compound for in vitro and in vivo proof-of-concept studies (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). From this effort, CYD-1-79 (<b>3</b>) was obtained and characterized as a selective 5-HT<sub>2C</sub>R PAM (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The PH moiety of <b>3</b> was modified to retain the 5-HT<sub>2C</sub>R PAM activity while engendering decreased molecular weight and complexity. Next, modifications to the undecyl substituent at the 4-position of the piperidine, which is termed the lipophilic tail (LT), were probed as an option for further improvements. In the current study, we chemically modified the LT position with shorter, compact fragments to reduce lipophilicity while maintaining the 5-HT<sub>2C</sub>R PAM activity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Additionally, we rationalized that the compact LT substituents would reduce the number of rotatable bonds and improve the drug-likeness of the 4-alkylpiperidine-2-carboxamide scaffold, which was further demonstrated by the calculated physicochemical properties for the synthesized test compounds herein (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_001.pdf" class="ext-link">Table S1</a>). Importantly, modifying the undecyl LT position with compact, cyclic moietiesâproviding increased structural rigidityâyielded small molecules that are advantageous for computational molecular modeling and docking studies to ultimately illuminate the features of the 5-HT<sub>2C</sub>R PAM binding site.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Medicinal chemistry strategy to achieve optimized 5-HT<sub>2C</sub>R PAMs from PNU-69176E (<b>1</b>). A lincomycin derivative, PNU-69176E (<b>1</b>), was the first synthetic small molecule reported to allosterically modulate 5-HT<sub>2C</sub>R. Subsequent work has focused on chemical modifications of the PH and the LT to engender drug-like properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82058" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82058" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Allosteric modulation of 5-HT<sub>2C</sub>R is a new endeavor with a small number of probe compounds identified in recent years.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23â25)</a> Our chemical approach is focused on the optimization of our previously reported compound <b>3</b>. Elevation of intracellular calcium (Ca<sub>i</sub><sup>2+</sup>) release is a key downstream impact of 5-HT<sub>2C</sub>R activation, which is oft utilized as a readout in functional cellular assays.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Compound <b>3</b> was shown to enhance Ca<sub>i</sub><sup>2+</sup> release by â¼23% above the maximal effect of 5-HT alone in Chinese hamster ovary (CHO) cells stably transfected with human (h)5-HT<sub>2C</sub>R. In the absence of 5-HT, <b>3</b> had no effect on Ca<sub>i</sub><sup>2+</sup> release, indicating the PAM nature of this compound. Compound <b>3</b> also exhibited in vivo efficacy to decrease locomotor activity and suppress cocaine-seeking during abstinence from cocaine self-administration in rats; <b>3</b> potentiated the substitution of low doses of the 5-HT<sub>2C</sub>R agonist WAY163909 in a drug discrimination assay.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Therefore, the 1,2-diol moiety in the PH position of <b>3</b> was considered a privileged fragment and was retained. Additional PH fragments were employed in the following chemical series based on their previously observed activity or inactivity as a basis of comparison.</div><div class="NLM_p">Initial structureâactivity relationship (SAR) studies of compound <b>1</b> showed that shorter alkyl chains (methyl to <i>n</i>-methyl groups) as LTs failed to exert positive allosteric modulatory actions at the 5-HT<sub>2C</sub>R site;<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> however, we reasoned that the volume of the LT, not the length, may play a role in compound activity. This hypothesis was based partially on in silico ligand minimization and electrostatic complementarity experiments comparing compound <b>1</b> with compound <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). First, the modeling shows how the replacement of the Î±-<span class="smallcaps smallerCapital">d</span>-galactopyranoside PH fragment with the simplified 1,2-diol fragment found in <b>3</b> retains key hydroxyl group orientations and thus potentially conserve H-bond partners and interaction distances. Second, the minimized alignment of the undecyl LT fragments is shown in a conformation that suggests an exploitation of a hydrophobic binding pocket due to lipophilic volume. Thus, we designed new small molecules to incorporate shorter LTs with aromatic and aliphatic rings able to provide a comparable volume to the longer alkyl chain counterparts. Crucially, these new analogues reduce the overall number of rotatable bonds and engender enhanced drug-like properties and development potential.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Volume, not length, of the undecyl moiety on PNU-69176E (<b>1</b>) and CYD-1-79 (<b>3</b>) may contribute to 5-HT<sub>2C</sub>R PAM activity. Compounds <b>1</b> and <b>3</b> favor similar minimized conformations, which lead to overlapping hydroxyl moieties in the PH and to a folded substructure for the undecyl LT. The preferred, contracted substructure for the undecyl LT suggests that hydrophobic volume is important.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Similar to our previously established synthetic route, a six-step protocol from <b>5</b> affords the target compounds.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> The iodinated ester of picolinic acid (<b>5</b>) underwent Suzuki (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) or Sonogashira coupling (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) to provide incorporation of various LTs that included aromatic rings (e.g., phenyl, phenethyl, 4â²-methylphenethyl, and 4â²-<i>t</i>-butylphenethyl fragments). Metal-catalyzed hydrogenation, Boc protection, and hydrolysis readily provided the (<i>cis</i>-2,4)-piperidyl carboxylic acids <b>9â10</b> and <b>25â28</b>. As a result of the metal-catalyzed reduction conditions, the pyridine ring was consistently reduced, whereas the aromatic LTs either did not undergo hydrogenation or were fully reduced into separable products. Therefore, isolable aliphatic versions of the aromatic LTs were obtained, and upon <i>N</i>,<i>N</i>,<i>N</i>â²,<i>N</i>â²-tetramethyl-<i>O</i>-(1<i>H</i>-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU)-mediated coupling to suitable amines and N-Boc deprotection, target compounds <b>11â17</b> and <b>29â39</b> were obtained. All isomers with the 2-amino-1-phenyl-1,3-propanediol PH were separable, consistent with our previous report.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> All other compounds were an inseparable mixture of isomers and were tested as such (<a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of CYD-1-79 Analogues with Compact Phenyl or Cyclohexyl LTs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) phenylboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, EtOH/H<sub>2</sub>O/PhMe = 2:1:1, reflux. (b) H<sub>2</sub>, PtO<sub>2</sub>, HCl/MeOH/H<sub>2</sub>O, rt, and 16 h. (c) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, MeOH, rt, and 16 h. (d) LiOH, THF/H<sub>2</sub>O (v/v = 2:1), rt, and 48 h. (e) amino alcohols, HBTU, DIPEA, DMF, rt, and 16 h. (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt.</p></p></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of CYD-1-79 Analogues with Phenethyl, Ethylcyclohexyl, or Substituted Phenethyl LTs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) phenylacetylenes, CuI, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, rt, and 12 h. (b) H<sub>2</sub>, PtO<sub>2</sub>, HCl/MeOH/H<sub>2</sub>O, rt, and 16 h. (c) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, MeOH, rt, and 16 h. (d) LiOH, THF/H<sub>2</sub>O (v/v = 2:1), rt, and 48 h. (e) Amino alcohols, HBTU, DIPEA, DMF, rt, and 16 h. (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, and rt.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Compound Screening in Vitro</h3><div class="NLM_p">A very well-characterized intracellular signaling pathway of 5-HT<sub>2C</sub>R is the stimulation of phospholipase CÎ² (PLCÎ²) via G<sub>Î±q/11</sub> proteins, leading to the production of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), resulting in Ca<sub>i</sub><sup>2+</sup> release from intracellular stores.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Thus, a fluorescence-based, in vitro Ca<sub>i</sub><sup>2+</sup> release assay was utilized to measure activation of this 5-HT<sub>2C</sub>R signaling pathway and provide functional characterization of the newly synthesized compounds. CHO cells stably transfected with the human 5-HT<sub>2C</sub>R (unedited INI isoform; h5-HT<sub>2C</sub>RâCHO cells) were used for screening of compounds in the Ca<sub>i</sub><sup>2+</sup> release assay. The maximum 5-HT-induced Ca<sub>i</sub><sup>2+</sup> release (<i>E</i><sub>max</sub>) was measured and normalized to 100% response. All test compounds were assessed in <b>4â6</b> biological replicates, each conducted in technical triplicates, and results are shown relative to the <i>E</i><sub>max</sub> of 5-HT alone. Compound <b>1</b> increased 5-HT-evoked release in titration studies and evoked a leftward shift of the 5-HT-evoked Ca<sub>i</sub><sup>2+</sup> response curve.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Therefore, the initial compound screen was conducted at 1 nM to determine the extent to which compounds enhanced Ca<sub>i</sub><sup>2+</sup> release elicited by increasing concentrations of 5-HT. Each test compound was added to the h5-HT<sub>2C</sub>RâCHO cells 15 min prior to the addition of 5-HT to determine intrinsic agonist activity. None of the compounds tested exhibited intrinsic activity to induce Ca<sub>i</sub><sup>2+</sup> release in h5-HT<sub>2C</sub>RâCHO prior to the addition of 5-HT (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_001.pdf" class="ext-link">Figure S1</a>). The assessment of compounds tested in the Ca<sub>i</sub><sup>2+</sup> release assay in h5-HT<sub>2C</sub>RâCHO cells is shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and all concentration response curve plots are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_001.pdf" class="ext-link">Figure S1</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effects of 4-Alkylpiperidine-2-carboxamide Derivatives (1 nM) on 5-HT-Induced Ca<sub>i</sub><sup>2+</sup> Release in h5-HT<sub>2C</sub>RâCHO Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0012.gif" alt="" id="gr12" /></img><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effects of 4-Alkylpiperidine-2-carboxamide Derivatives (1 nM) on 5-HT-Induced Ca<sub>i</sub><sup>2+</sup> Release in h5-HT<sub>2C</sub>RâCHO Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0013.gif" alt="" id="gr13" /></img><div></div></div><div class="NLM_p">Of the 22 compounds tested, several displayed 5-HT<sub>2C</sub>R PAM activity comparable to the previously reported <b>3</b>, which displayed an approximate 23% increase in the <i>E</i><sub>max</sub> for 5-HT-induced Ca<sub>i</sub><sup>2+</sup> release in h5-HT<sub>2C</sub>RâCHO cells.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Compounds (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>11</b> and (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>11</b> included a phenyl ring as the LT and incorporated a (<b>1<i>S</i></b>,<b>2<i>S</i></b>)-2-amino-1-phenyl-1,3-propanediol PH (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In our previous report, when combined with an undecyl LT, the (<b>1<i>S</i></b>,<b>2<i>S</i></b>)-2-amino-1-phenyl-1,3-propanediol PH displayed negative allosteric modulatory activity in (<b>2<i>S</i></b>,<b>4<i>R</i></b>) conformation.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> However, (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>11</b> showed no activity, while (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>11</b> displayed modest allosteric activity in the Ca<sub>i</sub><sup>2+</sup> assay. Intriguingly, both <b>12</b> and <b>13</b>, which incorporate an isomer [(<i>S</i>)-1,2-diol] of the same 1,2-diol moiety PH as compound <b>3</b>, displayed 5-HT-evoked <i>E</i><sub>max</sub> values of 127.4 Â± 8.79% (<i>p</i> < 0.05; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) and 117.9 Â± 4.71% (<i>p</i> < 0.05), respectively, close to the activity seen for <b>3</b> (123.2 Â± 4.1%, <i>p</i> < 0.05).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This outcome was observed even though the new analogues possess a phenyl ring and a cyclohexyl ring as the LT (<b>12</b> and <b>13</b>, respectively), which is an extreme departure from the 11-carbon tail in our previously reported compounds. These findings provide additional confirmation that the 1,2-diol moiety is a privileged fragment. 1,3-Propandiol as a PH did promote PAM activity when coupled with a phenyl LT (<b>14</b>, 118.8 Â± 2.92%, <i>p</i> < 0.05; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). The same PH with a cyclohexyl LT (<b>15</b>) and the retention of the phenyl or cyclohexyl LT with incorporation of a morpholino with a two-carbon spacer (<b>16</b> and <b>17</b>, respectively) did not result in positive allosteric effects.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of select compounds with shortened LT moieties provide evidence that hydrophobic volume contributes to target engagement. Data are plotted for compounds <b>12</b> (A), <b>14</b> (B), <b>35</b> (C), and <b>37</b> (D). The effects of these compounds on 5-HT-induced Ca<sub>i</sub><sup>2+</sup> release in h5-HT<sub>2C</sub>RâCHO cells are shown in the absence (black) and presence of the test compound (red) against the concentrationâresponse curve for 5-HT. The assessment of vehicle (HBSS, blue circle) or vehicle with test compound (green triangle) is also illustrated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Utilization of the PHs while incorporating either phenethyl or ethylcyclohexyl LTs resulted in a series of molecules with a range of activity (â¼94 to â¼117%) dependent on the type of PH incorporated (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Positive allosteric effects were not seen with the 1,2-diol and 1,3-diol PHs with either aforementioned LT (compounds <b>30â33</b>). For both the ethylcyclohexyl and phenethyl LT, the two-carbon spaced morpholino as the PH did not produce PAM effects (<b>34</b> and <b>36</b>). However, the addition of the morpholino with a three-carbon spacer did produce PAM effects, suggesting that there is a length requirement for morpholino fragment compounds (<b>35</b>, 118.2 Â± 3.61%, <i>p</i> < 0.05; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C; <b>37</b>, 117.9 Â± 5.90%, <i>p</i> < 0.05; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). An increase in the length and volume of the LT via the inclusion of a <i>t</i>-butyl or methyl in the 4-position of the phenethyl LT did not lead to active compounds (<b>38â39</b>), an interesting finding given previous suggestions that LT length is a critical component of PAM activity for this chemotype.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> These data reinforce the notion that a diol moiety PH, specifically an (<i>S</i>)-1,2-diol fragment, is an important structural element in 5-HT<sub>2C</sub>R PAMs (compounds <b>3</b> and <b>12</b>) and that the 5-HT<sub>2C</sub>R PAM pharmacophore accepts compact, cyclic LTs.</div><div class="NLM_p">Compared to <b>3</b>, in vitro characterization of <b>12</b> displayed a similar increase in the <i>E</i><sub>max</sub> of 5-HT-induced Ca<sub>i</sub><sup>2+</sup> release in the absence of a leftward shift in EC<sub>50</sub>, indicating that <b>12</b> improved the efficacy of 5-HT without a change in potency for 5-HT at 5-HT<sub>2C</sub>R. Compound <b>12</b> was counter-screened in h5-HT<sub>2A</sub>RâCHO cells, and no alteration in the <i>E</i><sub>max</sub> or EC<sub>50</sub> of 5-HT-induced Ca<sub>i</sub><sup>2+</sup> release was observed (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Likewise, the additional compounds [(<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>11</b>, <b>13</b>, <b>14</b>, <b>29</b>, <b>35</b>, <b>37</b>] that were validated in vitro as 5-HT<sub>2C</sub>R PAMs did not significantly alter the <i>E</i><sub>max</sub> or EC<sub>50</sub> of 5-HT-induced Ca<sub>i</sub><sup>2+</sup> release in h5-HT<sub>2A</sub>RâCHO cells. Thus, the herein identified 5-HT<sub>2C</sub>R PAMs exhibit selectivity against 5-HT<sub>2A</sub>R in vitro.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effects of Active 5-HT<sub>2C</sub>R PAMs (1 nM) on 5-HT-Induced Ca<sub>i</sub><sup>2+</sup> Release in h5-HT<sub>2A</sub>RâCHO Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0014.gif" alt="" id="gr14" /></img><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Molecular Modeling and Docking of 5-HT<sub>2C</sub>R PAMs</h3><div class="NLM_p">The narrow range of the elevated <i>E</i><sub>max</sub> values resulting from our 5-HT<sub>2C</sub>R PAMs suggests a conserved positive allosteric modulatory mechanism, likely originating from binding to a shared allosteric binding site. To probe possible binding sites, the SchrÃ¶dinger Drug Discovery Suite was used for modeling 5-HT<sub>2C</sub>R and for docking the 5-HT<sub>2C</sub>R PAM molecules. This effort utilized the recently reported 5-HT<sub>2C</sub>R X-ray crystal structure in complex with the orthosteric agonist ergotamine (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Ergotamine is larger than the 5-HT<sub>2C</sub>R endogenous agonist 5-HT, and ergotamine interacts with numerous 5-HT<sub>2C</sub>R residues throughout the transmembrane domains (TM) and extracellular loop 2 (ECL2). In this context, PAM docking protocols are improved because of the stabilization and resultant enhanced atomic resolution in the outer regions of the TM as well as the ECL2. However, to obtain a docking model that is representative of the 5-HT<sub>2C</sub>R conformation encountered by 5-HT<sub>2C</sub>R PAMs in vitro and in vivo, the Schrodinger Induced Fit Docking (IFD) utility was used to replace ergotamine with 5-HT and allow ligand-induced conformational flexibility. Briefly, the X-ray crystal structure of ergotamine-5-HT<sub>2C</sub>R (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>) was preprocessed and optimized with the SchrÃ¶dinger protein preparation wizard using default settings, and each ligand (5-HT and 5-HT<sub>2C</sub>R PAMs) was prepared with the LigPrep tool to generate three-dimensional (3D) conformations for docking. Serotonin was docked to the 5-HT<sub>2C</sub>R orthosteric site via IFD with a Glide grid centered on the ergotamine indole N atom and default values for side chain and residue flexibility. The resultant 5-HTâ5-HT<sub>2C</sub>R complex model (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) was checked against published site-directed mutagenesis studies to assess 5-HT orientation accuracy and was subsequently used for the remaining ligand docking.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Molecular docking illustrates the considerable overlap in ligand poses of six 5-HT<sub>2C</sub>R PAMs. Six small molecules with a 5-HT<sub>2C</sub>R PAM profile are represented in different colors along with the endogenous agonist 5-HT. A representative pose for each 5-HT<sub>2C</sub>R PAM was selected rationally from a top-scoring, enriched cluster docked to the 5-HT<sub>2C</sub>R X-ray crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>). A measurement from the 5-HT (magenta) indole N atom to the piperidine core N atom of compound <b>12</b> was found to be 13.5 Ã (illustrated by the dashed line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Selected compounds that displayed in vitro 5-HT<sub>2C</sub>R PAM functional activity were docked to the 5-HTâ5-HT<sub>2C</sub>R complex model using Glide XP precision and IFD without designated exclusion parameters, as the model contained a 5-HT molecule to block the interaction of PAMs with the orthosteric binding site. Scoring functions (GScore) and biological and chemical rationales were used for ligand pose clustering and selection. The result upon docking six PAMs [<b>12</b>, <b>13</b>, <b>14</b>, (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>29</b>, <b>35</b>, and <b>37</b>] to the 5-HTâ5-HT<sub>2C</sub>R model is a striking display of conformational agreement at a spatially distinct allosteric site (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The distance between the 5-HT indole N-atom and the piperidine ring N-atom from the core of <b>12</b> is 13.5 Ã. Surface mapping using electrostatics and polarity was used for further docking site characterization with <b>12</b>, which shows that the allosteric site is positioned near the extracellular-facing regions of 5-HT<sub>2C</sub>R (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Additionally, the PAM orientation reaches across the transmembrane bundle from a lipophilic pocket between TM2 and TM3 toward the polar residues located in TM6 and TM7 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Interestingly, the lipophilic and polar surfaces of the docking site correspond to the LT and PH moieties that have been featured in all active 5-HT<sub>2C</sub>R PAMs throughout our discovery and optimization efforts.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Docking site surface mapping illustrates the distinct location of the proposed allosteric site in relation to 5-HT bound to 5-HT<sub>2C</sub>R. (A) Side profile view of 5-HT<sub>2C</sub>R with the protein surface illustrated around the allosteric docking site in the transmembrane helical bundle. 5-HT (magenta) can be seen below the surface illustration. (B) Docking pose of <b>12</b> (green) is shown bridging the helical bundle at a site distinct from 5-HT (5-HT<sub>2C</sub>R PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The depth of the lipophilic pocket between TM2 and TM3 drew our attention and likely provides a volume for anchoring the PAM LT. A comparison of docking poses of the 4-phenyl substituted <b>12</b> and the 4-cyclohexyl substituted <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) reveals an aromatic, ÏâÏ stacking interaction between <b>12</b> and TRP130 located in TM3 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B), which is not present with the nonaromatic <b>13</b> and may prove to be an important feature of the lipophilic pocket. Of note, when viewing compounds <b>35</b> and <b>37</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), which contain a less polar morpholine PH and differ by an ethylcyclohexyl or phenethyl, respectively, the presence of an aromatic interaction between TRP130 and <b>37</b> may result in the phenethyl preferentially occupying the lipophilic pocket. Contrarily, <b>35</b> is unable to form an aromatic interaction with TRP130 in the lipophilic pocket and results in a flipped pose in which the morpholine occupies the lipophilic pocket. Consistent with our previous docking results for <b>3</b>,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> compound <b>12</b> forms contacts with SER334 in TM6 and a residue in the ECL2 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). Reducing the length and rotatable bond number in the LT of <b>12</b> may have allowed for an optimized binding orientation with the number of molecular contacts increasing accordingly compared to <b>3</b>. <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B shows the interaction diagram for <b>12</b> and includes an aromatic interaction with TRP130 (TM3); an H-bond interaction between the ionizable N atom of the piperidine ring and CYS207 (ECL2); H-bond interactions among the amide NH, 1,2-diol hydroxy group, and ASN351 (TM7); and an H-bond interaction between the remaining 1,2-diol hydroxy group and SER334 (TM6). The 4-cyclohexyl substituted <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C) lacks the ÏâÏ stacking ability of <b>12</b> while retaining activity, thus suggesting that the aromatic interaction is not a major contributor to functional activity. Additionally, the piperidine core configuration of <b>12</b> (<b>2<i>R</i></b>,<b>4<i>S</i></b>) as docked is notably different from that of <b>13</b> (<b>2<i>S</i></b>,<b>4<i>R</i></b>), and among the 5-HT<sub>2C</sub>R PAMs that returned rational poses, there was no consensus for the preferred conformation. Thus, these findings suggest that the piperidine core may not be critical for binding or functional activity once the PH and LT are in favorable positions.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Docking demonstrates that aromatic or aliphatic compact LTs orient toward the hydrophobic pocket between TM2 and TM3 of 5-HT<sub>2C</sub>R (5-HT<sub>2C</sub>R PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>). (A) This view features a cutaway of the surface illustration to show how the phenyl and cyclohexyl LTs of <b>12</b> (green) and <b>13</b> (blue) occupy a hydrophobic pocket within the transmembrane helical bundle. (B) Predicted interactions formed by docking <b>12</b> including a possible aromatic interaction with TRP130 in the hydrophobic pocket. (C) Predicted interactions formed by docking <b>13</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Following the prediction of a conserved allosteric docking site via the Schrodinger Drug Discovery Suite, an additional in silico methodology was employed to predict possible allosteric binding sites on 5-HT<sub>2C</sub>R without a priori PAM structural information. AlloSitePro is a computational tool featuring a support vector machine (SVM) decision engine based on topological and physicochemical properties of the binding pocket.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Thus, this methodology provides a ligand-independent allosteric site prediction, whereas by definition, docking provides a ligand-dependent allosteric site prediction. The web-based AlloSitePro was initiated using the ergotamine-5-HT<sub>2C</sub>R complex X-ray crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>). The coordinates for predicted allosteric binding site volumes were translated into magenta-colored sphere representation and superimposed on the molecular docking model (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A,B). When viewed simultaneously, the allosteric docking site surface map and the allosteric site prediction coordinates are highly convergent, providing further support for the described, putative 5-HT<sub>2C</sub>R allosteric site (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A).</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Comparison of the allosteric binding site surface map and an independent allosteric binding site prediction program for the 5-HT<sub>2C</sub>R model (5-HT<sub>2C</sub>R PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>). (A) Composite model displaying the docking site protein surface and predicted allosteric site volume (magenta balls) seen via cutaway to visualize the overlap between the models. (B) Volume (magenta) determined to be a probable binding pocket capable of accommodating an allosteric modulator. (C) From the same angle as panel B, the docking site protein surface is displayed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> In Vitro Assessment of Off-Target Effects of Compound <b>12</b></h3><div class="NLM_p">To evaluate off-target interactions for a panel of biologically relevant GPCRs and monoamine transporters, <b>12</b> was submitted to the National Institute of Mental Health (NIMH) Psychoactive Drug Screening Program (PDSP). At the assessed PAM concentration of 10 Î¼M, none of the receptor targets returned inhibition greater than 50%, a level considered above assay noise and indicative of test ligand interaction (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). This result improves upon our previously reported compound <b>3</b> (10 Î¼M), which exhibited marked inhibition of radioligand binding interactions at the dopamine transporter (DAT; 66.3%), dopamine D3 receptor (71.7%), and Î±2A and Î±2B receptors (85.1 and 80.7%, respectively).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Interestingly, <b>12</b> maintains the same 1,2-propanediol moiety in the PH position as <b>3</b>, differing only the LT position by replacing the undecyl moiety with a phenyl substituent. The undecyl to phenyl change results in a more compact, aromatic ligand, which could be expected to increase promiscuity among monoamine GPCRs. However, it is likely that the removal of the undecyl moiety reduces nonspecific lipophilic interactions, while the replacement with a phenyl group allows further site-specific interactions to occur, as suggested by molecular modeling. Thus, the selectivity profile of <b>12</b> against numerous GPCR orthosteric sites and the comparative analysis versus <b>3</b> provide evidence that the functional allosteric site occupied by <b>12</b> is not an evolutionarily residual binding pocket from another orthosteric site. From a development perspective, the selectivity profile strongly supports the advancement of <b>12</b> toward in vitro pharmacokinetic (PK) evaluation and in vivo rodent behavioral characterization.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Displacement of Radioligand Binding by Compound <b>12</b> (10 Î¼M) in a Broad Panel of Receptors and Transporters</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">receptor/transporter</th><th class="colsep0 rowsep0" align="center">radioligand</th><th class="colsep0 rowsep0" align="center" char=".">%Â inhibition (10Â Î¼M)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (Î¼M)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1A</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-8-OH-DPAT</td><td class="colsep0 rowsep0" align="char" char=".">28.4</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1B</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-GR125743</td><td class="colsep0 rowsep0" align="char" char=".">12.3</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1D</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-GR125743</td><td class="colsep0 rowsep0" align="char" char=".">15.3</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1E</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-5-HT</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2A</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-ketanserin</td><td class="colsep0 rowsep0" align="char" char=".">â4.3</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2B</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-LSD</td><td class="colsep0 rowsep0" align="char" char=".">â7.2</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2C</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-mesulergine</td><td class="colsep0 rowsep0" align="char" char=".">26.9</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>3</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-LY278584</td><td class="colsep0 rowsep0" align="char" char=".">22.3</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>5A</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-LSD</td><td class="colsep0 rowsep0" align="char" char=".">â4.3</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>6</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-LSD</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>7</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-LSD</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>1</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-SCH23390</td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>2</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-<i>N</i>-methylspiperone</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>3</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-<i>N</i>-methylspiperone</td><td class="colsep0 rowsep0" align="char" char=".">19.4</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>4</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-<i>N</i>-methylspiperone</td><td class="colsep0 rowsep0" align="char" char=".">â9.3</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>5</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-SCH23390</td><td class="colsep0 rowsep0" align="char" char=".">9.4</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DAT</td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-WIN35428</td><td class="colsep0 rowsep0" align="char" char=".">40.8</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SERT</td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-citalopram</td><td class="colsep0 rowsep0" align="char" char=".">47.5</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NET</td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-nisoxetine</td><td class="colsep0 rowsep0" align="char" char=".">74.4</td><td class="colsep0 rowsep0" align="left">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>1A</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-prazosin</td><td class="colsep0 rowsep0" align="char" char=".">â16.2</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>1B</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-prazosin</td><td class="colsep0 rowsep0" align="char" char=".">â11.0</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>1D</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-prazosin</td><td class="colsep0 rowsep0" align="char" char=".">â4.8</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>2A</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-rauwolscine</td><td class="colsep0 rowsep0" align="char" char=".">â7.6</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>2B</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-rauwolscine</td><td class="colsep0 rowsep0" align="char" char=".">14.5</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±<sub>2C</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-rauwolscine</td><td class="colsep0 rowsep0" align="char" char=".">â1.8</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î²<sub>1</sub></td><td class="colsep0 rowsep0" align="left">[<sup>125</sup>I]-pindolol</td><td class="colsep0 rowsep0" align="char" char=".">â7.7</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î²<sub>2</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-CGP12177</td><td class="colsep0 rowsep0" align="char" char=".">â15.9</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î²<sub>3</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-CGP12177</td><td class="colsep0 rowsep0" align="char" char=".">â11.2</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CB<sub>1</sub></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CB<sub>2</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-CP55940</td><td class="colsep0 rowsep0" align="char" char=".">30.6</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î´OR</td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-DADLE</td><td class="colsep0 rowsep0" align="char" char=".">â6.1</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ÎºOR</td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-U69593</td><td class="colsep0 rowsep0" align="char" char=".">13.4</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î¼OR</td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-DAMGO</td><td class="colsep0 rowsep0" align="char" char=".">23.3</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GABA<sub>A</sub></td><td class="colsep0 rowsep0" align="left">[<sup>3</sup>H]-muscimol</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="left">NT</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The percent (%) inhibition at multiple targets was tested at 10 Î¼M of compound <b>12</b>. Inhibition results >50% are considered to be a reliable indication that the test compound displaced the radioligand at the target binding site.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">For inhibition results >50%, a <i>K</i><sub>i</sub> value was obtained via a nonlinear regression analysis of radioligand competition isotherms. <i>K</i><sub>i</sub> values were calculated from best fit IC<sub>50</sub> values using the ChengâPrusoff equation. NT = not tested, the average <i>K</i><sub>i</sub> from repeated experiments was determined for NET.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vitro and in Vivo PK Profiling and in Silico Toxicological Profiling</h3><div class="NLM_p">The PK profile of <b>12</b> was assessed to determine whether this compound maintained favorable drug-like properties for utility as an in vivo probe. Additionally, in silico toxicological prediction scoring was used as a cautionary guide before in vivo rat behavioral assessments were made. Initially, <b>12</b> was subject to a battery of in vitro PK assessments, which returned an excellent profile (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In rat liver microsomal fractions spiked with NADPH, clearance (CL<sub>int</sub>) was <9.6 Î¼L/min mg and the half-life (<i>t</i><sub>1/2</sub>) was >240 min. Rat plasma protein binding studies displayed a free (unbound) fraction of 66% for <b>12</b>. Compound <b>12</b> was highly soluble in physiologically relevant conditions and did not display meaningful inhibition of any cytochrome P450 enzyme tested. In an efflux substrate assay utilizing a semipermeable membrane of MadinâDarby Canine Kidney (MDCK) cells expressing the P-glycoprotein (P-gp) efflux protein and the multidrug resistance mutation 1 (MDR1) gene (MDCKâMDR1), compound <b>12</b> exhibited a tolerable efflux ratio of 30.9. In silico toxicity profiling was performed using the ProTox-II web-based prediction tool, and <b>12</b> was predicted to belong to a low toxicity class with a high degree of safety predicted for the doses utilized for in vivo assessments (below).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> We also calculated the CNS multiparameter optimization (MPO) value for compound <b>12</b> to be 4.7. The CNS MPO values range from 0 to 6 with the higher MPO scores predicted to be more desirable for CNS-penetrant medication candidates (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_001.pdf" class="ext-link">Table S2</a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Last, the in vivo PK profile of <b>12</b> was obtained in male Sprague Dawley rats (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) and was observed as overall favorable and in line with our in vitro observations (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Specifically, 10 mg/kg of <b>12</b> administered intravenously (iv) (<i>t</i><sub>1/2</sub> = 1.25 Â± 0.02 h) or 20 mg/kg administered per os (po) (<i>t</i><sub>1/2</sub> = 4.4 Â± 0.5 h) resulted in appropriate blood plasma concentrations (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The brain concentrations of <b>12</b> administered at 10 mg/kg iv were 96.4 Â± 7.2 ng/g at 15 min and 94.0 Â± 1.3 ng/g) at 1 h. The brain-to-plasma ratios at 10 mg/kg iv were 0.07 Â± 0.0012 (15 min) and 0.11 Â± 0.0056 (1 h). The brain-to-plasma concentration ratios >0.04 are consistent with CNS penetration.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> These cumulative findings suggested that compound <b>12</b> would have adequate target exposure for in vivo rat behavioral assessments.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro PK Profile and in Silico Toxicity Prediction for Compound <b>12</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="4" align="center">compoundÂ <b>12</b></th></tr><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">in vitro PKs</th><th class="rowsep1 colsep0" colspan="2" align="center">in silico toxicity (ProTox-II)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat liver microsomal clearance (NADPH)</td><td class="colsep0 rowsep0" align="left">CL<sub>int</sub>Â =Â <9.6Â Î¼L/minÂ mg <i>t</i><sub>1/2</sub>Â =Â >240Â min</td><td class="colsep0 rowsep0" align="left">predicted LD<sub>50</sub></td><td class="colsep0 rowsep0" align="left">3990 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat plasma protein binding</td><td class="colsep0 rowsep0" align="left">Fu<sub>plasma</sub>Â =Â 66%</td><td class="colsep0 rowsep0" align="left">toxicity class 1â6 (1Â =Â high,Â 6Â =Â low)</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP3A4 inhibition</td><td class="colsep0 rowsep0" align="left">0.0% (10Â Î¼M)</td><td class="colsep0 rowsep0" align="left">prediction accuracy</td><td class="colsep0 rowsep0" align="left">69.26%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2C9 inhibition</td><td class="colsep0 rowsep0" align="left">0.0% (10Â Î¼M)</td><td class="colsep0 rowsep0" align="left">organ toxicity (probability)</td><td class="colsep0 rowsep0" align="left">inactive (0.83)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2D6 inhibition</td><td class="colsep0 rowsep0" align="left">1.9% (10Â Î¼M)</td><td class="colsep0 rowsep0" align="left">carcinogenicity (probability)</td><td class="colsep0 rowsep0" align="left">inactive (0.71)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2C19 inhibition</td><td class="colsep0 rowsep0" align="left">0.0% (10Â Î¼M)</td><td class="colsep0 rowsep0" align="left">immunotoxicity (probability)</td><td class="colsep0 rowsep0" align="left">inactive (0.99)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP1A2 inhibition</td><td class="colsep0 rowsep0" align="left">11.8% (10Â Î¼M)</td><td class="colsep0 rowsep0" align="left">mutagenicity (probability)</td><td class="colsep0 rowsep0" align="left">inactive (0.66)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinetic solubility (PBS;Â pHÂ 7.4)</td><td class="colsep0 rowsep0" align="left">>100Â Î¼M (2Â h)</td><td class="colsep0 rowsep0" align="left">cytotoxicity (probability)</td><td class="colsep0 rowsep0" align="left">inactive (0.76)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDCKâMDR1 permeability</td><td class="colsep0 rowsep0" align="left"><i>P</i><sub class="stack">app</sub><sup class="stack">AâB</sup>Â =Â 0.04Â ÃÂ 10<sup>â6</sup>Â cm/s</td><td class="colsep0 rowsep0" align="left">aryl hydrocarbon receptor (probability)</td><td class="colsep0 rowsep0" align="left">inactive (0.96)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><i>P</i><sub class="stack">app</sub><sup class="stack">BâA</sup>Â =Â 1.3Â ÃÂ 10<sup>â6</sup>Â cm/s</td><td class="colsep0 rowsep0" align="left">estrogen receptor Î± (probability)</td><td class="colsep0 rowsep0" align="left">inactive (0.90)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">efflux ratioÂ =Â 30.9</td><td class="colsep0 rowsep0" align="left">androgen receptor (probability)</td><td class="colsep0 rowsep0" align="left">inactive (0.95)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">In vitro PK included assessment of 10 Î¼M of compound <b>12</b> in liver microsomal clearance performed under NADPH-dependent conditions and cytochrome P450 enzymatic inhibition assays performed and represented as percent inhibition. The P-gp efflux substrate experiment employed MDCK cells expressing MDR1 gene. In silico toxicity prediction profile shown along with statistical probabilities (more information at <a href="http://tox.charite.de/protox_II/" class="extLink">http://tox.charite.de/protox_II/</a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo PK Profile and Brain Penetrability of Compound <b>12</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="8" align="center">PK profile of <b>12</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center">CL (LÂ h<sup>â1</sup>Â kg<sup>â1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0âinf</sub> (ngÂ·hÂ·mL<sup>â1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>F</i>Â (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">10,Â iv</td><td class="colsep0 rowsep0" align="center">1.25Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">3.28Â Â±Â 0.2</td><td class="colsep0 rowsep0" align="center">5.4Â Â±Â 0.3</td><td class="colsep0 rowsep0" align="center">2408.6Â Â±Â 216.8</td><td class="colsep0 rowsep0" align="center">3065.6Â Â±Â 184.7</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">20,Â po</td><td class="colsep0 rowsep0" align="center">4.4Â Â±Â 0.5</td><td class="colsep0 rowsep0" align="center">1.3Â Â±Â 0.34</td><td class="colsep0 rowsep0" align="center">10.89Â Â±Â 3.5</td><td class="colsep0 rowsep0" align="center">70.6Â Â±Â 23.7</td><td class="colsep0 rowsep0" align="center">411.3Â Â±Â 105.7</td><td class="colsep0 rowsep0" align="center">2244.7Â Â±Â 667.8</td><td class="colsep0 rowsep0" align="center">36.3Â Â±Â 11</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="5" align="center">brain penetration analysis of <b>12</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">time (h)</th><th class="colsep0 rowsep0" align="center">brain conc (ng/g)</th><th class="colsep0 rowsep0" align="center">plasma conc (ng/mL)</th><th class="colsep0 rowsep0" align="center">brain/plasma ratio</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">10,Â iv</td><td class="colsep0 rowsep0" align="center">0.25</td><td class="colsep0 rowsep0" align="center">96.4Â Â±Â 7.2</td><td class="colsep0 rowsep0" align="center">1486.5Â Â±Â 89.6</td><td class="colsep0 rowsep0" align="center">0.07Â Â±Â 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">10,Â iv</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">94.0Â Â±Â 1.3</td><td class="colsep0 rowsep0" align="center">892.1Â Â±Â 39.1</td><td class="colsep0 rowsep0" align="center">0.11Â Â±Â 0.005</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Values are the average of results [Â± standard error of the mean (SEM)] from male SpragueâDawley rats (<i>n</i> = 3/treatment group). Vehicle, 10% dimethyl sulfoxide (DMSO): 90% 2-hydroxypropyl-Î²-cyclodextrin (HP-Î²-CD). <i>T</i><sub>1/2</sub>, half-life; <i>T</i><sub>max</sub>, time of maximum concentration; CL, plasma clearance; <i>V</i><sub>ss</sub>, volume of distribution; <i>C</i><sub>max</sub>, maximum concentration; AUC<sub>0âinf</sub>, area under the plasma concentrationâtime curve; <i>F</i>, oral bioavailability; time, hours after dose for brain collection; brain conc, averaged concentration of <b>12</b> in tissue sample.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Not determined.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Analysis of Compound <b>12</b> in a Drug Discrimination Assay</h3><div class="NLM_p">The drug discrimination assay is a powerful in vivo tool for establishing the interoceptive (subjective) effects of novel compounds as well as for establishing their mechanisms of action in humans and animals.<a onclick="showRef(event, 'ref23 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref23 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43">(23,34â43)</a> This assay has been employed to reliably characterize the neurobiological profiles of 5-HT<sub>2C</sub>R agonists (i.e., Ro 60-0175 and WAY163909) as well as GPCR allosteric modulators.<a onclick="showRef(event, 'ref23 ref35 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref23 ref35 ref38 ref39 ref40 ref41 ref42">(23,35,38â42)</a> In the present series of studies, we trained rats (<i>n</i> = 13) to discriminate the selective 5-HT<sub>2C</sub>R agonist WAY163909 [0.75 mg/kg, intraperitoneal (ip); 15 min pretreatment] from an equivalent volume (1 mL/kg) of saline (0.9% NaCl) in a two-lever drug discrimination protocol under a fixed ratio 20 (FR20) schedule of water reinforcement.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In substitution tests, animals were tested for lever selection after the administration of various doses of the training drug WAY163909 or compound <b>12</b>. In combination tests, animals were administered <b>12</b> (0.5â2 mg/kg) with a dose of WAY163909 (0.5 mg/kg) that produced â¼50% WAY163909-appropriate responding when given alone. We also assessed the ability of the selective 5-HT<sub>2C</sub>R antagonist SB242084 to block the substitution of compound 12 plus a low dose of WAY163909.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p">All rats acquired the WAY163909 versus saline discrimination to criterion. The mean number of sessions required to meet the acquisition criterion (defined as 10 consecutive sessions with â¥80% of stimulus-appropriate responding) for the WAY163909 versus saline discrimination was 57 training sessions (range: 39â68). Substitution of a test drug for the training stimulus is typically a quantal rather than continuous function of stimulus similarity in the two-choice drug discrimination assay.<a onclick="showRef(event, 'ref23 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref23 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42">(23,34â42)</a> Thus, intermediate doses of WAY163909 evoke responding confined to one lever. Full substitution was defined as â¥80% of rats selecting the WAY163909-appropriate lever. Partial substitution was defined as â¥40% and <80% drug-appropriate responding. As can be seen in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A, 0% of rats (0/13 rats) chose the WAY163909-associated lever when administered saline or 0.125 mg/kg, while 92% (12/13 rats) and 100% (13/13) of rats chose the WAY163909-associated lever at the training dose (0.75 mg/kg) and 1.0 mg/kg of WAY163909, respectively (vs saline, <i>p</i> < 0.05). Intermediate doses of WAY163909 (0.25â0.625 mg/kg) resulted in a graded, quantal increase in the number of rats selecting the WAY163909-associated lever. The response rate (responses/min) observed following saline administration was significantly higher than following the injection of 0.75 mg/kg (<i>t</i><sub>12</sub> = 2.22, <i>p</i> < 0.05) and 1.0 mg/kg of WAY163909 (<i>t</i><sub>12</sub> = 3.74, <i>p</i> < 0.05). The response rates analyzed for the remaining doses of WAY163909 tested (0.125, 0.25, 0.50, 0.625, and 1.0 mg/kg, ip) did not differ relative to 0.75 mg/kg of WAY163909 (n.s.). Here, 0.5 and 0.625 mg/kg doses of WAY163909 resulted in 46 and 54%, respectively, of rats selecting the WAY163909-appropriate lever. Log-probit analyses indicate that the dose of WAY163909 predicted to result in 50% drug-associated responses (ED<sub>50</sub>) is 0.51 mg/kg, in agreement with our previous study (0.53 mg/kg).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>12</b> dose dependently augments the stimulus effects of the selective 5-HT<sub>2C</sub>R agonist WAY163909. (A) Doseâresponse relationship for WAY163909 is shown (<i>n</i> = 13 rats). Filled magenta circles denote the rats that chose either the saline- or the WAY163909-associated lever for each condition/dose. Closed black circles denote the mean percentage of rats selecting the WAY163909-associated lever (<i>Y</i>-axis) [*<i>p</i> < 0.05 vs saline (SAL)]. (B) Compound (Cmpd) <b>12</b> (0â2 mg/kg) or WAY163909 (0.5 mg/kg) was administered alone or combination as illustrated, with or without pretreatment with SB242084 (0.5 mg/kg). Open bars illustrate the mean percentage of rats selecting the WAY163909-associated lever during combination tests (<i>Y</i>-axis) [*<i>p</i> < 0.05 vs WAY163909 (0.5 mg/kg) alone and ^<i>p</i> < 0.05 vs combination of compound <b>12</b> plus WAY163909 following pretreatment with SB242084 (0.5 mg/kg). The details of the statistical analyses are found in the Experimental Section.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>12</b> did not exhibit intrinsic activity as a 5-HT<sub>2C</sub>R agonist in vitro (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). This result shaped the hypothesis that <b>12</b> would fail to substitute in the WAY163909 versus saline discrimination. As expected from in vitro analyses, <b>12</b> (0.5â5 mg/kg), administered ip 30 min prior to testing, evoked saline lever responding with no change in response rates (n.s.; <a href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_001.pdf" class="ext-link">Figure S2</a>). The observed lack of substitution supports the premise that <b>12</b> and the full 5-HT<sub>2C</sub>R agonist WAY163909 have dissociable discriminative stimulus effects.</div><div class="NLM_p last">We next tested the hypothesis that <b>12</b> would enhance the discriminative stimulus effects of a subthreshold dose of WAY163909 (0.5 mg/kg). Thus, rats were pretreated with <b>12</b> (0, 0.5, 1, or 2 mg/kg) 15 min before WAY163909 (0.5 mg/kg), followed 15 min later by placement in the chambers. <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B demonstrates that â¼53% of rats (7/13 rats) selected the drug-associated lever following WAY163909 (0.5 mg/kg). Pretreatment with 1 or 2 mg/kg of <b>12</b> plus WAY163909 (0.5 mg/kg) evoked â¼77% (10/13 rats) and â¼92% (12/13 rats) of rats selecting the WAY163909 lever, respectively, suggesting a synergistic substitution for the training drug (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). The selective 5-HT<sub>2C</sub>R antagonist SB242084 completely prevented the substitution of <b>12</b> (2 mg/kg) plus WAY163909 (0.5 mg/kg) in 13/13 rats. In summary, <b>12</b> did not evoke intrinsic 5-HT<sub>2C</sub>R agonist actions but potentiated a behavioral marker associated with 5-HT<sub>2C</sub>R agonist-mediated signaling in vivo.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A series of structurally optimized analogues were rationally designed and synthesized based on the scaffold of our previously reported 5-HT<sub>2C</sub>R PAM CYD-1-79 (<b>3</b>), bearing privileged diol PH moieties. Specifically, the reported investigation focused on the replacement of the undecyl LT moiety with hydrocarbon fragments (cyclic in nature) with a decreased length while approximately maintaining a similar molecular volume to maintain activity and improve drug-likeness. Compound <b>12</b> (CTW0415) displayed significant PAM activity at 5-HT<sub>2C</sub>R using a fluorescence-based, 5-HT-evoked Ca<sub>i</sub><sup>2+</sup> release assay and was shown to be inactive as an agonist or allosteric modulator at 5-HT<sub>2A</sub>R. An additional six compounds were characterized as 5-HT<sub>2C</sub>R PAMs, enriching our computational molecular modeling studies by providing an interesting array of chemical diversities. These molecular modeling and docking studies provide compelling support for a unique, spatially distinct 5-HT<sub>2C</sub>R allosteric binding site that bridges a hydrophobic pocket between the TM2 and TM3 helices to polar contacts on the TM6 and TM7 helices. One aspect to consider regarding the location of the suggested allosteric site is the evidence of metastable binding sites within transmembrane helical bundles that can briefly accommodate orthosteric ligands.<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45â47)</a> The transient nature of these binding pockets may provide a site or a portion of a binding site for specific allosteric modulators to exert negative or positive effects. Future computational and pharmacological experiments are needed to address these ideas.</div><div class="NLM_p last">Compound <b>12</b> was ultimately chosen for progression toward in vivo behavioral studies because of superior physicochemical properties, an appropriate MPO value, a highly selective off-target profile, and promising PKs. Moreover, the structure of <b>12</b> lends itself to additional medicinal chemistry efforts as the compound is well within the boundaries of Lipinskiâs rule of five. Compound <b>12</b> dose dependently potentiated the stimulus effects of the 5-HT<sub>2C</sub>R agonist WAY163909. Importantly, this effect was completely blocked by the 5-HT<sub>2C</sub>R antagonist SB242084, supporting the critical involvement in the synergism between <b>12</b> and a selective 5-HT<sub>2C</sub>R agonist in vivo. Taken together, <b>12</b> is an ideal lead compound for further optimization as a 5-HT<sub>2C</sub>R PAM, and the continued development of this class of molecules may be aided by the structural presentation of a putative 5-HT<sub>2C</sub>R allosteric binding site.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28374" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28374" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> General</h4><div class="NLM_p last">All commercially available starting materials and solvents were of reagent grade and used without further purification. Reactions were performed under a nitrogen atmosphere in dry glassware with magnetic stirring. Preparative column chromatography was performed using silica gel 60, particle size 0.063â0.200 mm (70â230 mesh, flash). Analytical thin-layer chromatography (TLC) was carried out employing silica gel 60 F254 plates (Merck, Darmstadt). Visualization of the developed chromatograms was performed with detection by UV (254 nm). NMR spectra were recorded on a Bruker-600 (<sup>1</sup>H, 600 MHz; <sup>13</sup>C, 150 MHz) or Bruker-300 (<sup>1</sup>H, 300 MHz; <sup>13</sup>C, 75 MHz) spectrometer. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded with TMS as an internal reference. Chemical shifts were expressed in ppm, and <i>J</i> values were given in Hz. High-resolution mass spectra were obtained from a Thermo Fisher LTQ Orbitrap Elite mass spectrometer. Parameters include the following: the nanoâESI spray voltage was 1.8 kV; the capillary temperature was 275 Â°C, and the resolution was 60,000; ionization was achieved by positive mode. Melting points were measured on a Thermo Scientific Electrothermal Digital Melting Point apparatus and uncorrected. The purity of final compounds was determined by analytical high-performance liquid chromatography (HPLC) using a Shimadzu HPLC system (model: CBM-20A LC-20AD SPD-20A UV/VIS). HPLC analysis conditions: Waters Î¼Bondapak C18 (300 Ã 3.9 mm); flow rate 0.5 mL/min; UV detection at 270 and 254 nm; linear gradient from 10% acetonitrile in water to 100% acetonitrile in water in 20 min, followed by 30 min of the last-named solvent [0.1% trifluoroacetic acid (TFA) was added into both acetonitrile and water]. All biologically evaluated compounds have been characterized with <sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS, and HPLC analyses for quality control to ensure a purity of >95%.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedure for the Synthesis of <b>11â17</b></h4><div class="NLM_p">To a solution of <b>9</b> or <b>10</b> (0.18 mmol) and amino alcohols (0.18 mmol) in 4 mL of dimethylformamide (DMF) was added HBTU (0.23 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) (0.45 mmol). The resulting mixture was stirred at room temperature for 16 h. DMF was removed under vacuum to give a brown oily residue, which was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and 10% citric aqueous solution (10 mL). The organic layer was separated and washed with saturated aqueous NaHCO<sub>3</sub> (10 mL). After drying over anhydrous Na<sub>2</sub>SO<sub>4</sub>, the solvent was removed under vacuum to afford an oily residue. This residue was purified with a silica gel column (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) and afforded the corresponding Boc-protected amide. The amide (0.13 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL), followed by the addition of TFA (250 Î¼L). The resulting mixture was stirred at room temperature. After 2 h, TLC showed that the starting material had disappeared. The solvent was removed under vacuum to give an oily residue. The residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and saturated NaHCO<sub>3</sub> aqueous solution (10 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give an oily residue. This residue was purified with a silica gel column (eluting with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), affording compounds <b>11â17</b>.</div><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> (<b>2<i>S</i></b>,<b>4<i>S</i></b>)-<i>N</i>-((<b>1<i>S</i></b>,<b>2<i>S</i></b>)-1,3-Dihydroxy-1-phenylpropan-2-yl)-4-phenylpiperidine-2-carboxamide ((<b>2<i>S</i></b>,<b>4<i>S</i></b>)-<b>11</b>) and (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<i>N</i>-((<b>1<i>S</i></b>,<b>2<i>S</i></b>)-1,3-Dihydroxy-1-phenylpropan-2-yl)-4-phenylpiperidine-2-carboxamide ((<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>11</b>)<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></h5><div class="NLM_p last">Compounds (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>11</b> (36 mg, 40%) and (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>11</b> (38 mg, 43%) were prepared from <b>9</b> (two steps). These two isomers could be separated by preparative TLC as a colorless amorphous gel. Compound (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>11</b>: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): Î´ 7.42 (m, 2H), 7.30 (m, 4H), 7.22 (m, 2H), 7.12 (d, 2H, <i>J</i> = 7.2 Hz), 5.06 (d, 1H, <i>J</i> = 4.2 Hz), 4.12 (m, 1H), 3.80 (m, 1H), 3.72 (m, 1H), 3.25 (dd, 1H, <i>J</i> = 3.0 Hz, 12.0 Hz), 3.10 (d, 1H, <i>J</i> = 12.0 Hz), 2.65 (m, 1H), 2.55 (m, 1H), 1.95 (d, 1H, <i>J</i> = 12.6 Hz), 1.75 (d, 1H, <i>J</i> = 12.6 Hz), 1.75 (m, 1H), 1.28 (q, 1H, <i>J</i> = 12.6 Hz). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>): Î´ 174.5, 145.2, 141.4, 128.4, 128.3 (2C), 127.7, 126.7 (2C), 126.4, 126.1 (2C), 125.9, 73.1, 62.9, 61.0, 56.5, 45.7, 42.0, 37.1, 32.9. HRMS: calcd for C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 355.2016; found, 355.2022. Compound (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>11</b>: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): Î´ 7.56 (d, 1H, <i>J</i> = 7.8 Hz), 7.26 (m, 4H), 7.17 (m, 3H), 7.09 (t, 1H, <i>J</i> = 7.2 Hz), 7.04 (d, 1H, <i>J</i> = 7.8 Hz), 4.96 (d, 1H, <i>J</i> = 1.8 Hz), 4.63 (br s, 3H), 4.12 (m, 1H), 3.77 (m, 1H), 3.69 (m, 1H), 3.38 (d, 1H, <i>J</i> = 12.0 Hz), 3.06 (d, 1H, <i>J</i> = 10.8 Hz), 2.59 (m, 1H), 2.54 (m, 1H), 1.87 (d, 1H, <i>J</i> = 10.8 Hz), 1.70 (d, 1H, <i>J</i> = 10.8 Hz), 1.44 (m, 1H), 1.27 (q, 1H, <i>J</i> = 13.2 Hz). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>): Î´ 173.2, 144.6, 141.5, 128.5 (2C), 128.2 (2C), 127.5, 126.6 (3C), 125.8 (2C), 72.8, 62.8, 59.8, 56.5, 44.9, 41.3, 36.7, 32.1. HRMS: calcd for C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 355.2016; found, 355.2019.</div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> (2,4-<i>cis</i>)-<i>N</i>-((<i>S</i>)-2,3-Dihydroxypropyl)-4-phenylpiperidine-2-carboxamide (<b>12</b>)</h5><div class="NLM_p last">Compound 12 (20 mg, 91%), a diastereomeric mixture, was prepared from 9 (two steps) as a whitish wax. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 7.43â7.23 (m, 2H), 7.22â7.12 (m, 3H), 3.77â3.61 (m, 1H), 3.57â3.40 (m, 2H), 3.40â3.07 (m, 8H), 2.92â2.58 (m, 2H), 2.28â2.06 (m, 1H), 1.92â1.75 (m, 1H), 1.68â1.40 (m, 2H) . <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 175.0, 174.9, 145.2, 128.5, 126.6, 126.4, 70.6, 70.5, 63.6, 63.5, 60.5, 45.8, 45.7, 42.19, 42.15, 41.8, 41.7, 37.5, 37.4, 33.07, 33.05. HRMS (ESI): calcd for C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 279.1703; found, 279.1696.</div></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> ((2,4-<i>cis</i>)-4-Cyclohexyl-<i>N</i>-((<i>S</i>)-2,3-dihydroxypropyl)piperidine-2-carboxamide (<b>13</b>)</h5><div class="NLM_p last">Compound <b>13</b> (20 mg, 80%), a diastereomeric mixture, was prepared from <b>10</b> (two steps) as a whitish wax. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>: CH<sub>3</sub>OD): Î´ 3.80â3.48 (m, 5H), 3.42 (d, <i>J</i> = 5.3 Hz, 2H), 3.38â3.22 (m, 1H), 3.16 (dd, <i>J</i> = 13.7, 6.7 Hz, 1H), 3.07 (d, <i>J</i> = 11.3 Hz, 1H), 2.53 (t, <i>J</i> = 11.3 Hz, 1H), 1.90 (d, <i>J</i> = 12.0 Hz, 1H), 1.81â1.49 (m, 6H), 1.42â0.72 (m, 10H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 175.55, 70.48, 63.47, 60.56, 45.71, 42.81, 41.70, 41.40, 33.79, 29.80, 29.30, 26.54, 26.44. HRMS (ESI): calcd for C<sub>15</sub>H<sub>28</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 285.2173; found, 258.2169.</div></div><div id="sec4_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> (2,4-<i>cis</i>)-<i>N</i>-(1,3-Dihydroxypropan-2-yl)-4-phenylpiperidine-2-carboxamide (<b>14</b>)</h5><div class="NLM_p last">Compound <b>14</b> (20 mg, 55.6%), a diastereomeric mixture, was prepared from <b>9</b> (two steps) as a whitish wax. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>: CH<sub>3</sub>OD): Î´ 7.31â7.24 (m, 2H), 7.23â7.13 (m, 3H), 3.91â3.79 (m, 1H), 3.76â3.57 (m, 4H), 3.52â3.29 (m, 5H), 3.25 (d, <i>J</i> = 12.7 Hz, 2H), 2.74 (m, 2H), 2.15 (d, <i>J</i> = 12.8 Hz, 1H), 1.84 (d, <i>J</i> = 12.8 Hz, 1H), 1.71â1.43 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 173.89, 145.17, 128.53, 126.65, 126.48, 61.80, 61.74, 60.48, 52.32, 45.63, 42.06, 37.25, 32.86. HRMS (ESI): calcd for C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 279.1703; found, 279.1700.</div></div><div id="sec4_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> (2,4-<i>cis</i>)-4-Cyclohexyl-<i>N</i>-(1,3-dihydroxypropan-2-yl)piperidine-2-carboxamide (<b>15</b>)</h5><div class="NLM_p last">Compound <b>15</b> (5 mg, 36%), a diastereomeric mixture, was prepared from <b>10</b> (two steps) as a whitish wax. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>: CH<sub>3</sub>OD): Î´ 3.88â3.78 (m, 1H), 3.70â3.60 (m, 4H), 3.41â3.29 (m, 1H), 3.21 (d, <i>J</i> = 12.5 Hz, 1H), 2.69 (t, <i>J</i> = 12.2 Hz, 1H), 2.02 (d, <i>J</i> = 13.0 Hz, 1H), 1.76â1.64 (m, 4H), 1.62 (d, <i>J</i> = 12.1 Hz, 1H), 1.36â1.25 (m, 1H), 1.25â1.13 (m, 5H), 1.13â1.03 (m, 2H), 0.98â0.86 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 172.82, 61.79, 60.02, 52.59, 45.12, 42.57, 40.71, 32.69, 29.76, 28.01, 26.50, 26.42. HRMS (ESI): calcd for C<sub>15</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 285.2173; found, 285.2169.</div></div><div id="sec4_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> (2,4-<i>cis</i>)-<i>N</i>-(2-Morpholinoethyl)-4-phenylpiperidine-2-carboxamide (<b>16</b>)</h5><div class="NLM_p last">Compound <b>16</b> (29 mg, 76%), a diastereomeric mixture, was prepared from <b>9</b> (two steps) as a whitish wax. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 7.39â6.87 (m, 5H), 4.01â3.72 (m, 7H), 3.75â3.44 (m, 5H), 3.29 (d, <i>J</i> = 10.9 Hz, 1H), 2.99â2.53 (m, 2H), 2.15 (d, <i>J</i> = 11.9 Hz, 1H), 1.86 (d, <i>J</i> = 11.7 Hz, 1H), 1.64 (dt, <i>J</i> = 24.8, 12.5 Hz, 2H)Â·<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): Î´ 172.46, 144.44, 128.56, 126.64, 126.55, 61.36, 59.73, 52.63, 41.40, 36.42, 31.62. HRMS (ESI): calcd for C<sub>18</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 318.2176; found, 318.2190.</div></div><div id="sec4_1_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> (2,4-<i>cis</i>)-4-Cyclohexyl-<i>N</i>-(2-morpholinoethyl)piperidine-2-carboxamide (<b>17</b>)</h5><div class="NLM_p last">Compound <b>17</b> (13 mg, 81%), a diastereomeric mixture, was prepared from <b>10</b> (two steps) as a whitish wax. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): Î´ 6.94 (s, 1H), 3.75â3.68 (m, 4H), 3.37 (q, <i>J</i> = 6.0 Hz, 2H), 3.16 (dd, <i>J</i> = 11.4, 2.7 Hz, 2H), 2.65 (td, <i>J</i> = 12.0, 2.6 Hz, 1H), 2.48 (dd, <i>J</i> = 11.8, 5.6 Hz, 6H), 2.08 (dd, <i>J</i> = 12.6, 2.0 Hz, 1H), 1.92 (s, 1H), 1.81â1.54 (m, 6H), 1.31â0.78 (m, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): Î´ 174.49, 166.62, 66.96, 61.24, 57.29, 53.43, 46.26, 42.96, 41.62, 35.42, 34.27, 30.05, 29.87, 29.60, 26.70, 26.61. HRMS (ESI): calcd for C<sub>18</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 324.2646; found, 324.2642.</div></div><div id="sec4_1_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<i>N</i>-((<b>1<i>R</i></b>,<b>2<i>R</i></b>)-1,3-Dihydroxy-1-phenylpropan-2-yl)-4-phenethylpiperidine-2-carboxamide ((<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>29</b>) and (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<i>N</i>-((<b>1<i>R</i></b>,<b>2<i>R</i></b>)-1,3-Dihydroxy-1-phenylpropan-2-yl)-4-phenethylpiperidine-2-carboxamide ((<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>29</b>)<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></h5><div class="NLM_p last">Compounds (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>29</b> (45 mg, 35%) and (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>29</b> (50 mg, 39%) were prepared from <b>25</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b>. These two isomers could be separated by preparative TLC as colorless amorphous gels. Compound (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>29</b>: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): Î´ 7.54 (br s, 1H), 7.39 (d, 2H, <i>J</i> = 7.2 Hz), 7.32 (m, 2H), 7.26 (m, 3H), 7.17 (m, 3H), 4.91 (d, 1H), 4.12 (dd, 1H, <i>J</i> = 5.4 Hz), 3.64 (dd, 1H, <i>J</i> = 5.4 Hz), 3.51 (dd, 1H, <i>J</i> = 5.4 Hz), 3.48 (m, 1H), 3.25 (m, 1H), 2.76 (m, 1H), 2.63 (t, 2H, <i>J</i> = 7.8 Hz), 2.08 (d, 1H, <i>J</i> = 12.6 Hz), 1.85 (d, 1H, <i>J</i> = 13.8 Hz), 1.26 (m, 1H), 1.16 (q, 1H, <i>J</i> = 12.6 Hz). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>): Î´ 171.6, 141.8, 141.5, 128.2, 128.1 (3C), 127.5, 126.1 (2C), 125.7, 72.1, 61.4, 58.9, 57.0, 48.0, 44.1, 38.0, 34.7, 34.2, 32.4, 29.6. HRMS: calcd for C<sub>23</sub>H<sub>30</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 383.2329; found, 383.2332. Compound (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>29</b>: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): Î´ 7.74 (br s, 1H), 7.32 (d, 2H, <i>J</i> = 7.8 Hz), 7.24 (m, 4H), 7.14 (m, 4H), 5.04 (br s, 2H), 4.97 (s, 1H), 4.12 (s, 1H), 3.77 (m, 1H), 3.70 (m, 1H), 3.38 (s, 2H), 3.34 (m, 1H), 3.02 (d, 1H, <i>J</i> = 9.6 Hz), 2.50 (m, 3H), 1.72 (d, 1H, <i>J</i> = 10.2 Hz), 1.61 (d, 1H, <i>J</i> = 10.2 Hz), 1.39 (m, 2H), 1.01 (m, 1H), 0.81 (m, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>): Î´ 172.2, 142.0, 141.6, 128.4 (2C), 128.2 (2C), 127.4, 125.9 (3C), 72.6, 62.7, 59.1, 56.6, 50.4, 44.2, 38.2, 35.1, 34.3, 32.5, 30.2. HRMS: calcd for C<sub>23</sub>H<sub>30</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 383.2329; found, 383.2334.</div></div><div id="sec4_1_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> (2,4-<i>cis</i>)-<i>N</i>-((S)-2,3-Dihydroxypropyl)-4-phenethylpiperidine-2-carboxamide (<b>30</b>)</h5><div class="NLM_p last">Compound <b>30</b> (20.0 mg, 55.4%), a diastereomeric mixture, was prepared from <b>25</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b> as a white solid. mp 103.2â104.3 Â°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 7.41â7.31 (m, 1H), 7.31â7.23 (m, 2H), 7.22â7.10 (m, 3H), 3.80â3.71 (m, 1H), 3.62â3.46 (m, 2H), 3.45â3.27 (m, 3H), 3.22 (dd, 2H, <i>J</i> = 11.6, 2.7 Hz), 3.18â3.09 (m, 1H), 2.62 (t, 3H, <i>J</i> = 8.0 Hz), 2.10 (d, 1H, <i>J</i> = 13.2 Hz), 1.73 (d, 1H, <i>J</i> = 13.3 Hz), 1.56 (q, 2H, <i>J</i> = 7.6, 7.2 Hz), 1.50â1.39 (m, 1H), 1.26 (s, 1H), 1.17â0.96 (m, 2H) <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): Î´ 175.5, 166.6, 142.3, 128.4, 128.3, 125.8, 70.9, 63.8, 63.7, 60.5, 45.6, 42.0, 38.7, 36.7, 35.5, 35.4, 32.7, 32.4. HRMS (ESI): calcd for C<sub>17</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 307.2016; found, 307.2009.</div></div><div id="sec4_1_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> (2,4-<i>cis</i>)-4-(2-Cyclohexylethyl)-<i>N</i>-((<i>S</i>)-2,3-dihydroxypropyl)piperidine-2-carboxamide (<b>31</b>)</h5><div class="NLM_p last">Compound <b>31</b> (44 mg, 94%), a diastereomeric mixture, was prepared from <b>26</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b> as a whitish wax. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): Î´ 7.44 (s, 1H), 3.90â3.66 (m, 4H), 3.62â3.42 (m, 2H), 3.44â3.30 (m, 2H), 3.30â3.17 (m, 1H), 3.13 (d, 1H, <i>J</i> = 12.0 Hz), 2.63 (t, 1H, <i>J</i> = 12.1 Hz), 2.02 (d, 1H, <i>J</i> = 12.5 Hz), 1.68 (d, 6H, <i>J</i> = 11.4 Hz), 1.37 (bs, 1H), 1.30â1.08 (m, 8H), 1.00 (t, 2H, <i>J</i> = 12.3 Hz), 0.94â0.77 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): Î´ 175.3, 70.9, 70.8, 63.8, 63.7, 60.5, 45.6, 42.0, 37.8, 36.8, 36.2, 36.1, 34.2, 33.4, 32.5, 26.7, 26.4. HRMS (ESI): calcd for C<sub>17</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 313.2486; found, 313.2486.</div></div><div id="sec4_1_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> (2,4-<i>cis</i>)-<i>N</i>-(1,3-Dihydroxypropan-2-yl)-4-phenethylpiperidine-2-carboxamide (<b>32</b>)</h5><div class="NLM_p last">Compound <b>32</b> (27 mg, 99%), a diastereomeric mixture, was prepared from <b>25</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b> as a white waxlike material. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 7.24â7.15 (m, 2H), 7.13â7.04 (m, 3H), 3.99 (s, 7H), 3.88â3.76 (m, 1H), 3.37 (d, 1H, <i>J</i> = 10.5 Hz), 3.18 (d, 1H, <i>J</i> = 11.7 Hz), 2.82â2.61 (m, 1H), 2.60â2.50 (m, 2H), 2.04 (d, 1H, <i>J</i> = 12.6 Hz), 1.75 (d, 1H, <i>J</i> = 12.6 Hz), 1.66â1.37 (m, 3H), 1.33â0.97 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 172.1, 141.9, 128.3, 128.1, 125.7, 61.2, 59.3, 52.7, 44.5, 38.2, 35.0, 34.5, 32.4, 30.3. HRMS (ESI): calcd for C<sub>17</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 307.2016; found, 307.2012.</div></div><div id="sec4_1_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> (2,4-<i>cis</i>)-4-(2-Cyclohexylethyl)-<i>N</i>-(1,3-dihydroxypropan-2-yl)piperidine-2-carboxamide (<b>33</b>)</h5><div class="NLM_p last">Compound <b>33</b> (20.7 mg, 76.6%), a diastereomeric mixture, was prepared from <b>26</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b>, as a whitish solid. mp 145.2â150.0 Â°C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 3.86 (t, 1H, <i>J</i> = 4.8 Hz), 3.80â3.57 (m, 4H), 3.48â3.33 (m, 1H), 3.23â3.06 (m, 2H), 2.70â2.54 (m, 1H), 2.00 (d, 1H, <i>J</i> = 13.1), 1.75â1.60 (m, 6H), 1.38 (bs, 2OH), 1.33â1.06 (m, 9H), 1.09â0.96 (m, 2H), 0.95â0.75 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 174.4, 61.8, 61.7, 60.4, 52.2, 45.5, 37.7, 36.5, 36.0, 34.1, 34.0, 33.3, 32.3, 26.6, 26.3. HRMS (ESI): calcd for C<sub>17</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 313.2486; found, 313.2487.</div></div><div id="sec4_1_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> (2,4-<i>cis</i>)-4-(2-Cyclohexylethyl)-<i>N</i>-(2-morpholinoethyl)piperidine-2-carboxamide (<b>34</b>)</h5><div class="NLM_p last">Compound <b>34</b> (43 mg, 93%), a diastereomeric mixture, was prepared from <b>26</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b> as a yellowish solid. mp 45.0â47.1 Â°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): Î´ 6.93 (t, 1H, <i>J</i> = 5.5 Hz), 3.80â3.59 (m, 4H), 3.35 (dtd, 2H, <i>J</i> = 6.7, 5.6, 5.0, 1.2 Hz), 3.14 (tt, 2H, <i>J</i> = 11.9, 2.4 Hz), 2.77â2.56 (m, 1H), 2.56â2.37 (m, 6H), 2.18â2.03 (m, 1H), 1.95 (d, 1H, <i>J</i> = 9.0 Hz), 1.82â1.58 (m, 6H), 1.40â1.30 (m, 1H), 1.34â1.08 (m, 8H), 1.08â0.96 (m, 1H), 0.96â0.74 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>: CD<sub>3</sub>OD): Î´ 174.3, 67.0, 57.3, 53.4, 46.0, 37.8, 37.2, 36.3, 35.4, 34.2, 33.4, 32.8, 26.7, 26.4. HRMS (ESI): calcd for C<sub>20</sub>H<sub>37</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 352.2959; found, 352.2952.</div></div><div id="sec4_1_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> (2,4-<i>cis</i>)-4-(2-Cyclohexylethyl)-<i>N</i>-(3-morpholinopropyl)piperidine-2-carboxamide (<b>35</b>)</h5><div class="NLM_p last">Compound <b>35</b> (33 mg, 99%), a diastereomeric mixture, was prepared from <b>26</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b> as a white wax-like solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): Î´ 7.51 (t, 1H, <i>J</i> = 5.5 Hz), 3.74 (td, 4H, <i>J</i> = 4.4, 1.5 Hz), 3.33 (m, 2H), 3.13 (m, 2H), 2.66 (td, 1H, <i>J</i> = 12.1, 2.7 Hz), 2.43 (m, 6H), 2.09 (dq, 1H, <i>J</i> = 12.8, 2.7 Hz), 1.81 (s, 1H), 1.67 (m, 8H), 1.35 (m, 1H), 1.19 (m, 8H), 1.03 (m, 1H), 0.86 (m, 3H). HRMS (ESI): calcd for C<sub>21</sub>H<sub>39</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 366.3115; found, 366.3112.</div></div><div id="sec4_1_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> (2,4-<i>cis</i>)-<i>N</i>-(2-Morpholinoethyl)-4-phenethylpiperidine-2-carboxamide (<b>36</b>)</h5><div class="NLM_p last">Compound <b>36</b> (45 mg, 96%), a diastereomeric mixture, was prepared from <b>25</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b> as a yellowish solid. mp 156.6â157.9 Â°C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): Î´ 7.31â7.24 (m, 2H), 7.12â7.13 (m, 3H), 6.94 (t, 1H, <i>J</i> = 5.6 Hz), 3.71 (t, 4H, <i>J</i> = 3.0 Hz), 3.36 (q, 2H, <i>J</i> = 6.0 Hz), 3.23â3.08 (m, 2H), 2.72â2.59 (m, 3H), 2.53â2.39 (m, 6H), 2.17 (dq, 1H, <i>J</i> = 12.7, 2.8 Hz), 1.73 (dt, 1H, <i>J</i> = 12.8, 2.8 Hz), 1.64â1.52 (m, 2H), 1.51â1.39 (m, 1H), 1.25 (bs, 1H), 1.18â1.04 (m, 1H), 1.03â0.91 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): Î´ 174.2, 166.7, 142.5, 128.3, 128.3, 125.7, 67.0, 60.8, 57.3, 53.4, 45.9, 38.9, 35.6, 35.4, 32.8, 32.6. HRMS (ESI): calcd for C<sub>20</sub>H<sub>31</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 346.2489; found, 346.2482.</div></div><div id="sec4_1_2_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> (2,4-<i>cis</i>)-<i>N</i>-(3-Morpholinopropyl)-4-phenethylpiperidine-2-carboxamide (<b>37</b>)</h5><div class="NLM_p last">Compound <b>37</b> (25 mg, 99%), a diastereomeric mixture, was prepared from <b>25</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b> as a white solid. mp 59.8â61.5 Â°C;. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): Î´ 7.53 (t, 1H, <i>J</i> = 5.2 Hz), 7.27 (m, 2H), 7.17 (m, 3H), 3.74 (dt, 4H, <i>J</i> = 4.4, 1.5 Hz), 3.34 (m, 2H), 3.14 (m, 2H), 2.64 (m, 3H), 2.43 (m, 6H), 2.18 (dq, 1H, <i>J</i> = 12.6, 2.8 Hz), 1.69 (m, 4H), 1.56 (m, 2H), 1.46 (m, 1H), 1.09 (ddd, 1H, <i>J</i> = 15, 12, 3 Hz), 0.96 (q, 1H, <i>J</i> = 12 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): Î´ 174.2, 142.4, 128.3, 128.2, 125.7, 66.9, 61.0, 57.7, 53.8, 45.9, 38.9, 38.6, 37.1, 35.7, 32.8, 32.6, 25.4. HRMS (ESI): calcd for C<sub>21</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 360.2646; found, 360.2638.</div></div><div id="sec4_1_2_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-4-(4-(<i>tert</i>-Butyl)phenethyl)-<i>N</i>-((<b>1<i>R</i></b>,<b>2<i>R</i></b>)-1,3-dihydroxy-1-phenylpropan-2-yl)piperidine-2-carboxamide ((<b>2<i>S</i></b>,<b>4<i>R</i></b>)-38) and (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-4-(4-(<i>tert</i>-Butyl)phenethyl)-<i>N</i>-((<b>1<i>R</i></b>,<b>2<i>R</i></b>)-1,3-dihydroxy-1-phenylpropan-2-yl)piperidine-2-carboxamide ((<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>38</b>)<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></h5><div class="NLM_p last">Compounds (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>38</b> (40 mg, 28%) and (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>38</b> (50 mg, 36%) were prepared from <b>27</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b>. These two isomers could be separated by preparative TLC as colorless amorphous gels. Compound (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>38</b>: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): Î´ 7.46 (br s, 1H), 7.39 (d, 2H, <i>J</i> = 7.2 Hz), 7.31 (m, 4H), 7.24 (t, 1H, <i>J</i> = 7.2 Hz), 7.10 (d, 1H, <i>J</i> = 8.4 Hz), 4.96 (d, 1H, <i>J</i> = 4.8 Hz), 4.09 (q, 1H, <i>J</i> = 5.4 Hz), 3.68 (m, 1H), 3.57 (m, 1H), 3.21 (dd, 1H, <i>J</i> = 3.0 Hz, 12.0 Hz), 3.12 (m, 1H), 2.63 (m, 1H), 2.57 (t, 2H, <i>J</i> = 7.8 Hz), 1.91 (d, 1H, <i>J</i> = 13.2 Hz), 1.76 (d, 1H, <i>J</i> = 12.6 Hz), 1.54 (m, 2H), 1.46 (m, 1H), 1.30 (s, 9H), 1.12 (qd, 1H, <i>J</i> = 3.6 Hz, 12.0 Hz), 0.91 (q, 1H, <i>J</i> = 12.6 Hz). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): Î´ 174.0, 148.5, 141.6, 139.0, 128.1 (2C), 127.8 (2C), 127.4, 126.0, 125.9, 125.1 (2C), 72.0, 61.8, 59.9, 56.6, 44.9, 38.5, 35.8, 34.9, 34.2, 31.9, 31.3, 31.1 (3C). HRMS: calcd for C<sub>27</sub>H<sub>38</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 439.2950; found, 439.2957. Compound (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>38</b>: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): Î´ 7.68 (br s, 1H), 7.38 (d, 2H, <i>J</i> = 7.8 Hz), 7.31 (m, 4H), 7.22 (t, 1H, <i>J</i> = 7.2 Hz), 7.11 (d, 2H, <i>J</i> = 8.4 Hz), 4.99 (d, 1H, <i>J</i> = 4.2 Hz), 4.11 (m, 1H), 3.75 (m, 1H), 3.66 (m, 1H), 3.47 (dd, 1H, <i>J</i> = 2.4 Hz, 12.6 Hz), 3.20 (d, 1H, <i>J</i> = 11.4 Hz), 2.72 (m, 1H), 2.56 (m, 2H), 1.87 (d, 1H, <i>J</i> = 13.2 Hz), 1.78 (d, 1H, <i>J</i> = 13.8 Hz), 1.52 (m, 3H), 1.31 (s, 9H), 1.18 (m, 1H), 0.96 (q, 1H, <i>J</i> = 12.0 Hz). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): Î´ 171.7, 148.7, 141.5, 138.8, 128.1 (2C), 127.8 (2C), 127.4, 125.9 (2C), 125.2 (2C), 72.4, 62.3, 59.0, 56.6, 44.2, 38.2, 34.8, 34.2, 31.9, 31.3 (4C), 30.1. HRMS: calcd for C<sub>27</sub>H<sub>38</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 439.2950; found, 439.2955.</div></div><div id="sec4_1_2_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<i>N</i>-((<b>1<i>S</i></b>,<b>2<i>S</i></b>)-1,3-Dihydroxy-1-phenylpropan-2-yl)-4-(4-methylphenethyl)piperidine-2-carboxamide ((<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>39</b>) and (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<i>N</i>-((<b>1<i>S</i></b>,<b>2<i>S</i></b>)-1,3-Dihydroxy-1-phenylpropan-2-yl)-4-(4-methylphenethyl)piperidine-2-carboxamide ((<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>39</b>)<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></h5><div class="NLM_p last">Compounds (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>39</b> (50 mg, 34%) and (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>39</b> (53 mg, 37%) were prepared from <b>28</b> (two steps) by a procedure similar to that used to prepare compound <b>11</b>. These two isomers could be separated by preparative TLC as colorless amorphous gels. Compound (<b>2<i>R</i></b>,<b>4<i>S</i></b>)-<b>39</b>: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): Î´ 7.46 (br s, 1H), 7.39 (d, 2H, <i>J</i> = 7.8 Hz), 7.31 (t, 2H, <i>J</i> = 7.8 Hz), 7.25 (t, 1H, <i>J</i> = 7.2 Hz), 7.09 (d, 2H, <i>J</i> = 8.4 Hz), 7.05 (d, 2H, <i>J</i> = 7.8 Hz), 4.97 (d, 1H, <i>J</i> = 4.2 Hz), 4.08 (d, 1H, <i>J</i> = 4.8 Hz), 3.69 (m, 1H), 3.58 (m, 1H), 3.15 (dd, 1H, <i>J</i> = 3.0 Hz, 12.0 Hz), 3.11 (m, 1H), 2.60 (m, 1H), 2.55 (t, 2H, <i>J</i> = 7.8 Hz), 2.31 (s, 3H), 1.86 (d, 1H, <i>J</i> = 13.2 Hz), 1.73 (d, 1H, <i>J</i> = 13.2 Hz), 1.50 (m, 2H), 1.42 (m, 1H), 1.09 (dq, 1H, <i>J</i> = 4.2 Hz, 12.6 Hz), 0.86 (q, 1H, <i>J</i> = 12.0 Hz). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): Î´ 174.3, 141.6, 139.1, 135.1, 128.9 (2C), 128.1 (2C), 128.0 (2C), 127.4, 126.0 (2C), 72.0, 61.9, 60.0, 56.5, 45.0, 38.6, 36.0, 35.0, 32.0, 31.5, 20.6. HRMS: calcd for C<sub>24</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 397.2486; found, 397.2490. Compound (<b>2<i>S</i></b>,<b>4<i>R</i></b>)-<b>39</b>: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): Î´ 7.45 (d, 1H, <i>J</i> = 8.4 Hz), 7.35 (d, 2H, <i>J</i> = 7.2 Hz), 7.25 (m, 2H), 7.18 (t, 1H, <i>J</i> = 7.2 Hz), 7.08 (d, 1H, <i>J</i> = 7.8 Hz), 7.02 (d, 1H, <i>J</i> = 8.4 Hz), 5.02 (d, 1H, <i>J</i> = 3.0 Hz), 4.65 (br s, 3H), 4.10 (m, 1H), 3.78 (m, 1H), 3.71 (m, 1H), 3.13 (d, 1H, <i>J</i> = 13.8 Hz), 2.94 (d, 1H, <i>J</i> = 12.0 Hz), 2.48 (t, 2H, <i>J</i> = 7.8 Hz), 2.41 (m, 1H), 2.31 (s, 3H), 1.74 (d, 1H, <i>J</i> = 12.0 Hz), 1.59 (d, 1H, <i>J</i> = 12.0 Hz), 1.39 (m, 2H), 1.31 (m, 1H), 0.90 (m, 1H), 0.78 (q, 1H, <i>J</i> = 12.6 Hz). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>): Î´ 173.5, 141.8, 139.1, 135.2, 129.1 (3C), 128.1 (3C), 127.4, 125.9 (2C), 72.7, 62.9, 59.8, 56.4, 44.7, 38.7, 36.1, 34.8, 32.1, 31.5, 21.0. HRMS: calcd for C<sub>24</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 397.2486; found, 397.2487.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> In Silico Molecular Docking</h3><div class="NLM_p last">Molecular modeling and ligand docking were performed in the Maestro (11.9) workspace using modules (LigPrep, Protein Preparation Wizard, IFD, and Glide) in the Small-Molecule Drug Discovery Suite (2019-1, SchrÃ¶dinger, LLC, New York, NY, 2017). The crystal structure of ergotamine-5-HT<sub>2C</sub>R (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>) was fetched from RCSB PDB bank and was preprocessed and optimized with the SchrÃ¶dinger Protein Preparation Wizard using default settings. All ligands (5-HT and 5-HT<sub>2C</sub>R PAMs) were created with Maestro 2D-sketcher and prepared with LigPrep to generate suitable 3D conformations for docking. IFD was used to dock 5-HT and replace ergotamine. For this initial model generation, a grid was applied via Glide on the ergotamineâ5-HT<sub>2C</sub>R structure centering on the indole N atom of ergotamine, as a representation of the orthosteric binding site. A new 5-HT-bound 5-HT<sub>2C</sub>R model was generated in this manner, allowing default flexibility and movement of amino acid residues surrounding the orthosteric site, now accommodating 5-HT. The 5-HT-bound 5-HT<sub>2C</sub>R model was exported as a single protein structure (both 5-HT and protein) and subsequently used for docking of the 5-HT<sub>2C</sub>R PAMs. No exclusion volumes were necessary to apply because of the presence of 5-HT in the orthosteric site. Compound <b>12</b> was pharmacologically validated as a 5-HT<sub>2C</sub>R PAM, thus <b>12</b> was docked to the model using the IFD protocol, allowing default residue flexibility. A rationally selected docking pose for <b>12</b> was used as a center for a new grid. This grid was applied for the standard docking of the remaining ligands, conducted with the Glide XP mode. All docked results were viewed in Maestro for visualization and clustering. Scoring functions (GScore) and biological and chemical rationale were used for ligand pose selection. For all ligands that were pharmacologically tested as a mixture of two isomers, both isomers were docked and analyzed. Visualization aids such as the protein surface predictions around the docking site were performed in the Maestro workspace.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Intracellular Calcium (Ca<sub>i</sub><sup>2+</sup>) Release Assay in h5-HT<sub>2</sub>RâCHO Cells</h3><div class="NLM_p last">The CHO cells stably transfected with the human unedited (INI) h5-HT<sub>2C</sub>R (h5-HT<sub>2C</sub>RâCHO cells) or the human h5-HT<sub>2A</sub>R (h5-HT<sub>2A</sub>RâCHO cells) were the generous gift from Drs. Kelly A. Berg and William P. Clarke (University of Texas Health Science Center, San Antonio). Cells were grown at 37 Â°C, 5% CO<sub>2</sub>, and 85% relative humidity environment in GlutaMax-MEM medium (Invitrogen, Carlsbad, CA) containing 5% fetal bovine serum (Atlanta Biologicals, Atlanta, GA) and 100 Î¼g/mL hygromycin (Mediatech, Manassas, VA) and were passaged when they reached 80% confluency. The Ca<sub>i</sub><sup>2+</sup> release assay was performed according to our recent publications.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Briefly, 14,000â16,000 cells/well [150 Î¼L; passages 6â16 (FlexStation 3; Molecular Devices) or 30,000 cells/well (FLIPR<sup>TETRA</sup>; Molecular Devices] were seeded in black-wall 96-well culture plates with optically clear flat bottoms. To ensure even plating of cells, the source reservoir was frequently agitated or triturated, and plates were maintained on a rotary shaker at a low speed for 20 min after plating and returned to the incubator overnight. Approximately 24 h after plating, the medium was replaced with the serum-free (SF) GlutaMax-MEM medium supplemented with 20 nM to 100 Î¼M putrescine (Sigma-Aldrich, St. Louis, MO), 20 nM to 100 Î¼M progesterone (Sigma-Aldrich), and 1:100 ITS (1000 mg/L of human recombinant insulin, 550 mg/L of human recombinant transferrin, and 0.67 mg/L of selenious acid; Corning Inc., Corning, NY) (SF + medium). Following a 3 h incubation, the SF + medium was replaced with 40 Î¼L of Hankâs balanced saline solution (HBSS; without CaCl<sub>2</sub> or MgCl<sub>2</sub>, pH 7.4) plus 40 Î¼L of calcium 4 dye solution (FLIPR No-wash kit, Molecular Devices, Sunnyvale CA, catalog no R8142) supplemented with 2.5 mM of water-soluble probenecid (Sigma-Aldrich) to inhibit extracellular transport of the dye. Plates were incubated with a dye solution for 60 min at 37 Â°C, 15 min at room temperature in the dark. Drug dilutions were prepared at 5Ã final concentration in 1Ã HBSS; delivery of compound (20 Î¼L/well) was followed 15 min later by 5-HT (10 pM to 10 Î¼M; 25 Î¼L/well). A baseline was established for each well before addition of the test compound and again before addition of 5-HT. The fluorescence read following the addition of 5-HT was used to assess allosteric modulation of 5-HT-evoked Ca<sub>i</sub><sup>2+</sup> release. Fluorescence was measured using FlexStation 3 (Molecular Devices) or FLIPR<sup>TETRA</sup> (130 gain, 60% intensity, and 0.3 s exposure). For FlexStation 3, a 17 s baseline was established before addition of compounds following which fluorescence was recorded every 1.7 s for a total 240 s. The maximum peak height was determined by SoftMax software (Pro 5.4.5) for each well. For FLIPR<sup>TETRA</sup>, a 10 s baseline was established before addition of compounds following which fluorescence was recorded every 1 s for 120 s following compound or for 360 s following 5-HT. The maximum peak height was determined by ScreenWorks 4.0 software for each well. After the final readings, cells were fixed in 2% paraformaldehyde (Sigma) overnight. The maximum 5-HT-induced Ca<sub>i</sub><sup>2+</sup> release (<i>E</i><sub>max</sub>) in the presence of test compound was determined using four-parameter nonlinear regression analysis (GraphPad Prism 7.04) and calculated from four to six biological replicates, each conducted in technical triplicates. The <i>E</i><sub>max</sub> for the test compound plus 5-HT was normalized to the <i>E</i><sub>max</sub> for 5-HT alone. Subsequent post hoc comparisons between means for <i>E</i><sub>max</sub> were made using Welchâs unpaired <i>t</i> test (GraphPad Prism). All statistical analyses were conducted with an experiment-wise error rate of Î± = 0.05. All treatment assignments were blinded to investigators who performed in vitro assays and end point statistical analyses.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> In Vivo PKs and Brain Penetration Analyses</h3><div class="NLM_p">Male SpragueâDawley rats (<i>n</i> = 3/treatment group; Charles River Laboratories) weighing 200â250 g at the beginning of the experiment were housed three per cage in a pathogen-free, temperature-controlled (20â26 Â°C), and humidity-controlled (40â70%) environment with a 12 h lightâdark cycle and ad libitum access to food and filtered water. Rats were randomly assigned to treatment groups. Vehicle [10% DMSO:90% HP-Î²-CD] or compound <b>12</b> dissolved in vehicle was administered to rats iv at 10 mg/kg or per os (po) at 20 mg/kg. Blood samples (0.3 mL) were collected from the retro-orbital sinus vein before dosing and at 0.08, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, and 24 h postdosing for iv administration and 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, and 24 h postdosing for po administration. The blood samples were placed in heparinized tubes and centrifuged at 12,000<i>g</i> for 5 min at 4 Â°C. Brain samples were collected at 0.25 and 1 h postdosing. All samples were stored at â20 Â°C. The concentration of <b>12</b> in each sample was analyzed by Sundia MediTech Co., Ltd. The study and the related standard operating procedures were reviewed and approved by the Sundia Institutional Animal Care and Use Committee. The Sundia animal facility is approved with yearly inspection by the Shanghai Laboratory Animal Management Committee.</div><div class="NLM_p last">The PK parameters of compound <b>12</b> were calculated according to a noncompartmental model using WinNonlin 8.1 (Pharsight Corporation, ver 5.3, Mountain View, CA, USA). The peak concentration (<i>C</i><sub>max</sub>) and time of peak concentration (<i>T</i><sub>max</sub>) were directly obtained from the plasma concentrationâtime plot. The elimination rate constant (Î») was obtained by the least-squares fitted terminal logâlinear portion of the slope of the plasma concentrationâtime profile. The elimination half-life (<i>t</i><sub>1/2</sub>) was evaluated according to 0.693/Î». The area under the plasma concentrationâtime curve from 0 to time <i>t</i> (AUC<sub>0â<i>t</i></sub>) was evaluated using the linear trapezoidal rule and further extrapolated to infinity (AUC<sub>0âinf</sub>) according to the following equation: AUC<sub>0âinf</sub> = AUC<sub>0â<i>t</i></sub> + <i>C</i><sub>last</sub>/Î». The PK parameters and brain concentrations are presented as mean Â± SEM. in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. All treatment assignments were blinded to investigators who performed PK assays and end point statistical analyses.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Effects of Compound <b>12</b> in a Drug Discrimination Assay</h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Drugs</h4><div class="NLM_p last">WAY163909 [(7b-<i>R</i>,10a-<i>R</i>)-1,2,3,4,8,9,10,10a-octahydro-7b<i>H</i>-cyclopenta[<i>b</i>][1,4] diazepino[6,7,1<i>hi</i>]indole] was a gift from Pfizer, Inc. (New York, NY) and was dissolved in 0.9% NaCl (vehicle employed for comparison to WAY163909). SB242084 [6-chloro-5-methyl-1-[[2-(2-methylpyrid-3-yloxy)pyrid-5-yl]carbamoyl]indoline dihydrochloride; Sigma Chemical Co., St. Louis, MO, USA] was dissolved in saline containing 10 mmol/L citric acid (Sigma Chemical Co.) and 8% 2-hydroxypropyl-Î²-cyclodextrin (Trappsol hydroxpropyl Î² cyclodextrin, pharmaceutical grade, Cyclodextrin Technologies Development Inc., High Springs, FL, USA) with the final pH of the solution adjusted to 5.6. SB242084, WAY163909, and compound <b>12</b> were injected ip at a volume of 1 mL/kg.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Animals</h4><div class="NLM_p last">Male SpragueâDawley rats (<i>n</i> = 13; Envigo) weighing 300â325 g (â¼60 days of age) at the beginning of the experiment were housed two per cage in a temperature- (21â23 Â°C) and humidity-controlled (45â50%) environment; lighting was maintained under a 12 h lightâdark cycle (0700â1900 h). Rats were maintained at 80â90% of their free-feeding weights by restricting access to water. Rats received water during daily training sessions (5â6 mL/rat/session), several hours after training (20 min), and over the weekend (36 h). Experiments were conducted during the light phase of the lightâdark cycle (between 0900 and 1200 h) and were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (2011) and with the approval of the Institutional Animal Care and Use Committee at the University of Texas Medical Branch.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Drug Discrimination Procedures</h4><div class="NLM_p">Full experimental details of the procedures and analyses have been previously described.<a onclick="showRef(event, 'ref23 ref34 ref41 ref49'); return false;" href="javascript:void(0);" class="ref ref23 ref34 ref41 ref49">(23,34,41,49)</a> Briefly, standard two-lever, water-reinforced drug discrimination procedures were used (Med Associates, St. Albans, USA). Each chamber was equipped with a water-filled dispenser mounted equidistantly between two retractable response levers on the wall and housed in a light- and sound-proof cubicle. Illumination came from a 28 V house light; ventilation and masking noise were provided by a ventilation fan. A computer with Med-PC IV software was used to run programs and record all experimental events.</div><div class="NLM_p">Rats were trained to discriminate an injection of WAY163909 (0.75 mg/kg; 1.0 mL/kg, ip) from saline (1.0 mL/kg, ip) administered 15 min before the beginning of training sessions. Daily sessions lasted 15 min and were conducted Monday through Friday. During the phase of errorless training, only the stimulus-appropriate (drug or saline) lever was present. Training began under a fixed ratio 1 (FR1) schedule of water reinforcement, and the FR requirement was incremented until all animals were responding reliably under an FR20 schedule for each experimental condition. Left and right levers were counterbalanced across rats for WAY163909/saline assignments. During this phase of training, WAY163909 and saline were administered randomly with the restriction that neither condition prevailed for more than three consecutive sessions. After responding stabilized, both levers were introduced simultaneously during 15 min training sessions. The rats were required to respond on the stimulus-appropriate (correct) lever to obtain water reinforcement. There were no programmed consequences for responding on the incorrect lever. This phase of training continued until the performance of all rats attained criterion (defined as mean accuracies of at least 80% stimulus-appropriate responding for 10 consecutive sessions).</div><div class="NLM_p last">Test sessions were initiated and conducted once or twice per week, with training sessions completed on intervening days. Rats were required to maintain accuracies >80% correct for saline and WAY163909 maintenance sessions, which immediately preceded all tests. During test sessions, animals were placed in the chambers and, upon completion of 20 responses on either lever, a single water reinforcer was delivered, and the house lights were turned off. The rat was removed from the chamber and returned to the colony. The test sessions were terminated after 15 min if the rats did not complete 20 responses on either lever; only data from rats that completed the test were included in data analysis. In substitution tests, rats were administered compound <b>12</b> (0.5, 1.0, 2.0, and 5.0 mg/kg, ip) 30 min before the beginning of the test. WAY163909 (0.125, 0.25, 0.5, 0.625, 0.75, or 1.0 mg/kg, ip), or saline was administered 15 min prior to the beginning of the test. In combination tests, rats were tested for lever selection following administration of compound <b>12</b> (0, 0.5, 1.0, or 2.0 mg/kg, ip) or vehicle 30 min and WAY163909 (0.5 mg/kg ip) or saline 15 min before the beginning of the test. In combination tests, SB242084 (0.5 mg/kg) was administered 15 min before administration of WAY163909. The dose of WAY163909 (0.5 mg/kg, ip) employed evoked â¼50% drug-appropriate responding. Full substitution was defined as â¥80% of rats selecting the WAY163909-appropriate lever. Partial substitution was defined as â¥40% and <80% drug-appropriate responding.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Statistical Analyses</h4><div class="NLM_p last">All treatment assignments were blinded to investigators who performed in vivo assays and end point statistical analyses. Rat performance in training and test sessions was expressed as the average percentage of rats selecting the WAY163909-associated lever because responding is typically a quantal rather than a continuous function of stimulus similarity in the two-choice drug discrimination assay.<a onclick="showRef(event, 'ref23 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref23 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42">(23,34â42)</a> Thus, intermediate doses of the training drug or substitution test responses are typically confined to one lever. During test sessions, the lever selection is defined by the initial FR20 schedule completion at which point the test terminates and the animal is removed from the chamber. Logistic regression analyses were used to determine the effects of increasing doses of WAY163909, compound <b>12</b>, or combination treatments on the probability that rats responded on the WAY163909-associated lever (binary response variable). The response rate (responses per minute) was calculated as the total number of responses emitted before completion of the first FR20 divided by the number of minutes taken to complete the first ratio. Response rates were analyzed using one-way ANOVA with Dunnettâs correction for comparisons to vehicle or control groups. Log-probit analyses were used to estimate the dose of WAY163909 predicted to elicit 50% WAY163909-associated lever responses (ED<sub>50</sub>). All statistical significance was set at an experimenter-wise error rate of Î± = 0.05.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01953" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01953?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01953</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Calculated physicochemical properties, radioligand binding data, cytotoxicity data, additional cellular assay data, docking protocol, and <sup>1</sup>H and <sup>13</sup>C NMR spectra for the compounds described in this paper (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Atomic coordinates of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings of PAM2 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_001.pdf">jm9b01953_si_001.pdf (3.82 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_002.pdb">jm9b01953_si_002.pdb (283.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_003.csv">jm9b01953_si_003.csv (2.42 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01953" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noelle C. Anastasio</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Chemical
Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5579-4213" title="Orcid link">http://orcid.org/0000-0001-5579-4213</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#89e7eae8e7e8fafde8c9fcfde4eba7ecedfc"><span class="__cf_email__" data-cfemail="026c61636c637176634277766f602c676677">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathryn A. Cunningham</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Chemical
Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4257-1739" title="Orcid link">http://orcid.org/0000-0002-4257-1739</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#91faf2e4fffff8fff6d1e4e5fcf3bff4f5e4"><span class="__cf_email__" data-cfemail="5a31392f343433343d1a2f2e3738743f3e2f">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Zhou</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Chemical
Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2811-1090" title="Orcid link">http://orcid.org/0000-0002-2811-1090</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b9d3d0c3d1d6ccf9cccdd4db97dcddcc"><span class="__cf_email__" data-cfemail="9df7f4e7f5f2e8dde8e9f0ffb3f8f9e8">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric A. Wold</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Chemical
Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6434-7562" title="Orcid link">http://orcid.org/0000-0001-6434-7562</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erik J. Garcia</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher T. Wild</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Chemical
Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joanna M. Miszkiel</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudia A. Soto</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5214-9136" title="Orcid link">http://orcid.org/0000-0002-5214-9136</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianping Chen</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Chemical
Biology Program and the Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Konrad Pazdrak</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert G. Fox</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>E.A.C., E.J.G., and C.T.W. contributed equally to this work. J.Z., K.A.C., and N.C.A. developed the concepts and approaches as well as supervised the work. E.A.W, C.T.W., and J.C. synthesized, purified, and characterized the reported compounds. E.A.W. performed the molecular docking and computational modeling. E.J.G., N.C.A., K.A.C, J.M.M., C.A.S., and K.P. performed and/or analyzed the in vitro cellular studies. E.J.G., R.G.F., K.A.C., and N.C.A. performed and/or analyzed the in vivo studies. E.A.W., E.J.G., K.A.C., N.C.A., and J.Z., wrote the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24428" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24428" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants R21 MH093844 (J.Z./K.A.C.), R01 DA038446 (J.Z./K.A.C.), K05 DA020087 (K.A.C.), P30 DA28821 (K.A.C.), T32 DA07287 (C.T.W. and E.A.W.), F31 DA038922 (C.T.W.), DA038446-S1 (E.J.G.), and F31 DA045511 (E.A.W.) from the National Institutes of Health, the John D. Stobo, M.D. Distinguished Chair Endowment Fund (J.Z.), the Center for Addiction Research at UTMB, R.A. Welch Foundation Chemistry and Biology Collaborative Grant from Gulf Coast Consortia (GCC) for Chemical Genomics, a training fellowship from the Keck Center for Interdisciplinary Bioscience Training of the GCC (NIGMS grant T32 GM089657-03 (C.T.W.), Sealy and Smith Foundation grant (to the Sealy Center for Structural Biology and Molecular Biophysics), and the John Sealy Memorial Endowment Fund. We thank Drs. Lawrence C. Sowers, Jason Herring, and Tianzhi Wang for the NMR spectroscopy assistance; Sonja J. Stutz assisted in some in vivo studies; Claudia M. Crawford, Carrie E. McAllister, and K.P. for conducting in vitro assays; and Marcy B. Jordan for helpful discussions during the development of this project. Receptor binding profiles and agonist functional data were generously provided by the National Institute of Mental Health Psychoactive Drug Screening Program (PDSP), contract no. HHSN-271-2013-00017-C (NIMH PDSP). The NIMH PDSP is directed by Dr. Bryan L. Roth at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda MD, USA.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">serotonin</p></td></tr><tr><td class="NLM_term">5-HT<sub>2A</sub>R</td><td class="NLM_def"><p class="first last">5-HT<sub>2A</sub> receptor</p></td></tr><tr><td class="NLM_term">5-HT<sub>2B</sub>R</td><td class="NLM_def"><p class="first last">5-HT<sub>2B</sub> receptor</p></td></tr><tr><td class="NLM_term">5-HT<sub>2C</sub>R</td><td class="NLM_def"><p class="first last">5-HT<sub>2C</sub> receptor</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">SUD</td><td class="NLM_def"><p class="first last">substance use disorder</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term">BMI</td><td class="NLM_def"><p class="first last">body mass index</p></td></tr><tr><td class="NLM_term">PAM</td><td class="NLM_def"><p class="first last">positive allosteric modulator</p></td></tr><tr><td class="NLM_term">NAM</td><td class="NLM_def"><p class="first last">negative allosteric modulator</p></td></tr><tr><td class="NLM_term">LT</td><td class="NLM_def"><p class="first last">lipophilic tail</p></td></tr><tr><td class="NLM_term">PH</td><td class="NLM_def"><p class="first last">polar head</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>,<i>N</i>â²,<i>N</i>â²-tetramethyl-<i>O</i>-(1<i>H</i>-benzotriazol-1-yl)uronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">PTLC</td><td class="NLM_def"><p class="first last">preparative thin layer chromatographic</p></td></tr><tr><td class="NLM_term">PLCÎ²</td><td class="NLM_def"><p class="first last">phospholipase CÎ²</p></td></tr><tr><td class="NLM_term">IP3</td><td class="NLM_def"><p class="first last">inositol-1,4,5-trisphosphate</p></td></tr><tr><td class="NLM_term">DAG</td><td class="NLM_def"><p class="first last">diacylglycerol</p></td></tr><tr><td class="NLM_term">Ca<sub>i</sub><sup>2+</sup></td><td class="NLM_def"><p class="first last">intracellular calcium</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">HP-Î²-CD</td><td class="NLM_def"><p class="first last">2-hydroxypropyl-Î²-cyclodextrin</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time of maximum concentration</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">plasma clearance</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">AUC<sub>0âinf</sub></td><td class="NLM_def"><p class="first last">area under the plasma concentrationâtime curve</p></td></tr><tr><td class="NLM_term">F</td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">IP</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">MadinâDarby Canine Kidney</p></td></tr><tr><td class="NLM_term">MPO</td><td class="NLM_def"><p class="first last">multiparameter optimization</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PLD</td><td class="NLM_def"><p class="first last">phospholipase D</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">ECL</td><td class="NLM_def"><p class="first last">extracellular loop</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane helix</p></td></tr><tr><td class="NLM_term">SVM</td><td class="NLM_def"><p class="first last">support vector machine</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23026" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23026" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Positive-allosteric modulation of the 5-HT2C receptor: implications for neuropsychopharmacology and neurotherapeutics</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">230</span>â <span class="NLM_lpage">231</span>, <span class="refDoi">Â DOI: 10.1038/s41386-018-0190-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1038%2Fs41386-018-0190-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=30202047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSrs73N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=230-231&author=J.+Zhouauthor=K.+A.+Cunningham&title=Positive-allosteric+modulation+of+the+5-HT2C+receptor%3A+implications+for+neuropsychopharmacology+and+neurotherapeutics&doi=10.1038%2Fs41386-018-0190-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Positive-allosteric modulation of the 5-HT2C receptor: implications for neuropsychopharmacology and neurotherapeutics</span></div><div class="casAuthors">Zhou, Jia; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">230-231</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review discussing pos.-allosteric modulation of the 5-HT2C receptor.  It also discusses its implications for neuropsychopharmacol. and neurotherapeutics.  It also highlights that, the chem. space for discovery of novel 5-HT2CR neuroprobes and therapeutics is now expanding to include allosteric 5-HT2CR modulators, providing the opportunity to explore cellular mechanisms of action, functional selectivity, neurochem. mechanisms, and neural sites of action for 5-HT2CR to control behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqGHrgKPZJYLVg90H21EOLACvtfcHk0li_8u9uuOQPyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSrs73N&md5=5a8f0c89577ad512d644be04b90bd37b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0190-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0190-x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DPositive-allosteric%2520modulation%2520of%2520the%25205-HT2C%2520receptor%253A%2520implications%2520for%2520neuropsychopharmacology%2520and%2520neurotherapeutics%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D230%26epage%3D231%26doi%3D10.1038%2Fs41386-018-0190-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tecott, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akana, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strack, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowenstein, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallman, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julius, D.</span></span> <span> </span><span class="NLM_article-title">Eating Disorder and Epilepsy in Mice Lacking 5-HT2c Serotonin Receptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">542</span>â <span class="NLM_lpage">546</span>, <span class="refDoi">Â DOI: 10.1038/374542a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1038%2F374542a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=7700379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaK2MXkvVKqtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=1995&pages=542-546&author=L.+H.+Tecottauthor=L.+M.+Sunauthor=S.+F.+Akanaauthor=A.+M.+Strackauthor=D.+H.+Lowensteinauthor=M.+F.+Dallmanauthor=D.+Julius&title=Eating+Disorder+and+Epilepsy+in+Mice+Lacking+5-HT2c+Serotonin+Receptors&doi=10.1038%2F374542a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors</span></div><div class="casAuthors">Tecott, Laurence H.; Sun, Linda M.; Akana, Susan F.; Strack, Alison M.; Lowenstein, Daniel H.; Dallman, Mary F.; Julius, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">6522</span>),
    <span class="NLM_cas:pages">542-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Serotonin (5-hydroxytryptamine, 5-HT) is a monoaminergic neurotransmitter that is believed to modulate numerous sensory, motor and behavioral processes in the mammalian nervous system.  These diverse responses are elicited through the activation of a large family of receptor subtypes.  The complexity of this signalling system and the paucity of selective drugs have made it difficult to define specific roles for 5-HT receptor subtypes, or to det. how serotonergic drugs modulate mood and behavior.  To address these issues, we have generated mutant mice lacking functional 5-HT2C receptors (previously termed 5-HT1C), prominent G-protein-coupled receptors that are widely expressed throughout the brain and spinal cord and which have been proposed to mediate numerous central nervous system (CNS) actions of serotonin.  Here we show that 5-HT2C receptor-deficient mice are overweight as a result of abnormal control of feeding behavior, establishing a role for this receptor in the serotonergic control of appetite.  Mutant animals are also prone to spontaneous death from seizures, suggesting that 5-HT2C receptors mediate tonic inhibition of neuronal network excitability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyfCSY65mvybVg90H21EOLACvtfcHk0lhNjAcdkgAlNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvVKqtr4%253D&md5=e87d8eac0789c2c012c34717d1fdbfe0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F374542a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F374542a0%26sid%3Dliteratum%253Aachs%26aulast%3DTecott%26aufirst%3DL.%2BH.%26aulast%3DSun%26aufirst%3DL.%2BM.%26aulast%3DAkana%26aufirst%3DS.%2BF.%26aulast%3DStrack%26aufirst%3DA.%2BM.%26aulast%3DLowenstein%26aufirst%3DD.%2BH.%26aulast%3DDallman%26aufirst%3DM.%2BF.%26aulast%3DJulius%26aufirst%3DD.%26atitle%3DEating%2520Disorder%2520and%2520Epilepsy%2520in%2520Mice%2520Lacking%25205-HT2c%2520Serotonin%2520Receptors%26jtitle%3DNature%26date%3D1995%26volume%3D374%26spage%3D542%26epage%3D546%26doi%3D10.1038%2F374542a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, T.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Lv, J.</span>; <span class="NLM_string-name">Song, Y.</span>; <span class="NLM_string-name">Fan, J.</span>; <span class="NLM_string-name">Liu, W.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Hall, F. S.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Cui, R.</span></span> <span> </span><span class="NLM_article-title">The role of 5-HT<sub>2c</sub> receptor on corticosterone-mediated food intake</span>.  <i>J. Biochem. Mol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">31</span>, DOI: <span class="refDoi">Â DOI: 10.1002/jbt.21890</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1002%2Fjbt.21890" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&author=T.+Ge&author=Z.+Zhang&author=J.+Lv&author=Y.+Song&author=J.+Fan&author=W.+Liu&author=X.+Wang&author=F.+S.+Hall&author=B.+Li&author=R.+Cui&title=The+role+of+5-HT2c+receptor+on+corticosterone-mediated+food+intake&doi=10.1002%2Fjbt.21890"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fjbt.21890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbt.21890%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DT.%26atitle%3DThe%2520role%2520of%25205-HT2c%2520receptor%2520on%2520corticosterone-mediated%2520food%2520intake%26jtitle%3DJ.%2520Biochem.%2520Mol.%2520Toxicol.%26date%3D2017%26volume%3D31%26doi%3D10.1002%2Fjbt.21890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halford, J. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawton, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, J. E.</span></span> <span> </span><span class="NLM_article-title">The 5-HT2 Receptor Agonist MK-212 Reduces Food Intake and Increases Resting but Prevents the Behavioural Satiety Sequence</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">41</span>â <span class="NLM_lpage">46</span>, <span class="refDoi">Â DOI: 10.1016/s0091-3057(96)00152-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2FS0091-3057%2896%2900152-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=8981607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaK2sXisVGisw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1997&pages=41-46&author=J.+C.+G.+Halfordauthor=C.+L.+Lawtonauthor=J.+E.+Blundell&title=The+5-HT2+Receptor+Agonist+MK-212+Reduces+Food+Intake+and+Increases+Resting+but+Prevents+the+Behavioural+Satiety+Sequence&doi=10.1016%2Fs0091-3057%2896%2900152-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The 5-HT2 receptor agonist MK-212 reduces food intake and increases resting but prevents the Behavioral Satiety Sequence</span></div><div class="casAuthors">Halford, J. C. G.; Lawton, C. L.; Blundell, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-46</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The 5-HT2C receptor is implicated in the relation between serotonin and satiety.  However, anorexia induced by the 5-HT2 receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) has been shown to delay, not advance behaviors assocd. with the onset of satiety, fragmenting eating behavior.  6-Chloro-2-(1-piperazinyl)pyrazine (MK-212) is also a selective agonist at the 5-HT2 receptor sites.  MK-212 has greater affinity for 5-HT2C receptor sites than DOI.  The effects of an ED50 dose of MK-212 (5.0 mg/kg i.p.) on the eating and other behaviors of the fasted rat were continuously monitored following the presentation of food.  Continuous monitoring provides the most powerful and valid form of behavioral anal.  Temporal profiles of behavior duration (dur) and frequency (frq) were generated.  Food intake was reduced 54% by MK-212.  The frequency of grooming was reduced.  Locomotion (dur, frq), rearing (dur, frq) and sniffing (dur) were all reduced.  The duration of resting increased.  This is consistent with enhanced satiety.  However, the Behavioral Satiety Sequence was not present after the administration of MK-212 (5.0 mg/kg).  The temporal structure of behavior produced by MK-212 was quite different from that produced by pre-feeding.  Initially resting dominated the behavioral profile.  Eating increased over time from a suppressed state in the initial stages of the observation period.  This lack of appearance of the Behavioral Satiety Sequence is more similar to a state of hyper-sedation than to DOI induced hyper-activity.  The time course of this sedation would not have been picked up by a simple categorical anal. of behavior.  Hence, temporal anal. is an essential tool in understanding of drug induced anorexia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOl2sgJTHwG7Vg90H21EOLACvtfcHk0lhfdR6emXru5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisVGisw%253D%253D&md5=c37e7ff0178331c157154df5d765a4ef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2896%2900152-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252896%252900152-9%26sid%3Dliteratum%253Aachs%26aulast%3DHalford%26aufirst%3DJ.%2BC.%2BG.%26aulast%3DLawton%26aufirst%3DC.%2BL.%26aulast%3DBlundell%26aufirst%3DJ.%2BE.%26atitle%3DThe%25205-HT2%2520Receptor%2520Agonist%2520MK-212%2520Reduces%2520Food%2520Intake%2520and%2520Increases%2520Resting%2520but%2520Prevents%2520the%2520Behavioural%2520Satiety%2520Sequence%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1997%26volume%3D56%26spage%3D41%26epage%3D46%26doi%3D10.1016%2Fs0091-3057%2896%2900152-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. J.</span></span> <span> </span><span class="NLM_article-title">Agonists of the Serotonin 5-HT2C Receptor: Preclinical and Clinical Progression in Multiple Diseases</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">438</span>â <span class="NLM_lpage">445</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=18600561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFWmtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=438-445&author=D.+A.+Wackerauthor=K.+J.+Miller&title=Agonists+of+the+Serotonin+5-HT2C+Receptor%3A+Preclinical+and+Clinical+Progression+in+Multiple+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases</span></div><div class="casAuthors">Wacker, Dean A.; Miller, Keith J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-445</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  The serotonin 5-HT2C receptor is a G-protein-coupled receptor and is 1 of the 14 subtypes that constitute the serotonin receptor family.  Agonists of 5-HT2C have been implicated as potential treatments for diseases of significant unmet medical need, including obesity and schizophrenia.  Despite approx. 10 years of discovery efforts, 5-HT2C agonists have only recently advanced into the clinic, likely because many of the early drug discovery efforts experienced significant difficulties with attaining receptor selectivity.  Several of these issues related to receptor selectivity have now been overcome, resulting in the entry of compds. into advanced clin. trials.  This review summarizes the progress in 5-HT2C agonist discovery and clin. development over the last 3 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1eDgqANEVarVg90H21EOLACvtfcHk0lgyhSIBIbJtmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFWmtbk%253D&md5=cd06a22cee150e5a0c658a4ce8876151</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26atitle%3DAgonists%2520of%2520the%2520Serotonin%25205-HT2C%2520Receptor%253A%2520Preclinical%2520and%2520Clinical%2520Progression%2520in%2520Multiple%2520Diseases%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2008%26volume%3D11%26spage%3D438%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabb, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazandarani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgaonker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukhina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukoff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig-Lipson, S.</span></span> <span> </span><span class="NLM_article-title">WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-selective Agonist with Anorectic Activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">862</span>â <span class="NLM_lpage">869</span>, <span class="refDoi">Â DOI: 10.1124/jpet.104.075382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1124%2Fjpet.104.075382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=15705738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFemtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2005&pages=862-869&author=J.+Dunlopauthor=A.+L.+Sabbauthor=H.+Mazandaraniauthor=J.+Zhangauthor=S.+Kalgaonkerauthor=E.+Shukhinaauthor=S.+Sukoffauthor=R.+L.+Vogelauthor=G.+Stackauthor=L.+Schechterauthor=B.+L.+Harrisonauthor=S.+Rosenzweig-Lipson&title=WAY-163909+%5B%287bR%2C+10aR%29-1%2C2%2C3%2C4%2C8%2C9%2C10%2C10a-Octahydro-7bH-cyclopenta-%5Bb%5D%5B1%2C4%5Ddiazepino%5B6%2C7%2C1hi%5Dindole%5D%2C+a+Novel+5-Hydroxytryptamine+2C+Receptor-selective+Agonist+with+Anorectic+Activity&doi=10.1124%2Fjpet.104.075382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino [6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity</span></div><div class="casAuthors">Dunlop, John; Sabb, Annmarie L.; Mazandarani, Hossein; Zhang, Jean; Kalgaonker, Sachin; Shukhina, Eugenia; Sukoff, Stacey; Vogel, Robert L.; Stack, Gary; Schechter, Lee; Harrison, Boyd L.; Rosenzweig-Lipson, Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">862-869</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacol. profile of WAY-163909, a novel 5-hydroxytryptamine (HT)2c (serotonin) receptor-selective agonist is presented.  WAY-163909 displaced [125I]2,5-dimethoxy-4-iodoamphetamine binding from human 5-HT2C receptor sites, in Chinese hamster ovary (CHO) cell membranes, with a Ki value of 10.5Â±1.1 nM.  Binding affinities detd. for the human 5-HT2A and 5-HT2B receptor subtypes were 212 and 485 nM, resp.  In functional studies, WAY-163909 stimulated the mobilization of intracellular calcium in CHO cells stably expressing the human 5-HT2C receptor with an EC50 value of 8 nM, and Emax relative to 5-HT of 90%.  WAY-163909 failed to stimulate calcium mobilization in cells expressing the human 5-HT2A receptor subtype (EC50 >> 10 Î¼M) and was a 5-HT2B receptor partial agonist (EC50 185 nM, Emax 40%).  WAY-163909 exhibited negligible affinity (<50% inhibition at 1 Î¼M) for other receptor sites examd., including human 5-HT1A, D2, and D3 receptors, and the 5-HT transporter binding site in rat cortical membranes.  WAY-163909 exhibited weak affinity for the human D4 (245 nM) and 5-HT7 (343 nM) receptor subtypes and the Î±1 binding site in rat cortical membranes (665 nM).  WAY-163909 produced a dose-dependent redn. in food intake in normal Sprague-Dawley rats (ED50 = 2.93 mg/kg), an effect blocked by a 5-HT2C receptor antagonist but not by a 5-HT2A or 5-HT2B receptor antagonist.  In addn., WAY-163909 decreased food intake in obese Zucker rats and diet-induced obese mice with ED50 values of 1.4 and 5.19 mg/kg i.p., resp., consistent with the potential utility of 5-HT2C receptor agonists as antiobesity agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_JwPfydNYXbVg90H21EOLACvtfcHk0lhMou0w1Dk_8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFemtrs%253D&md5=b168e527f17783126505de7e522a3b23</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.075382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.075382%26sid%3Dliteratum%253Aachs%26aulast%3DDunlop%26aufirst%3DJ.%26aulast%3DSabb%26aufirst%3DA.%2BL.%26aulast%3DMazandarani%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKalgaonker%26aufirst%3DS.%26aulast%3DShukhina%26aufirst%3DE.%26aulast%3DSukoff%26aufirst%3DS.%26aulast%3DVogel%26aufirst%3DR.%2BL.%26aulast%3DStack%26aufirst%3DG.%26aulast%3DSchechter%26aufirst%3DL.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26atitle%3DWAY-163909%2520%255B%25287bR%252C%252010aR%2529-1%252C2%252C3%252C4%252C8%252C9%252C10%252C10a-Octahydro-7bH-cyclopenta-%255Bb%255D%255B1%252C4%255Ddiazepino%255B6%252C7%252C1hi%255Dindole%255D%252C%2520a%2520Novel%25205-Hydroxytryptamine%25202C%2520Receptor-selective%2520Agonist%2520with%2520Anorectic%2520Activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D313%26spage%3D862%26epage%3D869%26doi%3D10.1124%2Fjpet.104.075382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howell, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Serotonin 5-HT<sub>2</sub> Receptor Interactions with Dopamine Function: Implications for Therapeutics in Cocaine Use Disorder</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">176</span>â <span class="NLM_lpage">197</span>, <span class="refDoi">Â DOI: 10.1124/pr.114.009514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1124%2Fpr.114.009514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=25505168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Oms7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=176-197&author=L.+L.+Howellauthor=K.+A.+Cunningham&title=Serotonin+5-HT2+Receptor+Interactions+with+Dopamine+Function%3A+Implications+for+Therapeutics+in+Cocaine+Use+Disorder&doi=10.1124%2Fpr.114.009514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder</span></div><div class="casAuthors">Howell, Leonard L.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-197, 22 pp.</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Cocaine exhibits prominent abuse liability, and chronic abuse can result in cocaine use disorder with significant morbidity.  Major advances have been made in delineating neurobiol. mechanisms of cocaine abuse; however, effective medications to treat cocaine use disorder remain to be discovered.  The present review will focus on the role of serotonin (5-HT; 5-hydroxytryptamine) neurotransmission in the neuropharmacol. of cocaine and related abused stimulants.  Extensive research suggests that the primary contribution of 5-HT to cocaine addiction is a consequence of interactions with dopamine (DA) neurotransmission.  The literature on the neurobiol. and behavioral effects of cocaine is well developed, so the focus of the review will be on cocaine with inferences made about other monoamine uptake inhibitors and releasers based on mechanistic considerations. 5-HT receptors are widely expressed throughout the brain, and several different 5-HT receptor subtypes have been implicated in mediating the effects of endogenous 5-HT on DA.  However, the 5-HT2A and 5-HT2C receptors in particular have been implicated as likely candidates for mediating the influence of 5-HT in cocaine abuse as well as to traits (e.g., impulsivity) that contribute to the development of cocaine use disorder and relapse in humans.  Lastly, new approaches are proposed to guide targeted development of serotonergic ligands for the treatment of cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrr8S3_2aD27Vg90H21EOLACvtfcHk0li6zSDgRdofSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Oms7w%253D&md5=f16fdf974beaa29f82770b9efdb43363</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009514%26sid%3Dliteratum%253Aachs%26aulast%3DHowell%26aufirst%3DL.%2BL.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DSerotonin%25205-HT2%2520Receptor%2520Interactions%2520with%2520Dopamine%2520Function%253A%2520Implications%2520for%2520Therapeutics%2520in%2520Cocaine%2520Use%2520Disorder%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D176%26epage%3D197%26doi%3D10.1124%2Fpr.114.009514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bubar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K.</span></span> <span> </span><span class="NLM_article-title">Prospects for Serotonin 5-HT2R Pharmacotherapy in Psychostimulant Abuse</span>. <i>Prog. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">319</span>â <span class="NLM_lpage">346</span>, <span class="refDoi">Â DOI: 10.1016/s0079-6123(08)00916-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2FS0079-6123%2808%2900916-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=18772040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2isbvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2008&pages=319-346&author=M.+Bubarauthor=K.+Cunningham&title=Prospects+for+Serotonin+5-HT2R+Pharmacotherapy+in+Psychostimulant+Abuse&doi=10.1016%2Fs0079-6123%2808%2900916-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse</span></div><div class="casAuthors">Bubar, Marcy J.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Brain Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">Serotonin-Dopamine Interaction</span>),
    <span class="NLM_cas:pages">319-346</span>CODEN:
                <span class="NLM_cas:coden">PBRRA4</span>;
        ISSN:<span class="NLM_cas:issn">0079-6123</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The serotonin (5-HT) neurotransmitter system provides fundamental modulatory regulation of the limbic-corticostriatal circuitry known to be vital in the development of addiction as well as the aspects of addiction that hinder recovery and contribute to relapse.  Thus, components of the 5-HT system may provide novel targets for the development of pharmacol. treatments for psychostimulant dependence, which is assocd. with significant aberrations in dopamine (DA) neurotransmission.  Two key modulators of DA signalling within the limbic-corticostriatal circuit are the 5-HT2A receptor (5-HT2AR) and the 5-HT2CR.  These receptors are known to control the neurochem. and behavioral effects of psychostimulants, and in particular the in vivo effects of cocaine.  Pre-clin. studies indicate that 5-HT2AR antagonists and/or 5-HT2CR agonists may effectively reduce craving and/or relapse, and likewise, enhance abstinence, while 5-HT2CR agonists may also effectively reduce cocaine intake in active cocaine users.  At present, the progression of studies to probe the effectiveness of 5-HT2AR and 5-HT2CR ligands in the clin. setting is hindered by a lack of available, selective 5-HT2AR antagonists or 5-HT2CR agonists for use in human cocaine abusers.  However, a no. of selective 5-HT2R ligands currently under development, or in early clin. trials for psychiatric and/or neurol. disorders, may soon be available for translational studies to explore their effectiveness in modulating drug use and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyn3HB6wnKjbVg90H21EOLACvtfcHk0lgq0KX-CI-iVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2isbvF&md5=6548a0982d3149c005857224efa2fd79</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0079-6123%2808%2900916-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6123%252808%252900916-3%26sid%3Dliteratum%253Aachs%26aulast%3DBubar%26aufirst%3DM.%26aulast%3DCunningham%26aufirst%3DK.%26atitle%3DProspects%2520for%2520Serotonin%25205-HT2R%2520Pharmacotherapy%2520in%2520Psychostimulant%2520Abuse%26jtitle%3DProg.%2520Brain%2520Res.%26date%3D2008%26volume%3D172%26spage%3D319%26epage%3D346%26doi%3D10.1016%2Fs0079-6123%2808%2900916-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sears, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emeson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiLeone, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Functional Status of the Serotonin 5-HT2C Receptor (5-HT2CR) Drives Interlocked Phenotypes that Precipitate Relapse-like Behaviors in Cocaine Dependence</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">360</span>â <span class="NLM_lpage">372</span>, <span class="refDoi">Â DOI: 10.1038/npp.2013.199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1038%2Fnpp.2013.199" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=360-372&author=N.+C.+Anastasioauthor=S.+J.+Stutzauthor=R.+G.+Foxauthor=R.+M.+Searsauthor=R.+B.+Emesonauthor=R.+J.+DiLeoneauthor=R.+T.+O%E2%80%99Neilauthor=L.+H.+Finkauthor=D.+Liauthor=T.+A.+Greenauthor=F.+G.+Moellerauthor=K.+A.+Cunningham&title=Functional+Status+of+the+Serotonin+5-HT2C+Receptor+%285-HT2CR%29+Drives+Interlocked+Phenotypes+that+Precipitate+Relapse-like+Behaviors+in+Cocaine+Dependence&doi=10.1038%2Fnpp.2013.199"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.199%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DStutz%26aufirst%3DS.%2BJ.%26aulast%3DFox%26aufirst%3DR.%2BG.%26aulast%3DSears%26aufirst%3DR.%2BM.%26aulast%3DEmeson%26aufirst%3DR.%2BB.%26aulast%3DDiLeone%26aufirst%3DR.%2BJ.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DR.%2BT.%26aulast%3DFink%26aufirst%3DL.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DT.%2BA.%26aulast%3DMoeller%26aufirst%3DF.%2BG.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DFunctional%2520Status%2520of%2520the%2520Serotonin%25205-HT2C%2520Receptor%2520%25285-HT2CR%2529%2520Drives%2520Interlocked%2520Phenotypes%2520that%2520Precipitate%2520Relapse-like%2520Behaviors%2520in%2520Cocaine%2520Dependence%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D360%26epage%3D372%26doi%3D10.1038%2Fnpp.2013.199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neelakantan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Lorcaserin Suppresses Oxycodone Self-administration and Relapse Vulnerability in Rats</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1065</span>â <span class="NLM_lpage">1073</span>, <span class="refDoi">Â DOI: 10.1021/acschemneuro.6b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Klt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1065-1073&author=H.+Neelakantanauthor=E.+D.+Hollidayauthor=R.+G.+Foxauthor=S.+J.+Stutzauthor=S.+D.+Comerauthor=M.+Haneyauthor=N.+C.+Anastasioauthor=F.+G.+Moellerauthor=K.+A.+Cunningham&title=Lorcaserin+Suppresses+Oxycodone+Self-administration+and+Relapse+Vulnerability+in+Rats&doi=10.1021%2Facschemneuro.6b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats</span></div><div class="casAuthors">Neelakantan, Harshini; Holliday, Erica D.; Fox, Robert G.; Stutz, Sonja J.; Comer, Sandra D.; Haney, Margaret; Anastasio, Noelle C.; Moeller, F. Gerard; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1065-1073</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Opioid use disorder (OUD) is a major public health problem.  High relapse rates and poor treatment retention continue to pose major challenges in OUD treatment.  Of the abused opioids, oxycodone is well described to maintain self-administration and evoke the durable conditioned responses ("cue reactivity") that result from pairing of opioid-related stimuli (e.g., paraphernalia) with repeated abuse.  Serotonin (5-HT) neurotransmission, particularly through the 5-HT2C receptor (5-HT2CR), regulates psychostimulant reward and cue reactivity, and in the present expts., the authors investigated the hypothesis that the selective 5-HT2CR agonist lorcaserin, which is FDA-approved for the treatment of obesity, will suppress oxycodone self-administration and oxycodone-assocd. cue reactivity in rats.  The authors found that lorcaserin inhibited oxycodone intake, an effect blocked by the selective 5-HT2CR antagonist SB242084.  Lorcaserin also decreased responding for the discrete cue complex ("cue reactivity") previously assocd. with delivery of oxycodone (i.e., stimulus lights, infusion pump sounds) in both abstinence and extinction-reinstatement models.  The selected dose range of lorcaserin (0.25-1 mg/kg) does not overtly alter spontaneous behaviors nor operant responding on inactive levers in the present study.  Taken together, the ability of lorcaserin to reduce the oxycodone self-administration and decrease cue reactivity assocd. with relapse highlights the therapeutic potential for lorcaserin in the treatment of OUD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmhGr8KOEwb7Vg90H21EOLACvtfcHk0ljVJqgw3_4RIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Klt7k%253D&md5=e67d9cd3074b5ea47b43d870b34e12b7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00413%26sid%3Dliteratum%253Aachs%26aulast%3DNeelakantan%26aufirst%3DH.%26aulast%3DHolliday%26aufirst%3DE.%2BD.%26aulast%3DFox%26aufirst%3DR.%2BG.%26aulast%3DStutz%26aufirst%3DS.%2BJ.%26aulast%3DComer%26aufirst%3DS.%2BD.%26aulast%3DHaney%26aufirst%3DM.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DMoeller%26aufirst%3DF.%2BG.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DLorcaserin%2520Suppresses%2520Oxycodone%2520Self-administration%2520and%2520Relapse%2520Vulnerability%2520in%2520Rats%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D1065%26epage%3D1073%26doi%3D10.1021%2Facschemneuro.6b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Innovative Therapeutic Intervention for Opioid Use Disorder</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">220</span>â <span class="NLM_lpage">221</span>, <span class="refDoi">Â DOI: 10.1038/npp.2017.192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1038%2Fnpp.2017.192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=29192668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCrs7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=220-221&author=F.+G.+Moellerauthor=K.+A.+Cunningham&title=Innovative+Therapeutic+Intervention+for+Opioid+Use+Disorder&doi=10.1038%2Fnpp.2017.192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Innovative Therapeutic Intervention For Opioid Use Disorder</span></div><div class="casAuthors">Moeller, F. Gerard; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">220-221</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The United States is in the grip of an opioid misuse and overdose crisis.  Progression from misuse to opioid use disorder (OUD) is marked by compulsive drug-taking and clin. significant impairment.  Behavioral interventions along with treatment with OUD pharmacotherapeutics, such as buprenorphine, mitigates withdrawal, reduces mortality, opioid intake, and opioid-seeking behaviors, as well as improves psychosocial functioning (Volkow et al, 2014).  Medication-assisted treatment is an important adjunct to the proper management of OUD patients, yet addnl. opportunities exist to enhance the probability of extended abstinence and recovery from OUD.  Dysregulation of the limbic-corticostriatal circuitry that subserves reward and adaptive behaviors contributes to OUD development as well as the vulnerability to relapse during abstinence.  Serotonin (5-HT) neurotransmission confers modulatory control over this circuitry, particularly through the 5-HT2C receptor (5-HT2CR) (for review) (Cunningham and Anastasio, 2014).  Selective 5-HT2CR agonists, which lack intrinsic abuse liability, curb self-administration of psychostimulants (eg, cocaine, nicotine) as well as assocd. sensitivity to drug-assocd. cues and impulsivity in preclin. studies (for review) (Cunningham and Anastasio, 2014).  These data sparked a clin. trial that demonstrated that the FDA-approved anti-obesity medication and first-in-class 5-HT2CR agonist lorcaserin (Belviq) increased abstinence from smoking (Shanahan et al, 2016).  Furthermore, the efficacy and safety of lorcaserin for cocaine use disorder is presently under study (https://clinicaltrials.gov/ct2/show/NCT03007394).  We have recently demonstrated the efficacy of lorcaserin to suppress intake of the semisynthetic opioid oxycodone as well as assocd. cue reactivity in both abstinence and extinction-reinstatement paradigms, effects which were blocked by the selective 5-HT2CR antagonist SB242084 (Neelakantan et al, 2017).  Lorcaserin pretreatment also decreases opioid-induced behavioral sensitization and the phys. signs of naloxone-pptd. withdrawal following chronic opioid exposure in mice (Wu et al, 2015).  Thus, the non-opioid medication lorcaserin acts as a 5-HT2CR agonist to influence aspects of opioid-evoked behaviors, suggesting that the 5-HT2CR system may play a key role in the shared mechanisms for addiction and relapse vulnerability across psychostimulant and opioid drug classes.  The development of pain medications with analgesic efficacy, but reduced abuse liability, remains a high priority.  Of equally high priority is the identification of therapeutic interventions that increase the maintenance of abstinence after cessation of opioid intake, even in high drug cue environments.  A selective 5-HT2CR agonist, such as lorcaserin, may provide a new avenue to add value to the outcomes of medication-assisted treatment in OUD (Figure 1).  The next step is to expand the present data set to definitively test the hypotheses that lorcaserin inhibits opioid withdrawal and countermands stress- and/or opioid-triggered relapse events, for example.  It is also possible that low doses of lorcaserin administered in combination with a partial Î¼-opioid agonist, with limited abuse liability but efficacy to suppress opioid-induced euphoria and withdrawal may reduce relapse risk via regulation of two signaling pathways.  The neurochem. mechanisms and sites of action for 5-HT2CR systems to control opioid-related behaviors are also of interest.  Finally, preclin. studies to evaluate low-dose combinations of a partial Î¼-opioid agonist plus lorcaserin will provide insight into the potential for translational value in clin. trials geared to reduce the devastation of opioid overdose and OUD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEmhsgJcd6n7Vg90H21EOLACvtfcHk0lhuL6caNEivUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCrs7nI&md5=5a1e0efbac3ecf97edfa3625b0b5614f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.192%26sid%3Dliteratum%253Aachs%26aulast%3DMoeller%26aufirst%3DF.%2BG.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DInnovative%2520Therapeutic%2520Intervention%2520for%2520Opioid%2520Use%2520Disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D220%26epage%3D221%26doi%3D10.1038%2Fnpp.2017.192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glicklich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Kam, M.</span></span> <span> </span><span class="NLM_article-title">Lorcaserin for Smoking Cessation and Associated Weight Gain: a Randomized 12-week Clinical Trial</span>. <i>Nicotine Tob. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">944</span>â <span class="NLM_lpage">951</span>, <span class="refDoi">Â DOI: 10.1093/ntr/ntw301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1093%2Fntr%2Fntw301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=27815511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsVyntrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=944-951&author=W.+R.+Shanahanauthor=J.+E.+Roseauthor=A.+Glicklichauthor=S.+Stubbeauthor=M.+Sanchez-Kam&title=Lorcaserin+for+Smoking+Cessation+and+Associated+Weight+Gain%3A+a+Randomized+12-week+Clinical+Trial&doi=10.1093%2Fntr%2Fntw301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial</span></div><div class="casAuthors">Shanahan, William R.; Rose, Jed E.; Glicklich, Alan; Stubbe, Scott; Sanchez-Kam, Matilde</div><div class="citationInfo"><span class="NLM_cas:title">Nicotine & Tobacco Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">944-951</span>CODEN:
                <span class="NLM_cas:coden">NTREF6</span>;
        ISSN:<span class="NLM_cas:issn">1469-994X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Introduction: Lorcaserin is a selective serotonin 2C receptor agonist approved by the Food and Drug Administration for chronic wt. management.  Preclin. data suggest that it may also be effective in smoking cessation through modulation of the dopaminergic reward system.  Methods: This was a 12-wk, randomized, double-blind, placebo-controlled trial conducted in 30 centers in the United States.  Six hundred three adult smokers with a Body Mass Index of 18.5-35 kg/m2 , averaging at least 10 cigarettes/day with no period of abstinence >3 mo for the past year were randomized to lorcaserin 10 mg once daily (QD), 10 mg twice daily (BID) or placebo; all received standardized smoking cessation counseling weekly.  The target quit date was day 15.  The primary endpoint was the exhaled carbon monoxide confirmed Continuous Abstinence Rate for weeks 9-12 (month 3).  Results: Continuous Abstinence Rates for month 3 were 5.6%, 8.7%, and 15.3% for the placebo, QD and BID groups, resp. (BID vs. placebo odds ratio 3.02, 95% confidence interval 1.47, 6.22, p = .0027).  Change in wt. at week 12 (randomized population) was -0.01, -0.35 and -0.98 kg, resp. (p = .0004, BID vs. placebo), and +0.73, +0.76, and -0.41 kg in participants achieving month 3 continuous abstinence.  The most frequent adverse events were headache, nausea, constipation, and fatigue.  Conclusions: Lorcaserin with counseling was assocd. with dose-related increases in smoking cessation and prevention of assocd. wt. gain over a 3-mo period.  Further investigation of lorcaserin in smoking cessation is warranted.  Trial Registration: ClinicalTrials.gov.  Identifier: NCT02044874 Implications: This randomized, controlled trial demonstrated that lorcaserin used in conjunction with std. cessation counseling was assocd. with dose-related increases in smoking cessation and prevention of assocd. wt. gain.  To our knowledge, this is the first demonstration in humans of a potential role of 5-HT2C agonism in the modulation of central neurol. circuits involved with reward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoerITmglXHkbVg90H21EOLACvtfcHk0ljHT1HG900fSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsVyntrs%253D&md5=c35a3194032c2533e4eae0235802dd90</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fntr%2Fntw301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fntr%252Fntw301%26sid%3Dliteratum%253Aachs%26aulast%3DShanahan%26aufirst%3DW.%2BR.%26aulast%3DRose%26aufirst%3DJ.%2BE.%26aulast%3DGlicklich%26aufirst%3DA.%26aulast%3DStubbe%26aufirst%3DS.%26aulast%3DSanchez-Kam%26aufirst%3DM.%26atitle%3DLorcaserin%2520for%2520Smoking%2520Cessation%2520and%2520Associated%2520Weight%2520Gain%253A%2520a%2520Randomized%252012-week%2520Clinical%2520Trial%26jtitle%3DNicotine%2520Tob.%2520Res.%26date%3D2017%26volume%3D19%26spage%3D944%26epage%3D951%26doi%3D10.1093%2Fntr%2Fntw301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farr, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrieli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyrou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koniaris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srnka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migdal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantzoros, C. S.</span></span> <span> </span><span class="NLM_article-title">Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-related Changes Correlate with Weight Loss Effects: a 4-Week-long Randomized, Placebo-controlled, Double-blind Clinical Trial</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">2943</span>â <span class="NLM_lpage">2953</span>, <span class="refDoi">Â DOI: 10.2337/db16-0635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.2337%2Fdb16-0635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=27385157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOrtL7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=2943-2953&author=O.+M.+Farrauthor=J.+Upadhyayauthor=A.+Gavrieliauthor=M.+Campauthor=N.+Spyrouauthor=H.+Kayeauthor=H.+Mathewauthor=M.+Vamviniauthor=A.+Koniarisauthor=H.+Kilimauthor=A.+Srnkaauthor=A.+Migdalauthor=C.+S.+Mantzoros&title=Lorcaserin+Administration+Decreases+Activation+of+Brain+Centers+in+Response+to+Food+Cues+and+These+Emotion-+and+Salience-related+Changes+Correlate+with+Weight+Loss+Effects%3A+a+4-Week-long+Randomized%2C+Placebo-controlled%2C+Double-blind+Clinical+Trial&doi=10.2337%2Fdb16-0635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin administration decreases activation of brain centers in response to food cues, these emotion-, salience-related changes correlate with weight loss effects: a 4-week-long randomized, placebo-controlled, double-blind clinical trial</span></div><div class="casAuthors">Farr, Olivia M.; Upadhyay, Jagriti; Gavrieli, Anna; Camp, Michelle; Spyrou, Nikolaos; Kaye, Harper; Mathew, Hannah; Vamvini, Maria; Koniaris, Anastasia; Kilim, Holly; Srnka, Alexandra; Migdal, Alexandra; Mantzoros, Christos S.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2943-2953</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Lorcaserin is a serotonin 5-hydroxytryptamine 2c receptor agonist effective in treating obesity.  Studies in rodents have shown that lorcaserin acts in the brain to exert its wt.-reducing effects, but this has not yet been studied in humans.  We performed a randomized, placebo-controlled, double-blind trial with 48 obese participants and used functional MRI to study the effects of lorcaserin on the brain.  Subjects taking lorcaserin had decreased brain activations in the attention-related parietal and visual cortices in response to highly palatable food cues at 1 wk in the fasting state and in the parietal cortex in response to any food cues at 4 wk in the fed state.  Decreases in emotion- and salience-related limbic activity, including the insula and amygdala, were attenuated at 4 wk.  Decreases in caloric intake, wt., and BMI correlated with activations in the amygdala, parietal, and visual cortices at baseline.  These data suggest that lorcaserin exerts its wt.-reducing effects by decreasing attention-related brain activations to food cues (parietal and visual cortices) and emotional and limbic activity (insula, amygdala).  Results indicating that baseline activation of the amygdala relates to increased efficacy suggest that lorcaserin would be of particular benefit to emotional eaters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLA0TdIp1TKLVg90H21EOLACvtfcHk0liva2AyVjHcHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOrtL7J&md5=e2f7f3842a6c75dc45d064376398256b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2337%2Fdb16-0635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb16-0635%26sid%3Dliteratum%253Aachs%26aulast%3DFarr%26aufirst%3DO.%2BM.%26aulast%3DUpadhyay%26aufirst%3DJ.%26aulast%3DGavrieli%26aufirst%3DA.%26aulast%3DCamp%26aufirst%3DM.%26aulast%3DSpyrou%26aufirst%3DN.%26aulast%3DKaye%26aufirst%3DH.%26aulast%3DMathew%26aufirst%3DH.%26aulast%3DVamvini%26aufirst%3DM.%26aulast%3DKoniaris%26aufirst%3DA.%26aulast%3DKilim%26aufirst%3DH.%26aulast%3DSrnka%26aufirst%3DA.%26aulast%3DMigdal%26aufirst%3DA.%26aulast%3DMantzoros%26aufirst%3DC.%2BS.%26atitle%3DLorcaserin%2520Administration%2520Decreases%2520Activation%2520of%2520Brain%2520Centers%2520in%2520Response%2520to%2520Food%2520Cues%2520and%2520These%2520Emotion-%2520and%2520Salience-related%2520Changes%2520Correlate%2520with%2520Weight%2520Loss%2520Effects%253A%2520a%25204-Week-long%2520Randomized%252C%2520Placebo-controlled%252C%2520Double-blind%2520Clinical%2520Trial%26jtitle%3DDiabetes%26date%3D2016%26volume%3D65%26spage%3D2943%26epage%3D2953%26doi%3D10.2337%2Fdb16-0635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maili, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swinford, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, F. G.</span></span> <span> </span><span class="NLM_article-title">Variation within the serotonin (5-HT) 5-HT2C receptor system aligns with vulnerability to cocaine cue reactivity</span>. <i>Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e369</span> <span class="refDoi">Â DOI: 10.1038/tp.2013.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1038%2Ftp.2013.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVCnsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&author=N.+C.+Anastasioauthor=S.+Liuauthor=L.+Mailiauthor=S.+E.+Swinfordauthor=S.+D.+Laneauthor=R.+G.+Foxauthor=S.+C.+Hamonauthor=D.+A.+Nielsenauthor=K.+A.+Cunninghamauthor=F.+G.+Moeller&title=Variation+within+the+serotonin+%285-HT%29+5-HT2C+receptor+system+aligns+with+vulnerability+to+cocaine+cue+reactivity&doi=10.1038%2Ftp.2013.131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Variation within the serotonin (5-HT) 5-HT2C receptor system aligns with vulnerability to cocaine cue reactivity</span></div><div class="casAuthors">Anastasio, N. C.; Liu, S.; Maili, L.; Swinford, S. E.; Lane, S. D.; Fox, R. G.; Hamon, S. C.; Nielsen, D. A.; Cunningham, K. A.; Moeller, F. G.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e369</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cocaine dependence remains a challenging public health problem with relapse cited as a major determinant in its chronicity and severity.  Environmental contexts and stimuli become reliably assocd. with its use leading to durable conditioned responses ('cue reactivity') that can predict relapse as well as treatment success.  Individual variation in the magnitude and influence of cue reactivity over behavior in humans and animals suggest that cue-reactive individuals may be at greater risk for the progression to addiction and/or relapse.  In the present translational study, we investigated the contribution of variation in the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) system in individual differences in cocaine cue reactivity in humans and rodents.  We found that cocaine-dependent subjects carrying a single nucleotide polymorphism (SNP) in the HTR2C gene that encodes for the conversion of cysteine to serine at codon 23 (Ser23 variant) exhibited significantly higher attentional bias to cocaine cues in the cocaine-word Stroop task than those carrying the Cys23 variant.  In a model of individual differences in cocaine cue reactivity in rats, we identified that high cocaine cue reactivity measured as appetitive approach behavior (lever presses reinforced by the discrete cue complex) correlated with lower 5-HT2CR protein expression in the medial prefrontal cortex and blunted sensitivity to the suppressive effects of the selective 5-HT2CR agonist WAY163909.  Our translational findings suggest that the functional status of the 5-HT2CR system is a mechanistic factor in the generation of vulnerability to cocaine-assocd. cues, an observation that opens new avenues for future development of biomarker and therapeutic approaches to suppress relapse in cocaine dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4-6Q9fk9SyLVg90H21EOLACvtfcHk0lir989W8NSCDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVCnsrk%253D&md5=9372b11e4f3479212fda09b936713bfc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Ftp.2013.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2013.131%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMaili%26aufirst%3DL.%26aulast%3DSwinford%26aufirst%3DS.%2BE.%26aulast%3DLane%26aufirst%3DS.%2BD.%26aulast%3DFox%26aufirst%3DR.%2BG.%26aulast%3DHamon%26aufirst%3DS.%2BC.%26aulast%3DNielsen%26aufirst%3DD.%2BA.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DMoeller%26aufirst%3DF.%2BG.%26atitle%3DVariation%2520within%2520the%2520serotonin%2520%25285-HT%2529%25205-HT2C%2520receptor%2520system%2520aligns%2520with%2520vulnerability%2520to%2520cocaine%2520cue%2520reactivity%26jtitle%3DPsychiatry%26date%3D2014%26volume%3D4%26doi%3D10.1038%2Ftp.2013.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, T. W.</span></span> <span> </span><span class="NLM_article-title">Drug Addiction: Updating Actions to Habits to Compulsions Ten Years On</span>. <i>Annu. Rev. Psychol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">50</span>, <span class="refDoi">Â DOI: 10.1146/annurev-psych-122414-033457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1146%2Fannurev-psych-122414-033457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=26253543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A280%3ADC%252BC287gvFSrtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=23-50&author=B.+J.+Everittauthor=T.+W.+Robbins&title=Drug+Addiction%3A+Updating+Actions+to+Habits+to+Compulsions+Ten+Years+On&doi=10.1146%2Fannurev-psych-122414-033457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Addiction: Updating Actions to Habits to Compulsions Ten Years On</span></div><div class="casAuthors">Everitt Barry J; Robbins Trevor W</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of psychology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A decade ago, we hypothesized that drug addiction can be viewed as a transition from voluntary, recreational drug use to compulsive drug-seeking habits, neurally underpinned by a transition from prefrontal cortical to striatal control over drug seeking and taking as well as a progression from the ventral to the dorsal striatum.  Here, in the light of burgeoning, supportive evidence, we reconsider and elaborate this hypothesis, in particular the refinements in our understanding of ventral and dorsal striatal mechanisms underlying goal-directed and habitual drug seeking, the influence of drug-associated Pavlovian-conditioned stimuli on drug seeking and relapse, and evidence for impairments in top-down prefrontal cortical inhibitory control over this behavior.  We further review animal and human studies that have begun to define etiological factors and individual differences in the propensity to become addicted to drugs, leading to the description of addiction endophenotypes, especially for cocaine addiction.  We consider the prospect of novel treatments for addiction that promote abstinence from and relapse to drug use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-E8ITY507OQ5nADWVYHg1fW6udTcc2eZ11Wgbf72qn7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287gvFSrtQ%253D%253D&md5=ae5829b8685d3a5a7c4ec46243125154</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1146%2Fannurev-psych-122414-033457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-psych-122414-033457%26sid%3Dliteratum%253Aachs%26aulast%3DEveritt%26aufirst%3DB.%2BJ.%26aulast%3DRobbins%26aufirst%3DT.%2BW.%26atitle%3DDrug%2520Addiction%253A%2520Updating%2520Actions%2520to%2520Habits%2520to%2520Compulsions%2520Ten%2520Years%2520On%26jtitle%3DAnnu.%2520Rev.%2520Psychol.%26date%3D2016%26volume%3D67%26spage%3D23%26epage%3D50%26doi%3D10.1146%2Fannurev-psych-122414-033457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span> <span> </span><span class="NLM_article-title">Hallucinogens</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">131</span>â <span class="NLM_lpage">181</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2003.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2Fj.pharmthera.2003.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=14761703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=131-181&author=D.+E.+Nichols&title=Hallucinogens&doi=10.1016%2Fj.pharmthera.2003.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Hallucinogens</span></div><div class="casAuthors">Nichols, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes.  They are considered physiol. safe and do not produce dependence or addiction.  Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts.  In the 1950s, after the virtually contemporaneous discovery of both serotonin (5-HT) and lysergic acid diethylamide (LSD-25), early brain research focused intensely on the possibility that LSD or other hallucinogens had a serotonergic basis of action and reinforced the idea that 5-HT was an important neurotransmitter in brain.  These ideas were eventually proven, and today it is believed that hallucinogens stimulate 5-HT2A receptors, esp. those expressed on neocortical pyramidal cells.  Activation of 5-HT2A receptors also leads to increased cortical glutamate levels presumably by a presynaptic receptor-mediated release from thalamic afferents.  These findings have led to comparisons of the effects of classical hallucinogens with certain aspects of acute psychosis and to a focus on thalamocortical interactions as key to understanding both the action of these substances and the neuroanatomical sites involved in altered states of consciousness (ASC).  In vivo brain imaging in humans using [18F]fluorodeoxyglucose has shown that hallucinogens increase prefrontal cortical metab., and correlations have been developed between activity in specific brain areas and psychol. elements of the ASC produced by hallucinogens.  The 5-HT2A receptor clearly plays an essential role in cognitive processing, including working memory, and ligands for this receptor may be extremely useful tools for future cognitive neuroscience research.  In addn., it appears entirely possible that utility may still emerge for the use of hallucinogens in treating alcoholism, substance abuse, and certain psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRl6lKmZ_4Y7Vg90H21EOLACvtfcHk0liJsR2Awvy1zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D&md5=7b5246f6479d76736c5a7223c60a9e99</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2003.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2003.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DD.%2BE.%26atitle%3DHallucinogens%26jtitle%3DPharmacol.%2520Ther.%26date%3D2004%26volume%3D101%26spage%3D131%26epage%3D181%26doi%3D10.1016%2Fj.pharmthera.2003.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corjay, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbaszade, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largent, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartig, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, D. W.</span></span> <span> </span><span class="NLM_article-title">Possible Role of Valvular Serotonin 5-HT(2B) Receptors in the Cardiopathy Associated with Fenfluramine</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">75</span>â <span class="NLM_lpage">81</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10617681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslCltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2000&pages=75-81&author=L.+W.+Fitzgeraldauthor=T.+C.+Burnauthor=B.+S.+Brownauthor=J.+P.+Pattersonauthor=M.+H.+Corjayauthor=P.+A.+Valentineauthor=J.+H.+Sunauthor=J.+R.+Linkauthor=I.+Abbaszadeauthor=J.+M.+Hollisauthor=B.+L.+Largentauthor=P.+R.+Hartigauthor=G.+F.+Hollisauthor=P.+C.+Meunierauthor=A.+J.+Robichaudauthor=D.+W.+Robertson&title=Possible+Role+of+Valvular+Serotonin+5-HT%282B%29+Receptors+in+the+Cardiopathy+Associated+with+Fenfluramine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine</span></div><div class="casAuthors">Fitzgerald, Lawrence W.; Burn, Timothy C.; Brown, Barry S.; Patterson, John P.; Corjay, Martha H.; Valentine, Patricia A.; Sun, Jung-Hui; Link, John R.; Abbaszade, Ilgar; Hollis, Jeannine M.; Largent, Brian L.; Hartig, Paul R.; Hollis, Gregory F.; Meunier, Paul C.; Robichaud, Albert J.; Robertson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dexfenfluramine was approved in the United States for longterm use as an appetite suppressant until it was reported to be assocd. with valvular heart disease.  The valvular changes (myofibroblast proliferation) are histopathol. indistinguishable from those obsd. in carcinoid disease or after long-term exposure to 5-hydroxytryptamine (5-HT)2-preferring ergot drugs (ergotamine, methysergide).  5-HT2 receptor stimulation is known to cause fibroblast mitogenesis, which could contribute to this lesion.  To elucidate the mechanism of "fenphen"-assocd. valvular lesions, we examd. the interaction of fenfluramine and its metabolite norfenfluramine with 5-HT2 receptor subtypes and examd. the expression of these receptors in human and porcine heart valves.  Fenfluramine binds weakly to 5-HT2A, 5-HT2B, and 5-HT2C receptors.  In contrast, norfenfluramine exhibited high affinity for 5-HT2B and 5-HT2C receptors and more moderate affinity for 5-HT2A receptors.  In cells expressing recombinant 5-HT2B receptors, norfenfluramine potently stimulated the hydrolysis of inositol phosphates, increased intracellular Ca2+, and activated the mitogen-activated protein kinase cascade, the latter of which has been linked to mitogenic actions of the 5-HT2B receptor.  The level of 5-HT2B and 5-HT2A receptor transcripts in heart valves was at least 300-fold higher than the levels of 5-HT2C receptor transcript, which were barely detectable.  We propose that preferential stimulation of valvular 5-HT2B receptors by norfenfluramine, ergot drugs, or 5-HT released from carcinoid tumors (with or without accompanying 5-HT2A receptor activation) may contribute to valvular fibroplasia in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmkbFOXGVxcLVg90H21EOLACvtfcHk0ljT2ZjfYT2YJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslCltA%253D%253D&md5=b99b778d0de695d377aa4f0006b6dc47</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DL.%2BW.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DBrown%26aufirst%3DB.%2BS.%26aulast%3DPatterson%26aufirst%3DJ.%2BP.%26aulast%3DCorjay%26aufirst%3DM.%2BH.%26aulast%3DValentine%26aufirst%3DP.%2BA.%26aulast%3DSun%26aufirst%3DJ.%2BH.%26aulast%3DLink%26aufirst%3DJ.%2BR.%26aulast%3DAbbaszade%26aufirst%3DI.%26aulast%3DHollis%26aufirst%3DJ.%2BM.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DHartig%26aufirst%3DP.%2BR.%26aulast%3DHollis%26aufirst%3DG.%2BF.%26aulast%3DMeunier%26aufirst%3DP.%2BC.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DRobertson%26aufirst%3DD.%2BW.%26atitle%3DPossible%2520Role%2520of%2520Valvular%2520Serotonin%25205-HT%25282B%2529%2520Receptors%2520in%2520the%2520Cardiopathy%2520Associated%2520with%2520Fenfluramine%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D57%26spage%3D75%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of G Protein-Coupled Receptors: An Emerging Approach of Drug Discovery</span>. <i>Austin J. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">3</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=3&author=C.+Wildauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+Modulation+of+G+Protein-Coupled+Receptors%3A+An+Emerging+Approach+of+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWild%26aufirst%3DC.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520Modulation%2520of%2520G%2520Protein-Coupled%2520Receptors%253A%2520An%2520Emerging%2520Approach%2520of%2520Drug%2520Discovery%26jtitle%3DAustin%2520J.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D2%26spage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">GPCR Allosteric Modulators: Mechanistic Advantages and Therapeutic Applications</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2002</span>â <span class="NLM_lpage">2006</span>, <span class="refDoi">Â DOI: 10.2174/1568026619999190101151837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.2174%2F1568026619999190101151837" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=2002-2006&author=E.+A.+Woldauthor=J.+Zhou&title=GPCR+Allosteric+Modulators%3A+Mechanistic+Advantages+and+Therapeutic+Applications&doi=10.2174%2F1568026619999190101151837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1568026619999190101151837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619999190101151837%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DGPCR%2520Allosteric%2520Modulators%253A%2520Mechanistic%2520Advantages%2520and%2520Therapeutic%2520Applications%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D18%26spage%3D2002%26epage%3D2006%26doi%3D10.2174%2F1568026619999190101151837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">88</span>â <span class="NLM_lpage">127</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=88-127&author=E.+A.+Woldauthor=J.+Chenauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+Modulation+of+Class+A+GPCRs%3A+Targets%2C+Agents%2C+and+Emerging+Concepts&doi=10.1021%2Facs.jmedchem.8b00875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span></div><div class="casAuthors">Wold, Eric A.; Chen, Jianping; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs.  Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases.  GPCR allosteric modulation is an innovative targeting approach that broadens the available small mol. toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clin. trials.  Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development.  This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chem. approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zBEGIhRgD7Vg90H21EOLACvtfcHk0ljpK8B4nk5h9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK&md5=c724b7cb534a9eb52c371961bb9c9b42</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00875%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520Modulation%2520of%2520Class%2520A%2520GPCRs%253A%2520Targets%252C%2520Agents%252C%2520and%2520Emerging%2520Concepts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D88%26epage%3D127%26doi%3D10.1021%2Facs.jmedchem.8b00875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Im, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chio, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span> <span> </span><span class="NLM_article-title">Positive Allosteric Modulator of the Human 5-HT<sub>2C</sub> Receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">78</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1124/mol.64.1.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1124%2Fmol.64.1.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=12815163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvV2qtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2003&pages=78-84&author=W.+B.+Imauthor=C.+L.+Chioauthor=G.+L.+Albertsauthor=D.+M.+Dinh&title=Positive+Allosteric+Modulator+of+the+Human+5-HT2C+Receptor&doi=10.1124%2Fmol.64.1.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulator of the human 5-HT2C receptor</span></div><div class="casAuthors">Im, Wha Bin; Chio, Christopher L.; Alberts, Glen L.; Dinh, Dac M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-84</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The human 5-hydroxytryptamine-2C (5-HT2C) receptor has been the target of potential anxiolytics and antiobesity drugs, and its pos. allosteric modulator was discovered to be L-threo-Î±-D-galacto-octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[(4-undecyl-2-piperidinyl)carbonyl]amino]-1-thiomonohydrochloride (2S-cis) (PNU-69176E).  The drug at low micromolar concns. (<25 Î¼M) markedly enhanced [3H]5-HT binding (more than 300%) by increasing its affinity for low-affinity sites but with no appreciable effect on antagonist ([3H]mesulergine) binding.  Functionally, PNU-69176E alone rendered receptors constitutively active, producing the phenotypes of 5-HT-activated receptors, as measured with mesulergine-sensitive guanosine 5'-O-(3-[35S]thio)triphosphate binding, transient inositol 1,4,5-triphosphate release, and [3H]inositol phosphate accumulation.  These actions of PNU-69176E were obsd. with the human 5-HT2C receptor expressed in several mammalian cell lines (human embryonic kidney 293, NIH3T3, and SH-EP) at variable receptor densities (6 to 45 pmol/mg of protein), but not with analogous 5-HT and dopamine receptors (human 5-HT2A, 5-HT2B, 5-HT6, 5-HT7, and dopamine D2-long and D3 receptors).  Structurally, PNU-69176E consists of a long alkyl chain and a polar moiety, including the Î±-D-galactopyranoside.  Its analogs with shorter alkyl chains (Me to n-hexyl instead of n-undecyl group) failed to enhance [3H]5-HT binding, and also long alkyl amides are without allosteric modulation.  We propose that PNU-69176E may represent a new class of membrane receptor modulators, which probably need a long alkyl chain as a membrane anchor and target a selective polar head group to receptor modulatory sites near the membrane surface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMdPZHNbAJJbVg90H21EOLACvtfcHk0lhO8Wt0oGTXDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvV2qtrs%253D&md5=26c9f18b3097e2a8921b7803bc836489</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fmol.64.1.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.64.1.78%26sid%3Dliteratum%253Aachs%26aulast%3DIm%26aufirst%3DW.%2BB.%26aulast%3DChio%26aufirst%3DC.%2BL.%26aulast%3DAlberts%26aufirst%3DG.%2BL.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26atitle%3DPositive%2520Allosteric%2520Modulator%2520of%2520the%2520Human%25205-HT2C%2520Receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D64%26spage%3D78%26epage%3D84%26doi%3D10.1124%2Fmol.64.1.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Exploration of Synthetic Approaches and Pharmacological Evaluation of PNU-69176E and its Stereoisomer as 5-HT<sub>2C</sub> Receptor Allosteric Modulators</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">538</span>â <span class="NLM_lpage">545</span>, <span class="refDoi">Â DOI: 10.1021/cn300020x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300020x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOqsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=538-545&author=C.+Dingauthor=N.+M.+Bremerauthor=T.+D.+Smithauthor=P.+K.+Seitzauthor=N.+C.+Anastasioauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Exploration+of+Synthetic+Approaches+and+Pharmacological+Evaluation+of+PNU-69176E+and+its+Stereoisomer+as+5-HT2C+Receptor+Allosteric+Modulators&doi=10.1021%2Fcn300020x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Synthetic Approaches and Pharmacological Evaluation of PNU-69176E and Its Stereoisomer as 5-HT2C Receptor Allosteric Modulators</span></div><div class="casAuthors">Ding, Chunyong; Bremer, Nicole M.; Smith, Thressa D.; Seitz, Patricia K.; Anastasio, Noelle C.; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">538-545</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric modulators of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) present a unique drug design strategy to augment the response to endogenous 5-HT in a site- and event-specific manner with great potential as novel central nervous system probes and therapeutics.  To date, PNU-69176E is the only reported selective pos. allosteric modulator for the 5-HT2CR.  For the first time, an optimized synthetic route to readily access PNU-69176E (1) and its diastereomer 2 has been established in moderate to good overall yields over 10 steps starting from com. available picolinic acid.  This synthetic approach not only enables a feasible prepn. of a sufficient amt. of 1 for use as a ref. compd. for secondary pharmacol. studies, but also provides an efficient synthesis of key intermediates to develop novel and simplified 5-HT2CR allosteric modulators.  Compd. 1 and its diastereomer 2 were functionally characterized in Chinese hamster ovary (CHO) cells stably transfected with the 5-HT2CR using an intracellular calcium (Cai2+) release assay.  Compd. 1 demonstrated efficacy and potency as an allosteric modulator for the 5-HT2CR with no intrinsic agonist activity.  Compd. 1 did not alter 5-HT-evoked Cai2+ in CHO cells stably transfected with the highly homologous 5-HT2AR.  In contrast, the diastereomer 2 did not alter 5-HT-evoked Cai2+ release in 5-HT2AR-CHO or 5-HT2CR-CHO cells or exhibit intrinsic agonist activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-ZC-7cVkBGrVg90H21EOLACvtfcHk0ljb1Tgl9zzPiA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOqsb0%253D&md5=1f635dd7796d2663f1ab08b92c7d7cb9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fcn300020x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300020x%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DBremer%26aufirst%3DN.%2BM.%26aulast%3DSmith%26aufirst%3DT.%2BD.%26aulast%3DSeitz%26aufirst%3DP.%2BK.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DExploration%2520of%2520Synthetic%2520Approaches%2520and%2520Pharmacological%2520Evaluation%2520of%2520PNU-69176E%2520and%2520its%2520Stereoisomer%2520as%25205-HT2C%2520Receptor%2520Allosteric%2520Modulators%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D538%26epage%3D545%26doi%3D10.1021%2Fcn300020x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miszkiel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">288</span>â <span class="NLM_lpage">305</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00401</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00401" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntFWit7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=288-305&author=C.+T.+Wildauthor=J.+M.+Miszkielauthor=E.+A.+Woldauthor=C.+A.+Sotoauthor=C.+Dingauthor=R.+M.+Hartleyauthor=M.+A.+Whiteauthor=N.+C.+Anastasioauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Design%2C+Synthesis%2C+and+Characterization+of+4-Undecylpiperidine-2-carboxamides+as+Positive+Allosteric+Modulators+of+the+Serotonin+%285-HT%29+5-HT2C+Receptor&doi=10.1021%2Facs.jmedchem.8b00401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor</span></div><div class="casAuthors">Wild, Christopher T.; Miszkiel, Joanna M.; Wold, Eric A.; Soto, Claudia A.; Ding, Chunyong; Hartley, Rachel M.; White, Mark A.; Anastasio, Noelle C.; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">288-305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cis-alkylpiperidinecarboxamides such as I were prepd. as pos. allosteric modulators of the 5-HT2c receptor for potential use in the prevention of cocaine addiction relapse.  I potentiated 5-HT-evoked intracellular calcium release in cells stably expressing the human 5-HT2c receptor but not cells expressing human 5-HT2a receptors.  Mol. docking calcns. of I at the 5-HT2c receptor identified a topog. distinct allosteric site.  The pharmacokinetics of I upon i.v. administration, its toxicity, and its selectivity for the 5-HT2c receptor over a variety of other competing receptors was detd.  I modulated 5-HT2c receptor-mediated spontaneous ambulation, partially substituted for the training dose of the 5-HT2c receptor agonist WAY163909, synergized with a low dose of WAY163909 to substitute fully for the stimulus effects of WAY163909, and attenuated relapse vulnerability as assessed in a rodent self-administration model, indicating its therapeutic promise for cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyQPhHrzQH-LVg90H21EOLACvtfcHk0lhJDP99stG-wg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntFWit7o%253D&md5=a783f4d24d6e8fb3af595d7948e4952d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00401%26sid%3Dliteratum%253Aachs%26aulast%3DWild%26aufirst%3DC.%2BT.%26aulast%3DMiszkiel%26aufirst%3DJ.%2BM.%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DSoto%26aufirst%3DC.%2BA.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DHartley%26aufirst%3DR.%2BM.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Characterization%2520of%25204-Undecylpiperidine-2-carboxamides%2520as%2520Positive%2520Allosteric%2520Modulators%2520of%2520the%2520Serotonin%2520%25285-HT%2529%25205-HT2C%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D288%26epage%3D305%26doi%3D10.1021%2Facs.jmedchem.8b00401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-CÃ¡rceles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VÃ¡zquez-Villa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RodrÃ­guez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codesido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruces, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loza, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlÃ©n, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BenhamÃº, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RodrÃ­guez de Fonseca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez-RodrÃ­guez, M. L.</span></span> <span> </span><span class="NLM_article-title">A Positive Allosteric Modulator of the Serotonin 5-HT2CReceptor for Obesity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9575</span>â <span class="NLM_lpage">9584</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00994</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00994" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslyrsL7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9575-9584&author=J.+Garc%C3%ADa-C%C3%A1rcelesauthor=J.+M.+Decaraauthor=H.+V%C3%A1zquez-Villaauthor=R.+Rodr%C3%ADguezauthor=E.+Codesidoauthor=J.+Crucesauthor=J.+Breaauthor=M.+I.+Lozaauthor=F.+Al%C3%A9nauthor=J.+Bottaauthor=P.+J.+McCormickauthor=J.+A.+Ballesterosauthor=B.+Benham%C3%BAauthor=F.+Rodr%C3%ADguez+de+Fonsecaauthor=M.+L.+L%C3%B3pez-Rodr%C3%ADguez&title=A+Positive+Allosteric+Modulator+of+the+Serotonin+5-HT2CReceptor+for+Obesity&doi=10.1021%2Facs.jmedchem.7b00994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A Positive Allosteric Modulator of the Serotonin 5-HT2C Receptor for Obesity</span></div><div class="casAuthors">Garcia-Carceles, Javier; Decara, Juan M.; Vazquez-Villa, Henar; Rodriguez, Ramon; Codesido, Eva; Cruces, Jacobo; Brea, Jose; Loza, Maria I.; Alen, Francisco; Botta, Joaquin; McCormick, Peter J.; Ballesteros, Juan A.; Benhamu, Bellinda; Rodriguez de Fonseca, Fernando; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9575-9584</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 5-HT2CR agonist lorcaserin, clin. approved for the treatment of obesity, causes important side effects mainly related to subtype selectivity.  In the search for 5-HT2CR allosteric modulators as safer antiobesity drugs, a chem. library from Vivia Biotech was screened using ExviTech platform.  Structural modifications of identified hit VA240 in synthesized analogs 6-41 afforded compd. 11 (N-[(1-benzyl-1H-indol-3-yl)methyl]pyridin-3-amine, VA012), which exhibited dose-dependent enhancement of serotonin efficacy, no significant off-target activities, and low binding competition with serotonin or other orthosteric ligands.  PAM 11 was very active in feeding inhibition in rodents, an effect that was not related to the activation of 5-HT2AR.  A combination of 11 with the SSRI sertraline increased the anorectic effect.  Subchronic administration of 11 reduced food intake and body wt. gain without causing CNS-related malaise.  The behavior of compd. 11 identified in this work supports the interest of a serotonin 5-HT2CR PAM as a promising therapeutic approach for obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXljb401CzwLVg90H21EOLACvtfcHk0lgQPubUMvy38Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslyrsL7K&md5=e5c1d03f3e25fa49072265c9ab77ea21</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00994%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-C%25C3%25A1rceles%26aufirst%3DJ.%26aulast%3DDecara%26aufirst%3DJ.%2BM.%26aulast%3DV%25C3%25A1zquez-Villa%26aufirst%3DH.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DR.%26aulast%3DCodesido%26aufirst%3DE.%26aulast%3DCruces%26aufirst%3DJ.%26aulast%3DBrea%26aufirst%3DJ.%26aulast%3DLoza%26aufirst%3DM.%2BI.%26aulast%3DAl%25C3%25A9n%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DJ.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26aulast%3DBallesteros%26aufirst%3DJ.%2BA.%26aulast%3DBenham%25C3%25BA%26aufirst%3DB.%26aulast%3DRodr%25C3%25ADguez%2Bde%2BFonseca%26aufirst%3DF.%26aulast%3DL%25C3%25B3pez-Rodr%25C3%25ADguez%26aufirst%3DM.%2BL.%26atitle%3DA%2520Positive%2520Allosteric%2520Modulator%2520of%2520the%2520Serotonin%25205-HT2CReceptor%2520for%2520Obesity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9575%26epage%3D9584%26doi%3D10.1021%2Facs.jmedchem.7b00994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqi, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, P. N.</span></span> <span> </span><span class="NLM_article-title">Identification of Dual Role of Piperazine-linked Phenyl Cyclopropyl Methanone as Positive Allosteric Modulator of 5-HT2C and Negative Allosteric Modulator of 5-HT2B Receptors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">499</span>â <span class="NLM_lpage">516</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.12.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2Fj.ejmech.2018.12.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=30622024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslaluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=499-516&author=K.+Singhauthor=C.+Sonaauthor=V.+Ojhaauthor=M.+Singhauthor=A.+Mishraauthor=A.+Kumarauthor=M.+I.+Siddiqiauthor=R.+P.+Tripathiauthor=P.+N.+Yadav&title=Identification+of+Dual+Role+of+Piperazine-linked+Phenyl+Cyclopropyl+Methanone+as+Positive+Allosteric+Modulator+of+5-HT2C+and+Negative+Allosteric+Modulator+of+5-HT2B+Receptors&doi=10.1016%2Fj.ejmech.2018.12.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT2C and negative allosteric modulator of 5-HT2B receptors</span></div><div class="casAuthors">Singh, Kartikey; Sona, Chandan; Ojha, Vikash; Singh, Maninder; Mishra, Ankita; Kumar, Ajeet; Siddiqi, Mohammad Imran; Tripathi, Rama P.; Yadav, Prem N.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">499-516</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Allosteric modulators of G-protein-coupled receptors have lately gained significant traction in drug discovery.  Recent studies have shown that allosteric modulation of serotonin 2C receptor (5-HT2C) as a viable strategy for the treatment of various central nervous system (CNS) disorders.  Considering the crit. role of 5-HT2C in the modulation of appetite, a selective pos. allosteric modulator (PAM) of 5-HT2C offers a new opportunity for anti-obesity therapeutic development.  In this study, Ph cyclopropyl-linked N-heterocycles were synthesized and evaluated at 5-HT2C for agonist and PAM activity.  Our study shows that imidazole linked Ph cyclopropyl methanones has PAM activity on both 5-HT2C and serotonin 2B receptor (5-HT2B).  Interestingly, piperazine linked Ph cyclopropyl methanones was active as PAM of 5-HT2C (increased the Emax of 5-HT to 139%), and as neg. allosteric modulator (NAM) of 5-HT2B (decreases EC50 of 5-HT 10 times without affecting Emax).  Similar effect of compd. I was obsd. with synthetic orthosteric agonist lorcaserin on 5-HT2B.  Mol. docking study revealed that all active compds. were binding to the predicted allosteric site on 5-HT2C and shared a common interacting residues.  Finally, compd. I suppressed food intake in Sprague Dawley (SD) rats similar to lorcaserin after i.c.v. administration.  Therefore, these results suggest that piperazine moiety is essential for dual activity (PAM & NAM) of compds. I, and supports the hypothesis of 5-HT2C PAM for the treatment of obesity similar to the full agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIZVtcltP7JLVg90H21EOLACvtfcHk0ljv2NGlYHnilA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslaluw%253D%253D&md5=e115d454720ac5755168af7045cb0e51</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.070%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DSona%26aufirst%3DC.%26aulast%3DOjha%26aufirst%3DV.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DMishra%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSiddiqi%26aufirst%3DM.%2BI.%26aulast%3DTripathi%26aufirst%3DR.%2BP.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26atitle%3DIdentification%2520of%2520Dual%2520Role%2520of%2520Piperazine-linked%2520Phenyl%2520Cyclopropyl%2520Methanone%2520as%2520Positive%2520Allosteric%2520Modulator%2520of%25205-HT2C%2520and%2520Negative%2520Allosteric%2520Modulator%2520of%25205-HT2B%2520Receptors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D499%26epage%3D516%26doi%3D10.1016%2Fj.ejmech.2018.12.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. S.</span></span> <span> </span><span class="NLM_article-title">Quantitative Changes in Intracellular Calcium and Extracellular-regulated Kinase Activation Measured in Parallel in CHO Cells Stably Expressing Serotonin (5-HT) 5-HT2A or 5-HT2C Receptors</span>. <i>BMC Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi">Â DOI: 10.1186/1471-2202-13-25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1186%2F1471-2202-13-25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=22397586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCgu7nL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=25&author=P.+K.+Seitzauthor=N.+M.+Bremerauthor=A.+G.+McGinnisauthor=K.+A.+Cunninghamauthor=C.+S.+Watson&title=Quantitative+Changes+in+Intracellular+Calcium+and+Extracellular-regulated+Kinase+Activation+Measured+in+Parallel+in+CHO+Cells+Stably+Expressing+Serotonin+%285-HT%29+5-HT2A+or+5-HT2C+Receptors&doi=10.1186%2F1471-2202-13-25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative changes in intracellular calcium and extracellular-regulated kinase activation measured in parallel in CHO cells stably expressing serotonin (5-HT) 5-HT2A or 5-HT2C receptors</span></div><div class="casAuthors">Seitz, Patricia K.; Bremer, Nicole M.; McGinnis, Andrew G.; Cunningham, Kathryn A.; Watson, Cheryl S.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25</span>CODEN:
                <span class="NLM_cas:coden">BNMEA6</span>;
        ISSN:<span class="NLM_cas:issn">1471-2202</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The serotonin (5-HT) 2A and 2C receptors (5-HT2AR and 5-HT2CR) are involved in a wide range of physiol. and behavioral processes in the mammalian central and peripheral nervous systems.  These receptors share a high degree of homol., have overlapping pharmacol. profiles, and utilize many of the same and richly diverse second messenger signaling systems.  We have developed quant. assays for cells stably expressing these two receptors involving minimal cell sample manipulations that dramatically improve parallel assessments of two signaling responses: intracellular calcium (Cai++) changes and activation (phosphorylation) of downstream kinases.  Such profiles are needed to begin to understand the simultaneous contributions from the multiplicity of signaling cascades likely to be initiated by serotonergic ligands.  Results: We optimized the Cai++ assay for stable cell lines expressing either 5-HT2AR or 5-HT2CR (including dye use and measurement parameters; cell d. and serum requirements).  We adapted a quant. 96-well plate immunoassay for pERK in the same cell lines.  Similar cell d. optima and time courses were obsd. for 5-HT2AR- and 5-HT2CR-expressing cells in generating both types of signaling.  Both cell lines also require serum-free preincubation for maximal agonist responses in the pERK assay.  However, 5-HT2AR-expressing cells showed significant release of Cai++ in response to 5-HT stimulation even when preincubated in serum-replete medium, while the response was completely eliminated by serum in 5-HT2CR-expressing cells.  Response to another serotonergic ligand (DOI) was eliminated by serum-replete preincubation in both cells lines.  Conclusions: These data expand our knowledge of differences in ligand-stimulated signaling cascades between 5-HT2AR and 5-HT2CR.  Our parallel assays can be applied to other cell and receptor systems for monitoring and dissecting concurrent signaling responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6M4u7LVn5PbVg90H21EOLACvtfcHk0lgOanJzocoDLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCgu7nL&md5=6b1b3b3c45590bda79f49f89d8e7fdbb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1186%2F1471-2202-13-25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2202-13-25%26sid%3Dliteratum%253Aachs%26aulast%3DSeitz%26aufirst%3DP.%2BK.%26aulast%3DBremer%26aufirst%3DN.%2BM.%26aulast%3DMcGinnis%26aufirst%3DA.%2BG.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DWatson%26aufirst%3DC.%2BS.%26atitle%3DQuantitative%2520Changes%2520in%2520Intracellular%2520Calcium%2520and%2520Extracellular-regulated%2520Kinase%2520Activation%2520Measured%2520in%2520Parallel%2520in%2520CHO%2520Cells%2520Stably%2520Expressing%2520Serotonin%2520%25285-HT%2529%25205-HT2A%2520or%25205-HT2C%2520Receptors%26jtitle%3DBMC%2520Neurosci.%26date%3D2012%26volume%3D13%26spage%3D25%26doi%3D10.1186%2F1471-2202-13-25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1381</span>â <span class="NLM_lpage">1398</span>, <span class="refDoi">Â DOI: 10.2174/1568026619666190709101449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.2174%2F1568026619666190709101449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=31288724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvV2is7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=1381-1398&author=E.+A.+Woldauthor=C.+T.+Wildauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Targeting+the+5-HT2C+Receptor+in+Biological+Context+and+the+Current+State+of+5-HT2C+Receptor+Ligand+Development&doi=10.2174%2F1568026619666190709101449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development</span></div><div class="casAuthors">Wold, Eric A.; Wild, Christopher T.; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1381-1398</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Serotonin (5-HT) 5-HT2C receptor (5-HT2CR) is recognized as a crit. mediator of diseaserelated pathways and behaviors based upon actions in the central nervous system (CNS).  Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia.  The most significant agonist discovery to date is the FDA approved anti-obesity medication lorcaserin.  In recent years, efforts towards developing other mechanisms to enhance receptor function have resulted in the discovery of Pos. Allosteric Modulators (PAMs) for the 5-HT2CR, with several mol. series now reported.  The biol. significance and context for signaling and function of the 5-HT2CR, and the current status of 5-HT2CR agonists and PAMs are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7Nb18Hq98iLVg90H21EOLACvtfcHk0lh_EP3RwOMPQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvV2is7fE&md5=e4f90bb137775feb1d6a601192e7c9a7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190709101449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190709101449%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DWild%26aufirst%3DC.%2BT.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DTargeting%2520the%25205-HT2C%2520Receptor%2520in%2520Biological%2520Context%2520and%2520the%2520Current%2520State%2520of%25205-HT2C%2520Receptor%2520Ligand%2520Development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D1381%26epage%3D1398%26doi%3D10.2174%2F1568026619666190709101449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HarpsÃ¸e, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolajsen, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BjÃ¸rn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span> <span> </span><span class="NLM_article-title">5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">719</span>â <span class="NLM_lpage">730</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2018.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2Fj.cell.2018.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=29398112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=719-730&author=Y.+Pengauthor=J.+D.+McCorvyauthor=K.+Harps%C3%B8eauthor=K.+Lansuauthor=S.+Yuanauthor=P.+Popovauthor=L.+Quauthor=M.+Puauthor=T.+Cheauthor=L.+F.+Nikolajsenauthor=X.-P.+Huangauthor=Y.+Wuauthor=L.+Shenauthor=W.+E.+Bj%C3%B8rn-Yoshimotoauthor=K.+Dingauthor=D.+Wackerauthor=G.+W.+Hanauthor=J.+Chengauthor=V.+Katritchauthor=A.+A.+Jensenauthor=M.+A.+Hansonauthor=S.+Zhaoauthor=D.+E.+Gloriamauthor=B.+L.+Rothauthor=R.+C.+Stevensauthor=Z.-J.+Liu&title=5-HT2C+Receptor+Structures+Reveal+the+Structural+Basis+of+GPCR+Polypharmacology&doi=10.1016%2Fj.cell.2018.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology</span></div><div class="casAuthors">Peng, Yao; McCorvy, John D.; Harpsoee, Kasper; Lansu, Katherine; Yuan, Shuguang; Popov, Petr; Qu, Lu; Pu, Mengchen; Che, Tao; Nikolajsen, Louise F.; Huang, Xi-Ping; Wu, Yiran; Shen, Ling; Bjoern-Yoshimoto, Walden E.; Ding, Kang; Wacker, Daniel; Han, Gye Won; Cheng, Jianjun; Katritch, Vsevolod; Jensen, Anders A.; Hanson, Michael A.; Zhao, Suwen; Gloriam, David E.; Roth, Bryan L.; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">719-730.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drugs frequently require interactions with multiple targets-via a process known as polypharmacol.-to achieve their therapeutic actions.  Currently, drugs targeting several serotonin receptors, including the 5-HT2C receptor, are useful for treating obesity, drug abuse, and schizophrenia.  The competing challenges of developing selective 5-HT2C receptor ligands or creating drugs with a defined polypharmacol. profile, esp. aimed at G protein-coupled receptors (GPCRs), remain extremely difficult.  Here, we solved two structures of the 5-HT2C receptor in complex with the highly promiscuous agonist ergotamine and the 5-HT2A-C receptor-selective inverse agonist ritanserin at resolns. of 3.0 Ã and 2.7 Ã, resp.  We analyzed their resp. binding poses to provide mechanistic insights into their receptor recognition and opposing pharmacol. actions.  This study investigates the structural basis of polypharmacol. at canonical GPCRs and illustrates how understanding characteristic patterns of ligand-receptor interaction and activation may ultimately facilitate drug design at multiple GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooMwdaPWz7FLVg90H21EOLACvtfcHk0ljAAbPALjZsAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D&md5=b6c7f55568544a8c363794fa12f18175</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DHarps%25C3%25B8e%26aufirst%3DK.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DPopov%26aufirst%3DP.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DNikolajsen%26aufirst%3DL.%2BF.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DBj%25C3%25B8rn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.-J.%26atitle%3D5-HT2C%2520Receptor%2520Structures%2520Reveal%2520the%2520Structural%2520Basis%2520of%2520GPCR%2520Polypharmacology%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D719%26epage%3D730%26doi%3D10.1016%2Fj.cell.2018.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manivet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, D.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maroteaux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellermann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Launay, J.-M.</span></span> <span> </span><span class="NLM_article-title">The Serotonin Binding Site of Human and Murine 5-HT<sub>2B</sub> Receptors: Molecular Modeling and Site-Directed Mutagenesis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">17170</span>â <span class="NLM_lpage">17178</span>, <span class="refDoi">Â DOI: 10.1074/jbc.m200195200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1074%2Fjbc.M200195200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=11859080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD38XjslWgs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=17170-17178&author=P.+Manivetauthor=B.+Schneiderauthor=J.+C.+Smithauthor=D.-S.+Choiauthor=L.+Maroteauxauthor=O.+Kellermannauthor=J.-M.+Launay&title=The+Serotonin+Binding+Site+of+Human+and+Murine+5-HT2B+Receptors%3A+Molecular+Modeling+and+Site-Directed+Mutagenesis&doi=10.1074%2Fjbc.m200195200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis</span></div><div class="casAuthors">Manivet, Philippe; Schneider, Benoit; Smith, Jeremy Christopher; Choi, Doo-Sup; Maroteaux, Luc; Kellermann, Odile; Launay, Jean-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">17170-17178</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Bacteriorhodopsin and rhodopsin crystal structures were used as templates to build structural models of the mouse and human serotonin (5-HT)-2B receptors (5-HT2BRs).  Serotonin was docked to the receptors, and the amino acids predicted to participate to its binding were subjected to mutagenesis.  5-HT binding affinity and 5-HT-induced inositol triphosphate prodn. were measured in LMTK- cells transfected with either wild-type or mutated receptor genes.  According to these measurements, the bacteriorhodopsin-based models of the 5-HT2BRs appear more confident than the rhodopsin-based ones.  Residues belonging to the transmembrane domains 3 and 6, i.e. Asp3.32, Ser3.36, Phe6.52, and Asn6.55, make direct contacts with 5-HT.  In addn., Trp3.28, Phe3.35, Phe6.52, and Phe7.38 form an arom. box surrounding 5-HT.  The specificity of human and mouse 5-HT2BRs may be reflected by different rearrangements of the arom. network upon 5-HT binding.  Two amino acids close to Pro5.50 in the human transmembrane domain 5 sequence were permuted to introduce a "mouse-like" sequence.  This change was enough to confer the human 5-HT2BR properties similar to those of the mouse.  Taken together, the computed models and the site-directed mutagenesis expts. give a structural explanation to (i) the different 5-HT pKD values measured with the human and mouse 5-HT2BRs (7.9 and 5.8, resp.) and (ii) the specificity of 5-HT binding to 5-HT2BRs as compared with other serotonergic G-protein coupled receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr51vp_1vjTJbVg90H21EOLACvtfcHk0lgMSqxUr87NXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjslWgs74%253D&md5=31a2c6e7a5a6551d46693e76bbb32b5f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M200195200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M200195200%26sid%3Dliteratum%253Aachs%26aulast%3DManivet%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DJ.%2BC.%26aulast%3DChoi%26aufirst%3DD.-S.%26aulast%3DMaroteaux%26aufirst%3DL.%26aulast%3DKellermann%26aufirst%3DO.%26aulast%3DLaunay%26aufirst%3DJ.-M.%26atitle%3DThe%2520Serotonin%2520Binding%2520Site%2520of%2520Human%2520and%2520Murine%25205-HT2B%2520Receptors%253A%2520Molecular%2520Modeling%2520and%2520Site-Directed%2520Mutagenesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D17170%26epage%3D17178%26doi%3D10.1074%2Fjbc.m200195200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Improved Method for the Identification and Validation of Allosteric Sites</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2358</span>â <span class="NLM_lpage">2363</span>, <span class="refDoi">Â DOI: 10.1021/acs.jcim.7b00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.7b00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlGlu7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=2358-2363&author=K.+Songauthor=X.+Liuauthor=W.+Huangauthor=S.+Luauthor=Q.+Shenauthor=L.+Zhangauthor=J.+Zhang&title=Improved+Method+for+the+Identification+and+Validation+of+Allosteric+Sites&doi=10.1021%2Facs.jcim.7b00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Improved Method for the Identification and Validation of Allosteric Sites</span></div><div class="casAuthors">Song, Kun; Liu, Xinyi; Huang, Wenkang; Lu, Shaoyong; Shen, Qiancheng; Zhang, Lu; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2358-2363</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric regulation induced by modulators binding to different, often distant, allosteric sites allows for exquisite control of protein functional activity.  The structural diversity of allosteric sites endows allosteric modulators with high selectivity and low toxicity.  Targeting allosteric sites, a novel tactic in drug discovery, has garnered much attention in the scientific community, and the identification of allosteric sites has become an important component of the development of allosteric drugs.  Here we present AllositePro, a method which predicts allosteric sites in proteins by combining pocket features with perturbation anal.  The performance of AllositePro is superior to that of the other currently available methods.  Using AllositePro, we predicted a novel allosteric site in cyclin-dependent kinase 2 (CDK2) and validated it by site-directed mutagenesis assay.  Thus, the AllositePro method provides an effective way to identify allosteric sites and could be a useful strategy for allosteric drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq23d-Zg0_4G7Vg90H21EOLACvtfcHk0liXlBUMqh82og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlGlu7vL&md5=fbc362245d0bfb34686e0bc2fb38203b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.7b00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.7b00014%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DImproved%2520Method%2520for%2520the%2520Identification%2520and%2520Validation%2520of%2520Allosteric%2520Sites%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26spage%3D2358%26epage%3D2363%26doi%3D10.1021%2Facs.jcim.7b00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrey, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preissner, R.</span></span> <span> </span><span class="NLM_article-title">ProTox-II: A Webserver for the Prediction of Toxicity of Chemicals</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">W257</span>â <span class="NLM_lpage">W263</span>, <span class="refDoi">Â DOI: 10.1093/nar/gky318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1093%2Fnar%2Fgky318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=29718510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVyrt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=W257-W263&author=P.+Banerjeeauthor=A.+O.+Eckertauthor=A.+K.+Schreyauthor=R.+Preissner&title=ProTox-II%3A+A+Webserver+for+the+Prediction+of+Toxicity+of+Chemicals&doi=10.1093%2Fnar%2Fgky318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">ProTox-II: a webserver for the prediction of toxicity of chemicals</span></div><div class="casAuthors">Banerjee, Priyanka; Eckert, Andreas O.; Schrey, Anna K.; Preissner, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">W1</span>),
    <span class="NLM_cas:pages">W257-W263</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Advancement in the field of computational research has made it possible for the in silico methods to offer significant benefits to both regulatory needs and requirements for risk assessments, and pharmaceutical industry to assess the safety profile of a chem.  Here, we present ProTox-II that incorporates mol. similarity, pharmacophores, fragment propensities and machine-learning models for the prediction of various toxicity endpoints; such as acute toxicity, hepatotoxicity, cytotoxicity, carcinogenicity, mutagenicity, immunotoxicity, adverse outcomes pathways (Tox21) and toxicity targets.  The predictive models are built on data from both in vitro assays (e.g.Tox21 assays, Ames bacterial mutation assays, hepG2 cytotoxicity assays, Immunotoxicity assays) and in vivo cases (e.g. carcinogenicity, hepatotoxicity).  The models have been validated on independent external sets and have shown strong performance.  ProTox-II provides a freely available webserver for in silico toxicity prediction for toxicologists, regulatory agencies, computational and medicinal chemists.  The webserver takes a two-dimensional chem. structure as an input and reports the possible toxicity profile of the chem. for 33 models with confidence scores, and an overall toxicity radar chart along with three most similar compds. with known acute toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0iLlkldrW27Vg90H21EOLACvtfcHk0ljfXjBnYXocIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVyrt7Y%253D&md5=c39b880461f53ae84341843feafe3e1c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky318%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DP.%26aulast%3DEckert%26aufirst%3DA.%2BO.%26aulast%3DSchrey%26aufirst%3DA.%2BK.%26aulast%3DPreissner%26aufirst%3DR.%26atitle%3DProTox-II%253A%2520A%2520Webserver%2520for%2520the%2520Prediction%2520of%2520Toxicity%2520of%2520Chemicals%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26spage%3DW257%26epage%3DW263%26doi%3D10.1093%2Fnar%2Fgky318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Moving Beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach to Enable Alignment of Druglike Properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>â <span class="NLM_lpage">449</span>, <span class="refDoi">Â DOI: 10.1021/cn100008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+Beyond+Rules%3A+The+Development+of+a+Central+Nervous+System+Multiparameter+Optimization+%28CNS+MPO%29+Approach+to+Enable+Alignment+of+Druglike+Properties&doi=10.1021%2Fcn100008c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-449</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The interplay among commonly used physicochem. properties in drug design was examd. and utilized to create a prospective design tool focused on the alignment of key druglike attributes.  Using a set of six physicochem. parameters ((a) lipophilicity, calcd. partition coeff. (ClogP); (b) calcd. distribution coeff. at pH = 7.4 (ClogD); (c) mol. wt. (MW); (d) topol. polar surface area (TPSA); (e) no. of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compds. (N = 11 303).  The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score â¥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates.  This anal. suggests that this algorithm could potentially be used to identify compds. with a higher probability of successfully testing hypotheses in the clinic.  In addn., a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set.  The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chem. design space through a holistic assessment approach.  Based on six physicochem. properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compds. with increased probability of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3Mvkgm_X5bVg90H21EOLACvtfcHk0lgxlbDLwI0RKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D&md5=e94998f65a420be6ee4dec4a987cb983</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520Beyond%2520Rules%253A%2520The%2520Development%2520of%2520a%2520Central%2520Nervous%2520System%2520Multiparameter%2520Optimization%2520%2528CNS%2520MPO%2529%2520Approach%2520to%2520Enable%2520Alignment%2520of%2520Druglike%2520Properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449%26doi%3D10.1021%2Fcn100008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, C. L.</span></span> <span> </span><span class="NLM_article-title">Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-Species Pharmacologic ExposureâResponse Relationships</span>. In  <i>Annual Reports in Medicinal Chemistry</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">2010</span>; Vol.  <span class="NLM_volume">45</span>, pp  <span class="NLM_fpage">55</span>â <span class="NLM_lpage">70</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2FS0065-7743%2810%2945004-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+L.+Shafferauthor=J.+E.+Macor&title=Defining+Neuropharmacokinetic+Parameters+in+CNS+Drug+Discovery+to+Determine+Cross-Species+Pharmacologic+Exposure%E2%80%93Response+Relationships"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2810%2945004-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26id%3Ddoi%3A10.1016%252FS0065-7743%252810%252945004-6%26sid%3Dliteratum%253Aachs%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26atitle%3DDefining%2520Neuropharmacokinetic%2520Parameters%2520in%2520CNS%2520Drug%2520Discovery%2520to%2520Determine%2520Cross-Species%2520Pharmacologic%2520Exposure%25E2%2580%2593Response%2520Relationships%26jtitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26pub%3DAcademic%2520Press%26date%3D2010%26volume%3D45%26spage%3D55%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soto, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbertson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">In Vivo and In Vitro Analyses of Novel Peptidomimetic Disruptors for the Serotonin 5-HT2C Receptor Interaction With Phosphatase and Tensin Homolog</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">907</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2019.00907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.3389%2Ffphar.2019.00907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=31507411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFShtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=907&author=C.+A.+Sotoauthor=H.+C.+Duauthor=R.+G.+Foxauthor=T.+Yangauthor=J.+Hoosonauthor=N.+C.+Anastasioauthor=S.+R.+Gilbertsonauthor=K.+A.+Cunningham&title=In+Vivo+and+In+Vitro+Analyses+of+Novel+Peptidomimetic+Disruptors+for+the+Serotonin+5-HT2C+Receptor+Interaction+With+Phosphatase+and+Tensin+Homolog&doi=10.3389%2Ffphar.2019.00907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo and in vitro analyses of novel peptidomimetic disruptors for the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog</span></div><div class="casAuthors">Soto, Claudia A.; Du, Huang-Chi; Fox, Robert G.; Yang, Taegyun; Hooson, James; Anastasio, Noelle C.; Gilbertson, Scott R.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">907</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Hypofunction of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in a variety of disorders including substance use disorders.  As such, approaches to enhance 5-HT2CR signaling display therapeutic potential.  In the present study, we show that disruption of the 5-HT2CR interaction with the protein phosphatase and tensin homolog (PTEN) via peptidomimetics enhances 5-HT2CR-mediating signaling in vitro and potentiates selective 5-HT2CR agonists in behavioral rodent models.  Overall, the present study provides further evidence that 5-HT2CR activity can be modulated through an allosteric protein-protein interaction.  This work provides the groundwork for the continued exploration of protein-protein interactions that can allosterically modulate this crit. receptor and other important G protein-coupled receptors (GPCRs) for new therapeutic development through mechanisms that may display clin. utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxgSjgfgTkfLVg90H21EOLACvtfcHk0ljMX_97r_iTTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFShtrw%253D&md5=c57f6c61b8e096f3b03db9930569c5f3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00907%26sid%3Dliteratum%253Aachs%26aulast%3DSoto%26aufirst%3DC.%2BA.%26aulast%3DDu%26aufirst%3DH.%2BC.%26aulast%3DFox%26aufirst%3DR.%2BG.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DHooson%26aufirst%3DJ.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DGilbertson%26aufirst%3DS.%2BR.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DIn%2520Vivo%2520and%2520In%2520Vitro%2520Analyses%2520of%2520Novel%2520Peptidomimetic%2520Disruptors%2520for%2520the%2520Serotonin%25205-HT2C%2520Receptor%2520Interaction%2520With%2520Phosphatase%2520and%2520Tensin%2520Homolog%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D907%26doi%3D10.3389%2Ffphar.2019.00907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F. C.</span></span> <span> </span><span class="NLM_article-title">Drug Discrimination in Neurobiology</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">337</span>â <span class="NLM_lpage">345</span>, <span class="refDoi">Â DOI: 10.1016/s0091-3057(99)00047-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2FS0091-3057%2899%2900047-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10515310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaK1MXmt1eksbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=337-345&author=F.+C.+Colpaert&title=Drug+Discrimination+in+Neurobiology&doi=10.1016%2Fs0091-3057%2899%2900047-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discrimination in Neurobiology</span></div><div class="casAuthors">Colpaert, F. C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-345</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 166 refs.  Areas of neurobiol. interest are identified towards which drug discrimination (DD) studies have made important contributions.  DD allows ligand actions to be analyzed at the whole organism level, with a neurobiol. specificity that is exquisite and often unrivalled.  DD analyses have thus been made of a vast array of CNS agents acting on receptors, enzymes, or ion channels, including most drugs of abuse.  DD uniquely offers access to the study of subjective drug effects in animals, using a methodol. that also is transposable to humans and has generated unprecedented models of pathol. (e.g., chronic pain, opiate addiction).  Parametric studies of such independent variables as training dose and reinforcement provide refined insights into the dynamic psychophysiol. mechanisms of both drug effects and behavior.  Three different mechanisms have been identified by which discriminative, and perhaps other behaviors, can come about.  DD also is superbly sensitive to small, partial activation of mol. substrates; this has enabled DD analyses to pioneer the unravelling of mol. mechanisms of drug action (attributing, f.ex., LSD's particular subjective effects to an unusual, partial activation of 5-HT, and perhaps other receptors).  DD has both oriented and served as a tool to conduct drug discovery research (e.g., pirenperone-risperidone, loperamide).  The DD response arguably constitutes a quantal, rather than graded, variable, and as such allows a comprehension of mol., pharmacol., and behavioral mechanisms that would have been otherwise inaccessible.  Perhaps most important are the following further contributions.  One is the notion that particular, different levels of receptor activation are assocd. with qualities of neurobiol. actions that also differ and are unique, this notion arguably constituting the most significant addn. to affinity and intrinsic activity since the earliest theor. conceptions of mol. pharmacol.  Another contribution consists of studies that render redundant the notion of tolerance and identify fundamental mechanisms of signal transduction; these mechanisms account for apparent tolerance, dependence, addiction, and sensitization, and appear to operate ubiquitously in a bewildering array of biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQOkeVux09GLVg90H21EOLACvtfcHk0li8i49GtqD19A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt1eksbk%253D&md5=67afd32d4245a597953605b545bf1c61</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2899%2900047-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252899%252900047-7%26sid%3Dliteratum%253Aachs%26aulast%3DColpaert%26aufirst%3DF.%2BC.%26atitle%3DDrug%2520Discrimination%2520in%2520Neurobiology%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1999%26volume%3D64%26spage%3D337%26epage%3D345%26doi%3D10.1016%2Fs0091-3057%2899%2900047-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F. C.</span></span> <span> </span><span class="NLM_article-title">Drug Discrimination: Methods of Manipulation, Measurement, and Analysis</span>. In  <i>Methods of Assessing the Reinforcing Properties of Abused Drugs</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozarth, M. A.</span></span>, Ed.; <span class="NLM_publisher-name">Springer New York</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">1987</span>; pp  <span class="NLM_fpage">341</span>â <span class="NLM_lpage">372</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1007%2F978-1-4612-4812-5_17" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&pages=341-372&author=F.+C.+Colpaertauthor=M.+A.+Bozarth&title=Methods+of+Assessing+the+Reinforcing+Properties+of+Abused+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2F978-1-4612-4812-5_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4612-4812-5_17%26sid%3Dliteratum%253Aachs%26aulast%3DColpaert%26aufirst%3DF.%2BC.%26atitle%3DDrug%2520Discrimination%253A%2520Methods%2520of%2520Manipulation%252C%2520Measurement%252C%2520and%2520Analysis%26btitle%3DMethods%2520of%2520Assessing%2520the%2520Reinforcing%2520Properties%2520of%2520Abused%2520Drugs%26aulast%3DBozarth%26aufirst%3DM.%2BA.%26pub%3DSpringer%2520New%2520York%26date%3D1987%26spage%3D341%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span> <span> </span><span class="NLM_article-title">Agonist and Antagonist Effects of Prototype Opiate Drugs in Rats Discriminating Fentanyl from Saline: Characteristics of Partial Generalization</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>230</i></span>,  <span class="NLM_fpage">193</span>â <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=6747824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaL2cXltVeqt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=1984&pages=193-199&author=F.+C.+Colpaertauthor=P.+A.+Janssen&title=Agonist+and+Antagonist+Effects+of+Prototype+Opiate+Drugs+in+Rats+Discriminating+Fentanyl+from+Saline%3A+Characteristics+of+Partial+Generalization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist and antagonist effects of prototype opiate drugs in rats discriminating fentanyl from saline:  characteristics of partial generalization</span></div><div class="casAuthors">Colpaert, Francis C.; Janssen, Paul A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">193-9</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The partial generalizations that prototype opiate drugs may produce in rats that are trained to discriminate 0.04 mg/kg of fentanyl citrate  [990-73-8] from saline were characterized.  Cyclazocine  [3572-80-3], nalorphine  [62-67-9], ketocyclazocine  [36292-69-0], and N-allylnormetazocine  [14198-28-8] produced partial generalization with fentanyl; the same compds. also partially antagonized fentanyl.  The fentanyl-like and the fentanyl-antagonist effects of these compds. occurred within similar ranges of dose.  An orderly incompatibility was apparent between the agonist and antagonist effects produced by each drug; cyclazocine, for example, was unlikely to antagonize fentanyl in animals in which it produced generalization, whereas it did antagonize fentanyl in animals in which it produced no generalization.  Cyclazocine, nalorphine, N-allylnormetazocine, and naloxone  [465-65-6] produced either fentanyl-like or fentanyl-antagonist effects in all animals tested.  A reliable relation was apparent among the agonist and antagonist effects of different opiate drugs; rats that generalized cyclazocine also were likely to generalize nalorphine and ketocyclazocine and were relatively less responsive to cyclazocine, nalorphine, N-allylnormetazocine, and naloxone as antagonists of fentanyl.  The results point to the importance of a no. of new methods in the anal. of drug discrimination data, which are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHZd6ZtPQWzrVg90H21EOLACvtfcHk0ljZ2iLJhuimbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXltVeqt7Y%253D&md5=7464e71aae4a0969689e4df3f38b107f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColpaert%26aufirst%3DF.%2BC.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26atitle%3DAgonist%2520and%2520Antagonist%2520Effects%2520of%2520Prototype%2520Opiate%2520Drugs%2520in%2520Rats%2520Discriminating%2520Fentanyl%2520from%2520Saline%253A%2520Characteristics%2520of%2520Partial%2520Generalization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1984%26volume%3D230%26spage%3D193%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stevens
Negus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, M. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination</span>. <i>Curr. Top. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">245</span>â <span class="NLM_lpage">259</span>, <span class="refDoi">Â DOI: 10.1007/7854_2016_36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1007%2F7854_2016_36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=27571746" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=245-259&author=S.+Stevens%0ANegusauthor=M.+L.+Banks&title=Pharmacokinetic-Pharmacodynamic+%28PKPD%29+Analysis+with+Drug+Discrimination&doi=10.1007%2F7854_2016_36"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2F7854_2016_36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7854_2016_36%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%2BNegus%26aufirst%3DS.%26aulast%3DBanks%26aufirst%3DM.%2BL.%26atitle%3DPharmacokinetic-Pharmacodynamic%2520%2528PKPD%2529%2520Analysis%2520with%2520Drug%2520Discrimination%26jtitle%3DCurr.%2520Top.%2520Behav.%2520Neurosci.%26date%3D2018%26volume%3D39%26spage%3D245%26epage%3D259%26doi%3D10.1007%2F7854_2016_36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCreary, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filip, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Discriminative Stimulus Properties of (Â±)-Fenfluramine: the Role of 5-HT<sub>2</sub> Receptor Subtypes</span>. <i>Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">212</span>â <span class="NLM_lpage">221</span>, <span class="refDoi">Â DOI: 10.1037/0735-7044.117.2.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1037%2F0735-7044.117.2.212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=12708517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivFehsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2003&pages=212-221&author=A.+C.+McCrearyauthor=M.+Filipauthor=K.+A.+Cunningham&title=Discriminative+Stimulus+Properties+of+%28%C2%B1%29-Fenfluramine%3A+the+Role+of+5-HT2+Receptor+Subtypes&doi=10.1037%2F0735-7044.117.2.212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discriminative stimulus properties of (Â±)-fenfluramine: the role of 5-HT2 receptor subtypes</span></div><div class="casAuthors">McCreary, Andrew C.; Filip, Malgorzata; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioral Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-221</span>CODEN:
                <span class="NLM_cas:coden">BENEDJ</span>;
        ISSN:<span class="NLM_cas:issn">0735-7044</span>.
    
            (<span class="NLM_cas:orgname">American Psychological Association</span>)
        </div><div class="casAbstract">The role of serotonin 5-HT2 receptors (5-HT2R) in the discriminative stimulus effects of fenfluramine was investigated.  Male Sprague-Dawley rats were trained to discriminate (Â±)-fenfluramine (2 mg/kg i.p.) from saline using a 2-lever, water-reinforced paradigm.  Drug-lever responding after fenfluramine was dose-dependent.  The 5-HT2C/1BR agonist mCPP and the 5-HT2CR agonist MK 212 fully substituted, whereas the 5-HT2A/2CR agonist DOI partially substituted, for the training drug.  The 5-HT2BR agonist BW 723C86 engendered saline-lever responding.  The 5-HT2C/2BR antagonist SB 206553 completely antagonized the fenfluramine discrimination as well as the full substitutions of mCPP and MK 212 and the partial substitution of DOI.  The selective 5-HT2AR antagonist M100907 partially suppressed the stimulus effects of fenfluramine, mCPP, and MK 212 and almost fully attenuated the partial substitution of DOI.  RS 102221, a selective 5-HT2CR antagonist that does not cross the blood-brain barrier, did not alter the fenfluramine cue.  Results demonstrate that the discriminative stimulus effects of fenfluramine are centrally mediated by 5-HT2CR and to some extent by 5-HT2AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq3wP3zWbZSbVg90H21EOLACvtfcHk0lgoWMZBPoUzEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivFehsbg%253D&md5=0b2669064bf27454e16ee63cfb8130df</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1037%2F0735-7044.117.2.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F0735-7044.117.2.212%26sid%3Dliteratum%253Aachs%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DFilip%26aufirst%3DM.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DDiscriminative%2520Stimulus%2520Properties%2520of%2520%2528%25C2%25B1%2529-Fenfluramine%253A%2520the%2520Role%2520of%25205-HT2%2520Receptor%2520Subtypes%26jtitle%3DBehav.%2520Neurosci.%26date%3D2003%26volume%3D117%26spage%3D212%26epage%3D221%26doi%3D10.1037%2F0735-7044.117.2.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Involvement of 5-HT2C Receptors in Mediating the Discriminative Stimulus Properties of m-Chlorophenylpiperazine (mCPP)</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">38</span>, <span class="refDoi">Â DOI: 10.1016/0014-2999(94)90690-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2F0014-2999%2894%2990690-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=8082704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaK2cXkt1Kktrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1994&pages=27-38&author=P.+M.+Callahanauthor=K.+A.+Cunningham&title=Involvement+of+5-HT2C+Receptors+in+Mediating+the+Discriminative+Stimulus+Properties+of+m-Chlorophenylpiperazine+%28mCPP%29&doi=10.1016%2F0014-2999%2894%2990690-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP)</span></div><div class="casAuthors">Callahan, Patrick M.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">27-38</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Rats were trained to discriminate the 5-HT receptor agonist m-chlorophenylpiperazine (mCPP; 1 mg/kg) from saline using a two-lever, water-reinforced drug discrimination task.  The antidepressant trazodone (1-8 mg/kg), the 5-HT1B/2C receptor agonists 1-(m-trifluoromethylphenyl)piperazine (TFMPP; 0.25-1 mg/kg) and MK 212 (0.125-1 mg/kg), and the mixed 5-HT1A/B receptor agonist RU 24969 (0.25-2 mg/kg) substituted fully for mCPP.  The 5-HT2A/2C receptor agonists 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 0.25-1 mg/kg) and d-lysergic acid diethylamide (LSD; 0.02-0.08 mg/kg) and the 5-HT releaser fenfluramine (0.5-2 mg/kg) also mimicked mCPP.  Agonists selective for the 5-HT1A or 5-HT3 receptor or the 5-HT reuptake site produced saline-lever responding.  The ergoline deriv. mesulergine (0.5-4 mg/kg) produced a partial agonist/antagonist profile.  The 5-HT1/2 receptor antagonist metergoline (0.125-1 mg/kg) completely blocked the mCPP cue whereas the 5-HT2A/2C receptor antagonists ketanserin and LY 53857 as well as all other 5-HT receptor antagonists failed to block the mCPP cue.  The dopamine receptor antagonists SCH 23390 and haloperidol were also ineffective mCPP antagonists.  Following pretreatment with the 5-HT synthesis inhibitor p-chlorophenylalanine (pCPA; 100 mg/kg/day) for 3 consecutive days, the discriminability of low doses of mCPP increased, whereas the effects of fenfluramine decreased.  The present results suggest that the discriminative stimulus effects of mCPP in rats are mediated primarily by postsynaptic 5-HT2C receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrebmnBj2zsK7Vg90H21EOLACvtfcHk0lhuhfsbmJIopQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkt1Kktrk%253D&md5=98623ad672842986facfc5cf3fa0a345</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2894%2990690-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252894%252990690-4%26sid%3Dliteratum%253Aachs%26aulast%3DCallahan%26aufirst%3DP.%2BM.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DInvolvement%2520of%25205-HT2C%2520Receptors%2520in%2520Mediating%2520the%2520Discriminative%2520Stimulus%2520Properties%2520of%2520m-Chlorophenylpiperazine%2520%2528mCPP%2529%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1994%26volume%3D257%26spage%3D27%26epage%3D38%26doi%3D10.1016%2F0014-2999%2894%2990690-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">m-Chlorophenylpiperazine (mCPP) Modulates the Discriminative Stimulus Effects of Cocaine Through Actions at the 5-HT<sub>2</sub>C Receptor</span>. <i>Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">157</span>â <span class="NLM_lpage">162</span>, <span class="refDoi">Â DOI: 10.1037/0735-7044.118.1.157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1037%2F0735-7044.118.1.157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=14979792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitVyqtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2004&pages=157-162&author=P.+S.+Frankelauthor=K.+A.+Cunningham&title=m-Chlorophenylpiperazine+%28mCPP%29+Modulates+the+Discriminative+Stimulus+Effects+of+Cocaine+Through+Actions+at+the+5-HT2C+Receptor&doi=10.1037%2F0735-7044.118.1.157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">m-Chlorophenylpiperazine (mCPP) modulates the discriminative stimulus effects of cocaine through actions at the 5-HT2C receptor</span></div><div class="casAuthors">Frankel, Paul S.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioral Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">157-162</span>CODEN:
                <span class="NLM_cas:coden">BENEDJ</span>;
        ISSN:<span class="NLM_cas:issn">0735-7044</span>.
    
            (<span class="NLM_cas:orgname">American Psychological Association</span>)
        </div><div class="casAbstract">Agonists acting at the serotonin-1B receptor (5-HT1BR) and 5-HT2CR have been reported to potentiate and block, resp., the discriminative stimulus effects of cocaine.  The present investigation reassessed the antagonistic effects of the mixed 5-HT2C/1BR agonist m-chlorophenylpiperazine (mCPP) on the discriminative stimulus effects of cocaine in the presence or absence of selective antagonism of the 5-HT1BR or 5-HT2CR.  The stimulus effects of cocaine were attenuated by mCPP at doses that reduced response rates.  The selective 5-HT2CR antagonist SB 242084, but not the selective 5-HT1BR antagonist GR 127935, reversed the mCPP-evoked attenuation of the cocaine cue and the suppression of response rates.  These results demonstrate that the suppressive effects of mCPP on cocaine discrimination are related to stimulation of the 5-HT2CR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq822S6caSBpLVg90H21EOLACvtfcHk0lj3DwL-vdUsLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitVyqtb0%253D&md5=6c61e7a449610957fc9c819edec93d4c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1037%2F0735-7044.118.1.157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F0735-7044.118.1.157%26sid%3Dliteratum%253Aachs%26aulast%3DFrankel%26aufirst%3DP.%2BS.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3Dm-Chlorophenylpiperazine%2520%2528mCPP%2529%2520Modulates%2520the%2520Discriminative%2520Stimulus%2520Effects%2520of%2520Cocaine%2520Through%2520Actions%2520at%2520the%25205-HT2C%2520Receptor%26jtitle%3DBehav.%2520Neurosci.%26date%3D2004%26volume%3D118%26spage%3D157%26epage%3D162%26doi%3D10.1037%2F0735-7044.118.1.157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span>; <span class="NLM_string-name">Young, R.</span></span> <span> </span><span class="NLM_article-title">Drug Discrimination and Development of Novel Agents and Pharmacological Tools</span>. In  <i>Drug Discrimination: Applications to Medicinal Chemistry and Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span>, <span class="NLM_string-name">Young, R.</span></span>, Eds.; <span class="NLM_publisher-name">John Wiley and Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">217</span>â <span class="NLM_lpage">238</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1002%2F9781118023150.ch7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=217-238&author=R.+A.+Glennon&author=R.+Youngauthor=R.+A.+Glennon&author=R.+Young&title=Drug+Discrimination%3A+Applications+to+Medicinal+Chemistry+and+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2F9781118023150.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118023150.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DDrug%2520Discrimination%2520and%2520Development%2520of%2520Novel%2520Agents%2520and%2520Pharmacological%2520Tools%26btitle%3DDrug%2520Discrimination%253A%2520Applications%2520to%2520Medicinal%2520Chemistry%2520and%2520Drug%2520Discovery%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26pub%3DJohn%2520Wiley%2520and%2520Sons%26date%3D2011%26spage%3D217%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathis, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmett-Oglesby, M. W.</span></span> <span> </span><span class="NLM_article-title">Quantal vs. Graded Generalization in Drug Discrimination: Measuring a Graded Response</span>. <i>J. Neurosci. Methods</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.1016/0165-0270(90)90005-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2F0165-0270%2890%2990005-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=2407907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A280%3ADyaK3c7ntlektw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1990&pages=23-33&author=D.+A.+Mathisauthor=M.+W.+Emmett-Oglesby&title=Quantal+vs.+Graded+Generalization+in+Drug+Discrimination%3A+Measuring+a+Graded+Response&doi=10.1016%2F0165-0270%2890%2990005-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Quantal vs. graded generalization in drug discrimination: measuring a graded response</span></div><div class="casAuthors">Mathis D A; Emmett-Oglesby M W</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroscience methods</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-33</span>
        ISSN:<span class="NLM_cas:issn">0165-0270</span>.
    </div><div class="casAbstract">In drug discrimination research, detection of drug stimuli by animals is used for investigating various properties of psychoactive drugs.  The major issue addressed by this paper is whether detection of drug stimuli by animals is a quantal or graded event.  Some data suggest that detection of a drug stimulus by animals is quantal in nature.  Thus, variations in drug stimulus substitution may only reflect variations in threshold for detecting the training stimulus rather than the current concept of these data reflecting graded responding to stimulus intensity.  Therefore, drug discrimination procedures may have limited utility for detecting quantitative differences in the subjective effects of varying drug doses.  In order to examine this problem, a method for measuring continuous response gradients in individual animals is needed.  Tests for quantal responding generally use the distribution of responses on two manipulanda as the dependent measure.  However, this variable may be inadequate for detecting a graded response, and may actually reflect loss of stimulus control or a deterioration in performance, rather than changes in response magnitude.  Most alternative measures utilize response rate.  Unfortunately, these measures are influenced by the direct rate-altering properties of some drugs.  One possible alternative method is conditioned taste aversion as the discriminative task.  This paradigm provides a means for not only ascertaining if graded discriminative responses occur in individual animals, but also more rapidly training a drug discrimination.  Thus, using conditioned taste aversion techniques for measuring a drug discrimination may provide better indices for detecting response gradations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKo3Q2_Hi_y0loaUqgkFHkfW6udTcc2eYQVMQzCggvbbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c7ntlektw%253D%253D&md5=216a85969e0fc540ce7d92ee1af44947</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2F0165-0270%2890%2990005-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-0270%252890%252990005-Z%26sid%3Dliteratum%253Aachs%26aulast%3DMathis%26aufirst%3DD.%2BA.%26aulast%3DEmmett-Oglesby%26aufirst%3DM.%2BW.%26atitle%3DQuantal%2520vs.%2520Graded%2520Generalization%2520in%2520Drug%2520Discrimination%253A%2520Measuring%2520a%2520Graded%2520Response%26jtitle%3DJ.%2520Neurosci.%2520Methods%26date%3D1990%26volume%3D31%26spage%3D23%26epage%3D33%26doi%3D10.1016%2F0165-0270%2890%2990005-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennett, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bright, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avenell, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stean, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromidge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middlemiss, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, T. P.</span></span> <span> </span><span class="NLM_article-title">SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">609</span>â <span class="NLM_lpage">620</span>, <span class="refDoi">Â DOI: 10.1016/s0028-3908(97)00038-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2FS0028-3908%2897%2900038-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=9225286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaK2sXktlSmu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=609-620&author=G.+A.+Kennettauthor=M.+D.+Woodauthor=F.+Brightauthor=B.+Trailauthor=G.+Rileyauthor=V.+Hollandauthor=K.+Y.+Avenellauthor=T.+Steanauthor=N.+Uptonauthor=S.+Bromidgeauthor=I.+T.+Forbesauthor=A.+M.+Brownauthor=D.+N.+Middlemissauthor=T.+P.+Blackburn&title=SB+242084%2C+a+Selective+and+Brain+Penetrant+5-HT+2C+Receptor+Antagonist&doi=10.1016%2Fs0028-3908%2897%2900038-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist</span></div><div class="casAuthors">Kennett, G. A.; Wood, M. D.; Bright, F.; Trail, B.; Riley, G.; Holland, V.; Avenell, K. Y.; Stean, T.; Upton, N.; Bromidge, S.; Forbes, I. T.; Brown, A. M.; Middlemiss, D. N.; Blackburn, T. P.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4/5</span>),
    <span class="NLM_cas:pages">609-620</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">SB 242084 has a high affinity (pKi 9.0) for the cloned human 5-HT2C receptor and 100- and 158-fold selectivity over the closely related cloned human 5-HT2B and 5-HT2A subtypes, resp.  SB 242084 had over 100-fold selectivity over a range of other 5-HT, dopamine and adrenergic receptors.  In studies of 5-HT-stimulated phosphatidylinositol hydrolysis using SH-SY5Y cells stably expressing the cloned human 5-HT2C receptor, SB 242084 acted as an antagonist with a pKb of 9.3, which closely resembled its corresponding receptor binding affinity.  SB 242084 potently inhibited m-chlorophenylpiperazine (mCPP, 7 mg/kg i.p. 20 min pre-test)-induced hypolocomotion in rats, a model of in vivo central 5-HT2C receptor function, with an ID50 of 0.11 mg/kg i.p., and 2.0 mg/kg p.o.  SB 242084 (0.1-1 mg/kg i.p.) exhibited an anxiolytic-like profile in the rat social interaction test, increasing time spent in social interaction, but having no effect on locomotion.  SB 242084 (0.1-1 mg/kg i.p.) also markedly increased punished responding in a rat Geller-Seifter conflict test of anxiety, but had no consistent effect on unpunished responding.  A large acute dose of SB 242084 (30 mg/kg p.o.) had no effect on seizure susceptibility in the rat maximal electroshock seizure threshold test.  Also, while SB 242084 (2 and 6 mg/kg p.o. 1 h pre-test) antagonized the hypophagic response to mCPP, neither acute nor subchronic administration of the drug, for 5 days at 2 or 6 mg/kg p.o. twice daily, affected food intake or wt. gain.  The results suggest that SB 242084 is the first reported selective potent and brain penetrant 5-HT2C receptor antagonist and has anxiolytic-like activity, but does not possess either proconvulsant or hyperphagic properties which are characteristic of mutant mice lacking the 5-HT2C receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosMHDoDrRiabVg90H21EOLACvtfcHk0lisTo9Ytj0Chg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlSmu7Y%253D&md5=75f9afeb2a2bb89e2303b64bbb0afbb5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2897%2900038-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252897%252900038-5%26sid%3Dliteratum%253Aachs%26aulast%3DKennett%26aufirst%3DG.%2BA.%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DBright%26aufirst%3DF.%26aulast%3DTrail%26aufirst%3DB.%26aulast%3DRiley%26aufirst%3DG.%26aulast%3DHolland%26aufirst%3DV.%26aulast%3DAvenell%26aufirst%3DK.%2BY.%26aulast%3DStean%26aufirst%3DT.%26aulast%3DUpton%26aufirst%3DN.%26aulast%3DBromidge%26aufirst%3DS.%26aulast%3DForbes%26aufirst%3DI.%2BT.%26aulast%3DBrown%26aufirst%3DA.%2BM.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26aulast%3DBlackburn%26aufirst%3DT.%2BP.%26atitle%3DSB%2520242084%252C%2520a%2520Selective%2520and%2520Brain%2520Penetrant%25205-HT%25202C%2520Receptor%2520Antagonist%26jtitle%3DNeuropharmacology%26date%3D1997%26volume%3D36%26spage%3D609%26epage%3D620%26doi%3D10.1016%2Fs0028-3908%2897%2900038-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fronik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaiser, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sejer
Pedersen, D.</span></span> <span> </span><span class="NLM_article-title">Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4126</span>â <span class="NLM_lpage">4134</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01601</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01601" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVyktbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4126-4134&author=P.+Fronikauthor=B.+I.+Gaiserauthor=D.+Sejer%0APedersen&title=Bitopic+Ligands+and+Metastable+Binding+Sites%3A+Opportunities+for+G+Protein-Coupled+Receptor+%28GPCR%29+Medicinal+Chemistry&doi=10.1021%2Facs.jmedchem.6b01601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry</span></div><div class="casAuthors">Fronik, Philipp; Gaiser, Birgit I.; Sejer Pedersen, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4126-4134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) belong to a large superfamily of membrane receptors mediating a variety of physiol. functions.  As such they are attractive targets for drug therapy.  However, it remains a challenge to develop subtype selective GPCR ligands, due to the high conservation of orthosteric binding sites.  Bitopic ligands have been employed to address the selectivity problem by combining (linking) an orthosteric ligand with an allosteric modulator, theor. leading to high-affinity subtype selective ligands.  However, it remains a challenge to identify suitable allosteric binding sites.  Computational studies on ligand binding to GPCRs have revealed transient, low-affinity binding sites, termed metastable binding sites.  Metastable binding sites may provide a new source of allosteric binding sites that could be exploited in the design of bitopic ligands.  Unlike the bitopic ligands that have been reported to date this type of bitopic ligands would be composed of two identical pharmacophores.  Herein, the authors outline the concept of bitopic ligands, review metastable binding sites and discuss their potential as a new source of allosteric binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpihAXt959S37Vg90H21EOLACvtfcHk0ljHvl1jwCKaRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVyktbw%253D&md5=a20875145b65a948c772e988ff1217bc</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01601%26sid%3Dliteratum%253Aachs%26aulast%3DFronik%26aufirst%3DP.%26aulast%3DGaiser%26aufirst%3DB.%2BI.%26aulast%3DSejer%2BPedersen%26aufirst%3DD.%26atitle%3DBitopic%2520Ligands%2520and%2520Metastable%2520Binding%2520Sites%253A%2520Opportunities%2520for%2520G%2520Protein-Coupled%2520Receptor%2520%2528GPCR%2529%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4126%26epage%3D4134%26doi%3D10.1021%2Facs.jmedchem.6b01601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaiser, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcher-RÃ¸rsted, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RÃ¸pke
JÃ¸rgensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WrÃ³bel, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frykman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BrÃ¤uner-Osborne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiesen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sejer Pedersen, D.</span></span> <span> </span><span class="NLM_article-title">Probing the Existence of a Metastable Binding Site at the Î²2-Adrenergic Receptor with Homobivalent Bitopic Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7806</span>â <span class="NLM_lpage">7839</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00595</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00595" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7806-7839&author=B.+I.+Gaiserauthor=M.+Danielsenauthor=E.+Marcher-R%C3%B8rstedauthor=K.+R%C3%B8pke%0AJ%C3%B8rgensenauthor=T.+M.+Wr%C3%B3belauthor=M.+Frykmanauthor=H.+Johanssonauthor=H.+Br%C3%A4uner-Osborneauthor=D.+E.+Gloriamauthor=J.+M.+Mathiesenauthor=D.+Sejer+Pedersen&title=Probing+the+Existence+of+a+Metastable+Binding+Site+at+the+%CE%B22-Adrenergic+Receptor+with+Homobivalent+Bitopic+Ligands&doi=10.1021%2Facs.jmedchem.9b00595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the Existence of a Metastable Binding Site at the Î²2-Adrenergic Receptor with Homobivalent Bitopic Ligands</span></div><div class="casAuthors">Gaiser, Birgit I.; Danielsen, Mia; Marcher-Roersted, Emil; Roepke Joergensen, Kira; Wrobel, Tomasz M.; Frykman, Mikael; Johansson, Henrik; Brauner-Osborne, Hans; Gloriam, David E.; Mathiesen, Jesper Mosolff; Sejer Pedersen, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7806-7839</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we report the development of bitopic ligands aimed at targeting the orthosteric binding site (OBS) and a metastable binding site (MBS) within the same receptor unit.  Previous mol. dynamics studies on ligand binding to the Î²2-adrenergic receptor (Î²2AR) suggested that ligands pause at transient, less-conserved MBSs.  We envisioned that MBSs can be regarded as allosteric binding sites and targeted by homobivalent bitopic ligands linking two identical pharmacophores.  Such ligands were designed based on docking of the antagonist (S)-alprenolol into the OBS and an MBS and synthesized.  Pharmacol. characterization revealed ligands with similar potency and affinity, slightly increased Î²2/Î²1AR-selectivity, and/or substantially slower Î²2AR off-rates compared to (S)-alprenolol.  Truncated bitopic ligands suggested the major contribution of the metastable pharmacophore to be a hydrophobic interaction with the Î²2AR, while the linkers alone decreased the potency of the orthosteric fragment.  Altogether, the study underlines the potential of targeting MBSs for improving the pharmacol. profiles of ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt_nqROQHIBrVg90H21EOLACvtfcHk0ljhHu7ufZ8vcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7%252FI&md5=411f11f6df72b940f3919b21510adf0b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00595%26sid%3Dliteratum%253Aachs%26aulast%3DGaiser%26aufirst%3DB.%2BI.%26aulast%3DDanielsen%26aufirst%3DM.%26aulast%3DMarcher-R%25C3%25B8rsted%26aufirst%3DE.%26aulast%3DR%25C3%25B8pke%2BJ%25C3%25B8rgensen%26aufirst%3DK.%26aulast%3DWr%25C3%25B3bel%26aufirst%3DT.%2BM.%26aulast%3DFrykman%26aufirst%3DM.%26aulast%3DJohansson%26aufirst%3DH.%26aulast%3DBr%25C3%25A4uner-Osborne%26aufirst%3DH.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26aulast%3DMathiesen%26aufirst%3DJ.%2BM.%26aulast%3DSejer%2BPedersen%26aufirst%3DD.%26atitle%3DProbing%2520the%2520Existence%2520of%2520a%2520Metastable%2520Binding%2520Site%2520at%2520the%2520%25CE%25B22-Adrenergic%2520Receptor%2520with%2520Homobivalent%2520Bitopic%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7806%26epage%3D7839%26doi%3D10.1021%2Facs.jmedchem.9b00595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlow, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhani, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Pathway and Mechanism of Drug Binding to G-Protein-Coupled Receptors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">13118</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1104614108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1073%2Fpnas.1104614108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=21778406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKit7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=13118&author=R.+O.+Drorauthor=A.+C.+Panauthor=D.+H.+Arlowauthor=D.+W.+Borhaniauthor=P.+Maragakisauthor=Y.+Shanauthor=H.+Xuauthor=D.+E.+Shaw&title=Pathway+and+Mechanism+of+Drug+Binding+to+G-Protein-Coupled+Receptors&doi=10.1073%2Fpnas.1104614108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pathway and mechanism of drug binding to G-protein-coupled receptors</span></div><div class="casAuthors">Dror, Ron O.; Pan, Albert C.; Arlow, Daniel H.; Borhani, David W.; Maragakis, Paul; Shan, Yibing; Xu, Huafeng; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">13118-13123, S13118/1-S13118/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">How drugs bind to their receptors-from initial assocn., through drug entry into the binding pocket, to adoption of the final bound conformation, or "pose"-has remained unknown, even for G-protein-coupled receptor modulators, which constitute 1/3 of all marketed drugs.  Here, the authors captured this pharmaceutically crit. process in at. detail using the 1st unbiased mol. dynamics simulations in which drug mols. spontaneously assoc. with G-protein-coupled receptors to achieve final poses matching those detd. crystallog.  The authors found that several beta blockers and a beta agonist all traversed the same well-defined, dominant pathway as they bound to the Î²1- and Î²2-adrenergic receptors, initially making contact with a vestibule on each receptor's extracellular surface.  Surprisingly, assocn. with this vestibule, at a distance of 15 Ã from the binding pocket, often presented the largest energetic barrier to binding, despite the fact that subsequent entry into the binding pocket required the receptor to deform and the drug to squeeze through a narrow passage.  The early barrier appeared to reflect the substantial dehydration that takes place as the drug assocs. with the vestibule.  The at.-level description of the binding process suggests opportunities for allosteric modulation and provides a structural foundation for future optimization of drug-receptor binding and unbinding rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKUYFtkTGwf7Vg90H21EOLACvtfcHk0linayLs3qqBKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKit7bE&md5=9cfa8673217931cacd586321309fa72e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104614108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104614108%26sid%3Dliteratum%253Aachs%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DPan%26aufirst%3DA.%2BC.%26aulast%3DArlow%26aufirst%3DD.%2BH.%26aulast%3DBorhani%26aufirst%3DD.%2BW.%26aulast%3DMaragakis%26aufirst%3DP.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DPathway%2520and%2520Mechanism%2520of%2520Drug%2520Binding%2520to%2520G-Protein-Coupled%2520Receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D13118%26doi%3D10.1073%2Fpnas.1104614108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Ding, C.</span>; <span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulators of 5-Hydroxytryptamine 2C Receptor (5-HT2CR)</span>. U.S. Patent <span class="NLM_patent">9,533,973 B2</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+Zhou&author=C.+Ding&author=K.+A.+Cunningham&title=Allosteric+Modulators+of+5-Hydroxytryptamine+2C+Receptor+%285-HT2CR%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520Modulators%2520of%25205-Hydroxytryptamine%25202C%2520Receptor%2520%25285-HT2CR%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filip, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Contribution of Serotonin (5-HT) 5-HT2 Receptor Subtypes to the Discriminative Stimulus Effects of Cocaine in Rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">482</span>â <span class="NLM_lpage">489</span>, <span class="refDoi">Â DOI: 10.1007/s00213-005-0197-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1007%2Fs00213-005-0197-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=16261316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Knt7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2006&pages=482-489&author=M.+Filipauthor=M.+J.+Bubarauthor=K.+A.+Cunningham&title=Contribution+of+Serotonin+%285-HT%29+5-HT2+Receptor+Subtypes+to+the+Discriminative+Stimulus+Effects+of+Cocaine+in+Rats&doi=10.1007%2Fs00213-005-0197-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats</span></div><div class="casAuthors">Filip, Malgorzata; Bubar, Marcy J.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">482-489</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">The serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor (5-HT2R) family is an important regulator of the behavioral responsiveness to cocaine.  The present study is an anal. of the role of the 5-HT2R subtypes (5-HT2AR, 5-HT2BR, and 5-HT2CR) in the discriminative stimulus effects of cocaine.  Male Wistar rats were trained to discriminate cocaine (10 mg/kg) from saline in a 2-lever, water-reinforced FR 20 task, and the authors investigated the ability of the 5-HT2AR antagonist 1(Z)-[2-(dimethylamino)ethoxyimino]-1(2-fluorophenyl)-3-(4-hydroxyphenyl)-2(E)-propene (SR 46349B), the 5-HT2BR antagonist N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl) urea (SB 204741), and the 5-HT2CR antagonist [(+)-cis-4,5,7a,8,9,10,11,11a-octahydro-7H-10-methylindolo(1,7-bC)(2,6)naphthyridine] (SDZ SER-082) to substitute for or to modulate the stimulus effects of cocaine.  Pretreatment with SR 46349B (0.5-1 mg/kg) resulted in a rightward shift of the cocaine dose-response curve, while SDZ SER-082 (1 mg/kg) shifted the dose-response for cocaine to the left; SB 204741 (1-3 mg/kg) was inactive.  Our pharmacol. analyses of selective antagonists of 5-HT2AR, 5-HT2BR, and 5-HT2CR indicate oppositional influence of 5-HT2AR and 5-HT2CR on the stimulus effects of cocaine and exclude a role for the 5-HT2BR.  These data suggest that 5-HT2AR and 5-HT2CR may be important in modulating the subjective effects of cocaine in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYQE4xqM8ubVg90H21EOLACvtfcHk0lht3ZJNcD8Njg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Knt7vE&md5=1371e379951f683e82ed8bbd31ef7a4b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs00213-005-0197-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-005-0197-y%26sid%3Dliteratum%253Aachs%26aulast%3DFilip%26aufirst%3DM.%26aulast%3DBubar%26aufirst%3DM.%2BJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DContribution%2520of%2520Serotonin%2520%25285-HT%2529%25205-HT2%2520Receptor%2520Subtypes%2520to%2520the%2520Discriminative%2520Stimulus%2520Effects%2520of%2520Cocaine%2520in%2520Rats%26jtitle%3DPsychopharmacology%26date%3D2006%26volume%3D183%26spage%3D482%26epage%3D489%26doi%3D10.1007%2Fs00213-005-0197-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philippe  De DeurwaerdÃ¨re</span>, <span class="hlFld-ContribAuthor ">Abdeslam  Chagraoui</span>, <span class="hlFld-ContribAuthor ">Kathryn A.  Cunningham</span>. </span><span class="cited-content_cbyCitation_article-title">Editorial: Contemporary Perspective on 5-HT2C Receptor Function and Its Pharmacological Targeting. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.606414" title="DOI URL">https://doi.org/10.3389/fphar.2020.606414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.606414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.606414%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DEditorial%25253A%252BContemporary%252BPerspective%252Bon%252B5-HT2C%252BReceptor%252BFunction%252Band%252BIts%252BPharmacological%252BTargeting%26aulast%3DDe%2BDeurwaerd%25C3%25A8re%26aufirst%3DPhilippe%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irene  Fasciani</span>, <span class="hlFld-ContribAuthor ">Francesco  Petragnano</span>, <span class="hlFld-ContribAuthor ">Gabriella  Aloisi</span>, <span class="hlFld-ContribAuthor ">Francesco  Marampon</span>, <span class="hlFld-ContribAuthor ">Marco  Carli</span>, <span class="hlFld-ContribAuthor ">Marco  Scarselli</span>, <span class="hlFld-ContribAuthor ">Roberto  Maggio</span>, <span class="hlFld-ContribAuthor ">Mario  Rossi</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (11)
                                     , 388. <a href="https://doi.org/10.3390/ph13110388" title="DOI URL">https://doi.org/10.3390/ph13110388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13110388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13110388%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DAllosteric%252BModulators%252Bof%252BG%252BProtein-Coupled%252BDopamine%252Band%252BSerotonin%252BReceptors%25253A%252BA%252BNew%252BClass%252Bof%252BAtypical%252BAntipsychotics%26aulast%3DFasciani%26aufirst%3DIrene%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D11%26spage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Highlighted compounds resulting from the search for synthetic small-molecule 5-HT<sub>2C</sub>R PAMs. Highlighted here are lead compounds from the published 5-HT<sub>2C</sub>R PAM drug discovery campaigns. The <i>C</i> log <i>P</i>, calculated in ChemDraw 18.0, for each compound displays a trend in high lipophilicity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Medicinal chemistry strategy to achieve optimized 5-HT<sub>2C</sub>R PAMs from PNU-69176E (<b>1</b>). A lincomycin derivative, PNU-69176E (<b>1</b>), was the first synthetic small molecule reported to allosterically modulate 5-HT<sub>2C</sub>R. Subsequent work has focused on chemical modifications of the PH and the LT to engender drug-like properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Volume, not length, of the undecyl moiety on PNU-69176E (<b>1</b>) and CYD-1-79 (<b>3</b>) may contribute to 5-HT<sub>2C</sub>R PAM activity. Compounds <b>1</b> and <b>3</b> favor similar minimized conformations, which lead to overlapping hydroxyl moieties in the PH and to a folded substructure for the undecyl LT. The preferred, contracted substructure for the undecyl LT suggests that hydrophobic volume is important.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of CYD-1-79 Analogues with Compact Phenyl or Cyclohexyl LTs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) phenylboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, EtOH/H<sub>2</sub>O/PhMe = 2:1:1, reflux. (b) H<sub>2</sub>, PtO<sub>2</sub>, HCl/MeOH/H<sub>2</sub>O, rt, and 16 h. (c) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, MeOH, rt, and 16 h. (d) LiOH, THF/H<sub>2</sub>O (v/v = 2:1), rt, and 48 h. (e) amino alcohols, HBTU, DIPEA, DMF, rt, and 16 h. (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of CYD-1-79 Analogues with Phenethyl, Ethylcyclohexyl, or Substituted Phenethyl LTs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) phenylacetylenes, CuI, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, rt, and 12 h. (b) H<sub>2</sub>, PtO<sub>2</sub>, HCl/MeOH/H<sub>2</sub>O, rt, and 16 h. (c) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, MeOH, rt, and 16 h. (d) LiOH, THF/H<sub>2</sub>O (v/v = 2:1), rt, and 48 h. (e) Amino alcohols, HBTU, DIPEA, DMF, rt, and 16 h. (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, and rt.</p></p></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of select compounds with shortened LT moieties provide evidence that hydrophobic volume contributes to target engagement. Data are plotted for compounds <b>12</b> (A), <b>14</b> (B), <b>35</b> (C), and <b>37</b> (D). The effects of these compounds on 5-HT-induced Ca<sub>i</sub><sup>2+</sup> release in h5-HT<sub>2C</sub>RâCHO cells are shown in the absence (black) and presence of the test compound (red) against the concentrationâresponse curve for 5-HT. The assessment of vehicle (HBSS, blue circle) or vehicle with test compound (green triangle) is also illustrated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Molecular docking illustrates the considerable overlap in ligand poses of six 5-HT<sub>2C</sub>R PAMs. Six small molecules with a 5-HT<sub>2C</sub>R PAM profile are represented in different colors along with the endogenous agonist 5-HT. A representative pose for each 5-HT<sub>2C</sub>R PAM was selected rationally from a top-scoring, enriched cluster docked to the 5-HT<sub>2C</sub>R X-ray crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>). A measurement from the 5-HT (magenta) indole N atom to the piperidine core N atom of compound <b>12</b> was found to be 13.5 Ã (illustrated by the dashed line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Docking site surface mapping illustrates the distinct location of the proposed allosteric site in relation to 5-HT bound to 5-HT<sub>2C</sub>R. (A) Side profile view of 5-HT<sub>2C</sub>R with the protein surface illustrated around the allosteric docking site in the transmembrane helical bundle. 5-HT (magenta) can be seen below the surface illustration. (B) Docking pose of <b>12</b> (green) is shown bridging the helical bundle at a site distinct from 5-HT (5-HT<sub>2C</sub>R PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Docking demonstrates that aromatic or aliphatic compact LTs orient toward the hydrophobic pocket between TM2 and TM3 of 5-HT<sub>2C</sub>R (5-HT<sub>2C</sub>R PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>). (A) This view features a cutaway of the surface illustration to show how the phenyl and cyclohexyl LTs of <b>12</b> (green) and <b>13</b> (blue) occupy a hydrophobic pocket within the transmembrane helical bundle. (B) Predicted interactions formed by docking <b>12</b> including a possible aromatic interaction with TRP130 in the hydrophobic pocket. (C) Predicted interactions formed by docking <b>13</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Comparison of the allosteric binding site surface map and an independent allosteric binding site prediction program for the 5-HT<sub>2C</sub>R model (5-HT<sub>2C</sub>R PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a>). (A) Composite model displaying the docking site protein surface and predicted allosteric site volume (magenta balls) seen via cutaway to visualize the overlap between the models. (B) Volume (magenta) determined to be a probable binding pocket capable of accommodating an allosteric modulator. (C) From the same angle as panel B, the docking site protein surface is displayed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/medium/jm9b01953_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>12</b> dose dependently augments the stimulus effects of the selective 5-HT<sub>2C</sub>R agonist WAY163909. (A) Doseâresponse relationship for WAY163909 is shown (<i>n</i> = 13 rats). Filled magenta circles denote the rats that chose either the saline- or the WAY163909-associated lever for each condition/dose. Closed black circles denote the mean percentage of rats selecting the WAY163909-associated lever (<i>Y</i>-axis) [*<i>p</i> < 0.05 vs saline (SAL)]. (B) Compound (Cmpd) <b>12</b> (0â2 mg/kg) or WAY163909 (0.5 mg/kg) was administered alone or combination as illustrated, with or without pretreatment with SB242084 (0.5 mg/kg). Open bars illustrate the mean percentage of rats selecting the WAY163909-associated lever during combination tests (<i>Y</i>-axis) [*<i>p</i> < 0.05 vs WAY163909 (0.5 mg/kg) alone and ^<i>p</i> < 0.05 vs combination of compound <b>12</b> plus WAY163909 following pretreatment with SB242084 (0.5 mg/kg). The details of the statistical analyses are found in the Experimental Section.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01953/20200716/images/large/jm9b01953_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01953&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02125" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02125" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Positive-allosteric modulation of the 5-HT2C receptor: implications for neuropsychopharmacology and neurotherapeutics</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">230</span>â <span class="NLM_lpage">231</span>, <span class="refDoi">Â DOI: 10.1038/s41386-018-0190-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1038%2Fs41386-018-0190-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=30202047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSrs73N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=230-231&author=J.+Zhouauthor=K.+A.+Cunningham&title=Positive-allosteric+modulation+of+the+5-HT2C+receptor%3A+implications+for+neuropsychopharmacology+and+neurotherapeutics&doi=10.1038%2Fs41386-018-0190-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Positive-allosteric modulation of the 5-HT2C receptor: implications for neuropsychopharmacology and neurotherapeutics</span></div><div class="casAuthors">Zhou, Jia; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">230-231</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review discussing pos.-allosteric modulation of the 5-HT2C receptor.  It also discusses its implications for neuropsychopharmacol. and neurotherapeutics.  It also highlights that, the chem. space for discovery of novel 5-HT2CR neuroprobes and therapeutics is now expanding to include allosteric 5-HT2CR modulators, providing the opportunity to explore cellular mechanisms of action, functional selectivity, neurochem. mechanisms, and neural sites of action for 5-HT2CR to control behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqGHrgKPZJYLVg90H21EOLACvtfcHk0lilUGhCQasuDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSrs73N&md5=5a8f0c89577ad512d644be04b90bd37b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0190-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0190-x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DPositive-allosteric%2520modulation%2520of%2520the%25205-HT2C%2520receptor%253A%2520implications%2520for%2520neuropsychopharmacology%2520and%2520neurotherapeutics%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D230%26epage%3D231%26doi%3D10.1038%2Fs41386-018-0190-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tecott, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akana, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strack, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowenstein, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallman, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julius, D.</span></span> <span> </span><span class="NLM_article-title">Eating Disorder and Epilepsy in Mice Lacking 5-HT2c Serotonin Receptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">542</span>â <span class="NLM_lpage">546</span>, <span class="refDoi">Â DOI: 10.1038/374542a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1038%2F374542a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=7700379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaK2MXkvVKqtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=1995&pages=542-546&author=L.+H.+Tecottauthor=L.+M.+Sunauthor=S.+F.+Akanaauthor=A.+M.+Strackauthor=D.+H.+Lowensteinauthor=M.+F.+Dallmanauthor=D.+Julius&title=Eating+Disorder+and+Epilepsy+in+Mice+Lacking+5-HT2c+Serotonin+Receptors&doi=10.1038%2F374542a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors</span></div><div class="casAuthors">Tecott, Laurence H.; Sun, Linda M.; Akana, Susan F.; Strack, Alison M.; Lowenstein, Daniel H.; Dallman, Mary F.; Julius, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">6522</span>),
    <span class="NLM_cas:pages">542-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Serotonin (5-hydroxytryptamine, 5-HT) is a monoaminergic neurotransmitter that is believed to modulate numerous sensory, motor and behavioral processes in the mammalian nervous system.  These diverse responses are elicited through the activation of a large family of receptor subtypes.  The complexity of this signalling system and the paucity of selective drugs have made it difficult to define specific roles for 5-HT receptor subtypes, or to det. how serotonergic drugs modulate mood and behavior.  To address these issues, we have generated mutant mice lacking functional 5-HT2C receptors (previously termed 5-HT1C), prominent G-protein-coupled receptors that are widely expressed throughout the brain and spinal cord and which have been proposed to mediate numerous central nervous system (CNS) actions of serotonin.  Here we show that 5-HT2C receptor-deficient mice are overweight as a result of abnormal control of feeding behavior, establishing a role for this receptor in the serotonergic control of appetite.  Mutant animals are also prone to spontaneous death from seizures, suggesting that 5-HT2C receptors mediate tonic inhibition of neuronal network excitability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyfCSY65mvybVg90H21EOLACvtfcHk0lhF6mNAprMdIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvVKqtr4%253D&md5=e87d8eac0789c2c012c34717d1fdbfe0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F374542a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F374542a0%26sid%3Dliteratum%253Aachs%26aulast%3DTecott%26aufirst%3DL.%2BH.%26aulast%3DSun%26aufirst%3DL.%2BM.%26aulast%3DAkana%26aufirst%3DS.%2BF.%26aulast%3DStrack%26aufirst%3DA.%2BM.%26aulast%3DLowenstein%26aufirst%3DD.%2BH.%26aulast%3DDallman%26aufirst%3DM.%2BF.%26aulast%3DJulius%26aufirst%3DD.%26atitle%3DEating%2520Disorder%2520and%2520Epilepsy%2520in%2520Mice%2520Lacking%25205-HT2c%2520Serotonin%2520Receptors%26jtitle%3DNature%26date%3D1995%26volume%3D374%26spage%3D542%26epage%3D546%26doi%3D10.1038%2F374542a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, T.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Lv, J.</span>; <span class="NLM_string-name">Song, Y.</span>; <span class="NLM_string-name">Fan, J.</span>; <span class="NLM_string-name">Liu, W.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Hall, F. S.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Cui, R.</span></span> <span> </span><span class="NLM_article-title">The role of 5-HT<sub>2c</sub> receptor on corticosterone-mediated food intake</span>.  <i>J. Biochem. Mol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">31</span>, DOI: <span class="refDoi">Â DOI: 10.1002/jbt.21890</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1002%2Fjbt.21890" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&author=T.+Ge&author=Z.+Zhang&author=J.+Lv&author=Y.+Song&author=J.+Fan&author=W.+Liu&author=X.+Wang&author=F.+S.+Hall&author=B.+Li&author=R.+Cui&title=The+role+of+5-HT2c+receptor+on+corticosterone-mediated+food+intake&doi=10.1002%2Fjbt.21890"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fjbt.21890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbt.21890%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DT.%26atitle%3DThe%2520role%2520of%25205-HT2c%2520receptor%2520on%2520corticosterone-mediated%2520food%2520intake%26jtitle%3DJ.%2520Biochem.%2520Mol.%2520Toxicol.%26date%3D2017%26volume%3D31%26doi%3D10.1002%2Fjbt.21890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halford, J. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawton, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, J. E.</span></span> <span> </span><span class="NLM_article-title">The 5-HT2 Receptor Agonist MK-212 Reduces Food Intake and Increases Resting but Prevents the Behavioural Satiety Sequence</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">41</span>â <span class="NLM_lpage">46</span>, <span class="refDoi">Â DOI: 10.1016/s0091-3057(96)00152-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2FS0091-3057%2896%2900152-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=8981607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaK2sXisVGisw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1997&pages=41-46&author=J.+C.+G.+Halfordauthor=C.+L.+Lawtonauthor=J.+E.+Blundell&title=The+5-HT2+Receptor+Agonist+MK-212+Reduces+Food+Intake+and+Increases+Resting+but+Prevents+the+Behavioural+Satiety+Sequence&doi=10.1016%2Fs0091-3057%2896%2900152-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The 5-HT2 receptor agonist MK-212 reduces food intake and increases resting but prevents the Behavioral Satiety Sequence</span></div><div class="casAuthors">Halford, J. C. G.; Lawton, C. L.; Blundell, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-46</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The 5-HT2C receptor is implicated in the relation between serotonin and satiety.  However, anorexia induced by the 5-HT2 receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) has been shown to delay, not advance behaviors assocd. with the onset of satiety, fragmenting eating behavior.  6-Chloro-2-(1-piperazinyl)pyrazine (MK-212) is also a selective agonist at the 5-HT2 receptor sites.  MK-212 has greater affinity for 5-HT2C receptor sites than DOI.  The effects of an ED50 dose of MK-212 (5.0 mg/kg i.p.) on the eating and other behaviors of the fasted rat were continuously monitored following the presentation of food.  Continuous monitoring provides the most powerful and valid form of behavioral anal.  Temporal profiles of behavior duration (dur) and frequency (frq) were generated.  Food intake was reduced 54% by MK-212.  The frequency of grooming was reduced.  Locomotion (dur, frq), rearing (dur, frq) and sniffing (dur) were all reduced.  The duration of resting increased.  This is consistent with enhanced satiety.  However, the Behavioral Satiety Sequence was not present after the administration of MK-212 (5.0 mg/kg).  The temporal structure of behavior produced by MK-212 was quite different from that produced by pre-feeding.  Initially resting dominated the behavioral profile.  Eating increased over time from a suppressed state in the initial stages of the observation period.  This lack of appearance of the Behavioral Satiety Sequence is more similar to a state of hyper-sedation than to DOI induced hyper-activity.  The time course of this sedation would not have been picked up by a simple categorical anal. of behavior.  Hence, temporal anal. is an essential tool in understanding of drug induced anorexia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOl2sgJTHwG7Vg90H21EOLACvtfcHk0lggbgK3xCY-mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisVGisw%253D%253D&md5=c37e7ff0178331c157154df5d765a4ef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2896%2900152-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252896%252900152-9%26sid%3Dliteratum%253Aachs%26aulast%3DHalford%26aufirst%3DJ.%2BC.%2BG.%26aulast%3DLawton%26aufirst%3DC.%2BL.%26aulast%3DBlundell%26aufirst%3DJ.%2BE.%26atitle%3DThe%25205-HT2%2520Receptor%2520Agonist%2520MK-212%2520Reduces%2520Food%2520Intake%2520and%2520Increases%2520Resting%2520but%2520Prevents%2520the%2520Behavioural%2520Satiety%2520Sequence%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1997%26volume%3D56%26spage%3D41%26epage%3D46%26doi%3D10.1016%2Fs0091-3057%2896%2900152-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. J.</span></span> <span> </span><span class="NLM_article-title">Agonists of the Serotonin 5-HT2C Receptor: Preclinical and Clinical Progression in Multiple Diseases</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">438</span>â <span class="NLM_lpage">445</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=18600561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFWmtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=438-445&author=D.+A.+Wackerauthor=K.+J.+Miller&title=Agonists+of+the+Serotonin+5-HT2C+Receptor%3A+Preclinical+and+Clinical+Progression+in+Multiple+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases</span></div><div class="casAuthors">Wacker, Dean A.; Miller, Keith J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-445</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  The serotonin 5-HT2C receptor is a G-protein-coupled receptor and is 1 of the 14 subtypes that constitute the serotonin receptor family.  Agonists of 5-HT2C have been implicated as potential treatments for diseases of significant unmet medical need, including obesity and schizophrenia.  Despite approx. 10 years of discovery efforts, 5-HT2C agonists have only recently advanced into the clinic, likely because many of the early drug discovery efforts experienced significant difficulties with attaining receptor selectivity.  Several of these issues related to receptor selectivity have now been overcome, resulting in the entry of compds. into advanced clin. trials.  This review summarizes the progress in 5-HT2C agonist discovery and clin. development over the last 3 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1eDgqANEVarVg90H21EOLACvtfcHk0lhi4lv0_W1CsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFWmtbk%253D&md5=cd06a22cee150e5a0c658a4ce8876151</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26atitle%3DAgonists%2520of%2520the%2520Serotonin%25205-HT2C%2520Receptor%253A%2520Preclinical%2520and%2520Clinical%2520Progression%2520in%2520Multiple%2520Diseases%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2008%26volume%3D11%26spage%3D438%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunlop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabb, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazandarani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgaonker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukhina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukoff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig-Lipson, S.</span></span> <span> </span><span class="NLM_article-title">WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-selective Agonist with Anorectic Activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">862</span>â <span class="NLM_lpage">869</span>, <span class="refDoi">Â DOI: 10.1124/jpet.104.075382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1124%2Fjpet.104.075382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=15705738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFemtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2005&pages=862-869&author=J.+Dunlopauthor=A.+L.+Sabbauthor=H.+Mazandaraniauthor=J.+Zhangauthor=S.+Kalgaonkerauthor=E.+Shukhinaauthor=S.+Sukoffauthor=R.+L.+Vogelauthor=G.+Stackauthor=L.+Schechterauthor=B.+L.+Harrisonauthor=S.+Rosenzweig-Lipson&title=WAY-163909+%5B%287bR%2C+10aR%29-1%2C2%2C3%2C4%2C8%2C9%2C10%2C10a-Octahydro-7bH-cyclopenta-%5Bb%5D%5B1%2C4%5Ddiazepino%5B6%2C7%2C1hi%5Dindole%5D%2C+a+Novel+5-Hydroxytryptamine+2C+Receptor-selective+Agonist+with+Anorectic+Activity&doi=10.1124%2Fjpet.104.075382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino [6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity</span></div><div class="casAuthors">Dunlop, John; Sabb, Annmarie L.; Mazandarani, Hossein; Zhang, Jean; Kalgaonker, Sachin; Shukhina, Eugenia; Sukoff, Stacey; Vogel, Robert L.; Stack, Gary; Schechter, Lee; Harrison, Boyd L.; Rosenzweig-Lipson, Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">862-869</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacol. profile of WAY-163909, a novel 5-hydroxytryptamine (HT)2c (serotonin) receptor-selective agonist is presented.  WAY-163909 displaced [125I]2,5-dimethoxy-4-iodoamphetamine binding from human 5-HT2C receptor sites, in Chinese hamster ovary (CHO) cell membranes, with a Ki value of 10.5Â±1.1 nM.  Binding affinities detd. for the human 5-HT2A and 5-HT2B receptor subtypes were 212 and 485 nM, resp.  In functional studies, WAY-163909 stimulated the mobilization of intracellular calcium in CHO cells stably expressing the human 5-HT2C receptor with an EC50 value of 8 nM, and Emax relative to 5-HT of 90%.  WAY-163909 failed to stimulate calcium mobilization in cells expressing the human 5-HT2A receptor subtype (EC50 >> 10 Î¼M) and was a 5-HT2B receptor partial agonist (EC50 185 nM, Emax 40%).  WAY-163909 exhibited negligible affinity (<50% inhibition at 1 Î¼M) for other receptor sites examd., including human 5-HT1A, D2, and D3 receptors, and the 5-HT transporter binding site in rat cortical membranes.  WAY-163909 exhibited weak affinity for the human D4 (245 nM) and 5-HT7 (343 nM) receptor subtypes and the Î±1 binding site in rat cortical membranes (665 nM).  WAY-163909 produced a dose-dependent redn. in food intake in normal Sprague-Dawley rats (ED50 = 2.93 mg/kg), an effect blocked by a 5-HT2C receptor antagonist but not by a 5-HT2A or 5-HT2B receptor antagonist.  In addn., WAY-163909 decreased food intake in obese Zucker rats and diet-induced obese mice with ED50 values of 1.4 and 5.19 mg/kg i.p., resp., consistent with the potential utility of 5-HT2C receptor agonists as antiobesity agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_JwPfydNYXbVg90H21EOLACvtfcHk0lguODxIbrVqAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFemtrs%253D&md5=b168e527f17783126505de7e522a3b23</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.075382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.075382%26sid%3Dliteratum%253Aachs%26aulast%3DDunlop%26aufirst%3DJ.%26aulast%3DSabb%26aufirst%3DA.%2BL.%26aulast%3DMazandarani%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKalgaonker%26aufirst%3DS.%26aulast%3DShukhina%26aufirst%3DE.%26aulast%3DSukoff%26aufirst%3DS.%26aulast%3DVogel%26aufirst%3DR.%2BL.%26aulast%3DStack%26aufirst%3DG.%26aulast%3DSchechter%26aufirst%3DL.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26atitle%3DWAY-163909%2520%255B%25287bR%252C%252010aR%2529-1%252C2%252C3%252C4%252C8%252C9%252C10%252C10a-Octahydro-7bH-cyclopenta-%255Bb%255D%255B1%252C4%255Ddiazepino%255B6%252C7%252C1hi%255Dindole%255D%252C%2520a%2520Novel%25205-Hydroxytryptamine%25202C%2520Receptor-selective%2520Agonist%2520with%2520Anorectic%2520Activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D313%26spage%3D862%26epage%3D869%26doi%3D10.1124%2Fjpet.104.075382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howell, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Serotonin 5-HT<sub>2</sub> Receptor Interactions with Dopamine Function: Implications for Therapeutics in Cocaine Use Disorder</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">176</span>â <span class="NLM_lpage">197</span>, <span class="refDoi">Â DOI: 10.1124/pr.114.009514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1124%2Fpr.114.009514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=25505168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Oms7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=176-197&author=L.+L.+Howellauthor=K.+A.+Cunningham&title=Serotonin+5-HT2+Receptor+Interactions+with+Dopamine+Function%3A+Implications+for+Therapeutics+in+Cocaine+Use+Disorder&doi=10.1124%2Fpr.114.009514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder</span></div><div class="casAuthors">Howell, Leonard L.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-197, 22 pp.</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Cocaine exhibits prominent abuse liability, and chronic abuse can result in cocaine use disorder with significant morbidity.  Major advances have been made in delineating neurobiol. mechanisms of cocaine abuse; however, effective medications to treat cocaine use disorder remain to be discovered.  The present review will focus on the role of serotonin (5-HT; 5-hydroxytryptamine) neurotransmission in the neuropharmacol. of cocaine and related abused stimulants.  Extensive research suggests that the primary contribution of 5-HT to cocaine addiction is a consequence of interactions with dopamine (DA) neurotransmission.  The literature on the neurobiol. and behavioral effects of cocaine is well developed, so the focus of the review will be on cocaine with inferences made about other monoamine uptake inhibitors and releasers based on mechanistic considerations. 5-HT receptors are widely expressed throughout the brain, and several different 5-HT receptor subtypes have been implicated in mediating the effects of endogenous 5-HT on DA.  However, the 5-HT2A and 5-HT2C receptors in particular have been implicated as likely candidates for mediating the influence of 5-HT in cocaine abuse as well as to traits (e.g., impulsivity) that contribute to the development of cocaine use disorder and relapse in humans.  Lastly, new approaches are proposed to guide targeted development of serotonergic ligands for the treatment of cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrr8S3_2aD27Vg90H21EOLACvtfcHk0lh03hfAMBC42w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Oms7w%253D&md5=f16fdf974beaa29f82770b9efdb43363</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009514%26sid%3Dliteratum%253Aachs%26aulast%3DHowell%26aufirst%3DL.%2BL.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DSerotonin%25205-HT2%2520Receptor%2520Interactions%2520with%2520Dopamine%2520Function%253A%2520Implications%2520for%2520Therapeutics%2520in%2520Cocaine%2520Use%2520Disorder%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D176%26epage%3D197%26doi%3D10.1124%2Fpr.114.009514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bubar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K.</span></span> <span> </span><span class="NLM_article-title">Prospects for Serotonin 5-HT2R Pharmacotherapy in Psychostimulant Abuse</span>. <i>Prog. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">319</span>â <span class="NLM_lpage">346</span>, <span class="refDoi">Â DOI: 10.1016/s0079-6123(08)00916-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2FS0079-6123%2808%2900916-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=18772040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2isbvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2008&pages=319-346&author=M.+Bubarauthor=K.+Cunningham&title=Prospects+for+Serotonin+5-HT2R+Pharmacotherapy+in+Psychostimulant+Abuse&doi=10.1016%2Fs0079-6123%2808%2900916-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse</span></div><div class="casAuthors">Bubar, Marcy J.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Brain Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">Serotonin-Dopamine Interaction</span>),
    <span class="NLM_cas:pages">319-346</span>CODEN:
                <span class="NLM_cas:coden">PBRRA4</span>;
        ISSN:<span class="NLM_cas:issn">0079-6123</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The serotonin (5-HT) neurotransmitter system provides fundamental modulatory regulation of the limbic-corticostriatal circuitry known to be vital in the development of addiction as well as the aspects of addiction that hinder recovery and contribute to relapse.  Thus, components of the 5-HT system may provide novel targets for the development of pharmacol. treatments for psychostimulant dependence, which is assocd. with significant aberrations in dopamine (DA) neurotransmission.  Two key modulators of DA signalling within the limbic-corticostriatal circuit are the 5-HT2A receptor (5-HT2AR) and the 5-HT2CR.  These receptors are known to control the neurochem. and behavioral effects of psychostimulants, and in particular the in vivo effects of cocaine.  Pre-clin. studies indicate that 5-HT2AR antagonists and/or 5-HT2CR agonists may effectively reduce craving and/or relapse, and likewise, enhance abstinence, while 5-HT2CR agonists may also effectively reduce cocaine intake in active cocaine users.  At present, the progression of studies to probe the effectiveness of 5-HT2AR and 5-HT2CR ligands in the clin. setting is hindered by a lack of available, selective 5-HT2AR antagonists or 5-HT2CR agonists for use in human cocaine abusers.  However, a no. of selective 5-HT2R ligands currently under development, or in early clin. trials for psychiatric and/or neurol. disorders, may soon be available for translational studies to explore their effectiveness in modulating drug use and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyn3HB6wnKjbVg90H21EOLACvtfcHk0lg2aYyMlVmiSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2isbvF&md5=6548a0982d3149c005857224efa2fd79</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0079-6123%2808%2900916-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6123%252808%252900916-3%26sid%3Dliteratum%253Aachs%26aulast%3DBubar%26aufirst%3DM.%26aulast%3DCunningham%26aufirst%3DK.%26atitle%3DProspects%2520for%2520Serotonin%25205-HT2R%2520Pharmacotherapy%2520in%2520Psychostimulant%2520Abuse%26jtitle%3DProg.%2520Brain%2520Res.%26date%3D2008%26volume%3D172%26spage%3D319%26epage%3D346%26doi%3D10.1016%2Fs0079-6123%2808%2900916-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sears, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emeson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiLeone, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Functional Status of the Serotonin 5-HT2C Receptor (5-HT2CR) Drives Interlocked Phenotypes that Precipitate Relapse-like Behaviors in Cocaine Dependence</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">360</span>â <span class="NLM_lpage">372</span>, <span class="refDoi">Â DOI: 10.1038/npp.2013.199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1038%2Fnpp.2013.199" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=360-372&author=N.+C.+Anastasioauthor=S.+J.+Stutzauthor=R.+G.+Foxauthor=R.+M.+Searsauthor=R.+B.+Emesonauthor=R.+J.+DiLeoneauthor=R.+T.+O%E2%80%99Neilauthor=L.+H.+Finkauthor=D.+Liauthor=T.+A.+Greenauthor=F.+G.+Moellerauthor=K.+A.+Cunningham&title=Functional+Status+of+the+Serotonin+5-HT2C+Receptor+%285-HT2CR%29+Drives+Interlocked+Phenotypes+that+Precipitate+Relapse-like+Behaviors+in+Cocaine+Dependence&doi=10.1038%2Fnpp.2013.199"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.199%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DStutz%26aufirst%3DS.%2BJ.%26aulast%3DFox%26aufirst%3DR.%2BG.%26aulast%3DSears%26aufirst%3DR.%2BM.%26aulast%3DEmeson%26aufirst%3DR.%2BB.%26aulast%3DDiLeone%26aufirst%3DR.%2BJ.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DR.%2BT.%26aulast%3DFink%26aufirst%3DL.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DT.%2BA.%26aulast%3DMoeller%26aufirst%3DF.%2BG.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DFunctional%2520Status%2520of%2520the%2520Serotonin%25205-HT2C%2520Receptor%2520%25285-HT2CR%2529%2520Drives%2520Interlocked%2520Phenotypes%2520that%2520Precipitate%2520Relapse-like%2520Behaviors%2520in%2520Cocaine%2520Dependence%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D360%26epage%3D372%26doi%3D10.1038%2Fnpp.2013.199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neelakantan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Lorcaserin Suppresses Oxycodone Self-administration and Relapse Vulnerability in Rats</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1065</span>â <span class="NLM_lpage">1073</span>, <span class="refDoi">Â DOI: 10.1021/acschemneuro.6b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Klt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1065-1073&author=H.+Neelakantanauthor=E.+D.+Hollidayauthor=R.+G.+Foxauthor=S.+J.+Stutzauthor=S.+D.+Comerauthor=M.+Haneyauthor=N.+C.+Anastasioauthor=F.+G.+Moellerauthor=K.+A.+Cunningham&title=Lorcaserin+Suppresses+Oxycodone+Self-administration+and+Relapse+Vulnerability+in+Rats&doi=10.1021%2Facschemneuro.6b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats</span></div><div class="casAuthors">Neelakantan, Harshini; Holliday, Erica D.; Fox, Robert G.; Stutz, Sonja J.; Comer, Sandra D.; Haney, Margaret; Anastasio, Noelle C.; Moeller, F. Gerard; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1065-1073</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Opioid use disorder (OUD) is a major public health problem.  High relapse rates and poor treatment retention continue to pose major challenges in OUD treatment.  Of the abused opioids, oxycodone is well described to maintain self-administration and evoke the durable conditioned responses ("cue reactivity") that result from pairing of opioid-related stimuli (e.g., paraphernalia) with repeated abuse.  Serotonin (5-HT) neurotransmission, particularly through the 5-HT2C receptor (5-HT2CR), regulates psychostimulant reward and cue reactivity, and in the present expts., the authors investigated the hypothesis that the selective 5-HT2CR agonist lorcaserin, which is FDA-approved for the treatment of obesity, will suppress oxycodone self-administration and oxycodone-assocd. cue reactivity in rats.  The authors found that lorcaserin inhibited oxycodone intake, an effect blocked by the selective 5-HT2CR antagonist SB242084.  Lorcaserin also decreased responding for the discrete cue complex ("cue reactivity") previously assocd. with delivery of oxycodone (i.e., stimulus lights, infusion pump sounds) in both abstinence and extinction-reinstatement models.  The selected dose range of lorcaserin (0.25-1 mg/kg) does not overtly alter spontaneous behaviors nor operant responding on inactive levers in the present study.  Taken together, the ability of lorcaserin to reduce the oxycodone self-administration and decrease cue reactivity assocd. with relapse highlights the therapeutic potential for lorcaserin in the treatment of OUD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmhGr8KOEwb7Vg90H21EOLACvtfcHk0liCyj3IpOf01w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Klt7k%253D&md5=e67d9cd3074b5ea47b43d870b34e12b7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00413%26sid%3Dliteratum%253Aachs%26aulast%3DNeelakantan%26aufirst%3DH.%26aulast%3DHolliday%26aufirst%3DE.%2BD.%26aulast%3DFox%26aufirst%3DR.%2BG.%26aulast%3DStutz%26aufirst%3DS.%2BJ.%26aulast%3DComer%26aufirst%3DS.%2BD.%26aulast%3DHaney%26aufirst%3DM.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DMoeller%26aufirst%3DF.%2BG.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DLorcaserin%2520Suppresses%2520Oxycodone%2520Self-administration%2520and%2520Relapse%2520Vulnerability%2520in%2520Rats%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D1065%26epage%3D1073%26doi%3D10.1021%2Facschemneuro.6b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Innovative Therapeutic Intervention for Opioid Use Disorder</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">220</span>â <span class="NLM_lpage">221</span>, <span class="refDoi">Â DOI: 10.1038/npp.2017.192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1038%2Fnpp.2017.192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=29192668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCrs7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=220-221&author=F.+G.+Moellerauthor=K.+A.+Cunningham&title=Innovative+Therapeutic+Intervention+for+Opioid+Use+Disorder&doi=10.1038%2Fnpp.2017.192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Innovative Therapeutic Intervention For Opioid Use Disorder</span></div><div class="casAuthors">Moeller, F. Gerard; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">220-221</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The United States is in the grip of an opioid misuse and overdose crisis.  Progression from misuse to opioid use disorder (OUD) is marked by compulsive drug-taking and clin. significant impairment.  Behavioral interventions along with treatment with OUD pharmacotherapeutics, such as buprenorphine, mitigates withdrawal, reduces mortality, opioid intake, and opioid-seeking behaviors, as well as improves psychosocial functioning (Volkow et al, 2014).  Medication-assisted treatment is an important adjunct to the proper management of OUD patients, yet addnl. opportunities exist to enhance the probability of extended abstinence and recovery from OUD.  Dysregulation of the limbic-corticostriatal circuitry that subserves reward and adaptive behaviors contributes to OUD development as well as the vulnerability to relapse during abstinence.  Serotonin (5-HT) neurotransmission confers modulatory control over this circuitry, particularly through the 5-HT2C receptor (5-HT2CR) (for review) (Cunningham and Anastasio, 2014).  Selective 5-HT2CR agonists, which lack intrinsic abuse liability, curb self-administration of psychostimulants (eg, cocaine, nicotine) as well as assocd. sensitivity to drug-assocd. cues and impulsivity in preclin. studies (for review) (Cunningham and Anastasio, 2014).  These data sparked a clin. trial that demonstrated that the FDA-approved anti-obesity medication and first-in-class 5-HT2CR agonist lorcaserin (Belviq) increased abstinence from smoking (Shanahan et al, 2016).  Furthermore, the efficacy and safety of lorcaserin for cocaine use disorder is presently under study (https://clinicaltrials.gov/ct2/show/NCT03007394).  We have recently demonstrated the efficacy of lorcaserin to suppress intake of the semisynthetic opioid oxycodone as well as assocd. cue reactivity in both abstinence and extinction-reinstatement paradigms, effects which were blocked by the selective 5-HT2CR antagonist SB242084 (Neelakantan et al, 2017).  Lorcaserin pretreatment also decreases opioid-induced behavioral sensitization and the phys. signs of naloxone-pptd. withdrawal following chronic opioid exposure in mice (Wu et al, 2015).  Thus, the non-opioid medication lorcaserin acts as a 5-HT2CR agonist to influence aspects of opioid-evoked behaviors, suggesting that the 5-HT2CR system may play a key role in the shared mechanisms for addiction and relapse vulnerability across psychostimulant and opioid drug classes.  The development of pain medications with analgesic efficacy, but reduced abuse liability, remains a high priority.  Of equally high priority is the identification of therapeutic interventions that increase the maintenance of abstinence after cessation of opioid intake, even in high drug cue environments.  A selective 5-HT2CR agonist, such as lorcaserin, may provide a new avenue to add value to the outcomes of medication-assisted treatment in OUD (Figure 1).  The next step is to expand the present data set to definitively test the hypotheses that lorcaserin inhibits opioid withdrawal and countermands stress- and/or opioid-triggered relapse events, for example.  It is also possible that low doses of lorcaserin administered in combination with a partial Î¼-opioid agonist, with limited abuse liability but efficacy to suppress opioid-induced euphoria and withdrawal may reduce relapse risk via regulation of two signaling pathways.  The neurochem. mechanisms and sites of action for 5-HT2CR systems to control opioid-related behaviors are also of interest.  Finally, preclin. studies to evaluate low-dose combinations of a partial Î¼-opioid agonist plus lorcaserin will provide insight into the potential for translational value in clin. trials geared to reduce the devastation of opioid overdose and OUD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEmhsgJcd6n7Vg90H21EOLACvtfcHk0ljkR6d0xDVMYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCrs7nI&md5=5a1e0efbac3ecf97edfa3625b0b5614f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.192%26sid%3Dliteratum%253Aachs%26aulast%3DMoeller%26aufirst%3DF.%2BG.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DInnovative%2520Therapeutic%2520Intervention%2520for%2520Opioid%2520Use%2520Disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26spage%3D220%26epage%3D221%26doi%3D10.1038%2Fnpp.2017.192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glicklich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Kam, M.</span></span> <span> </span><span class="NLM_article-title">Lorcaserin for Smoking Cessation and Associated Weight Gain: a Randomized 12-week Clinical Trial</span>. <i>Nicotine Tob. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">944</span>â <span class="NLM_lpage">951</span>, <span class="refDoi">Â DOI: 10.1093/ntr/ntw301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1093%2Fntr%2Fntw301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=27815511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsVyntrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=944-951&author=W.+R.+Shanahanauthor=J.+E.+Roseauthor=A.+Glicklichauthor=S.+Stubbeauthor=M.+Sanchez-Kam&title=Lorcaserin+for+Smoking+Cessation+and+Associated+Weight+Gain%3A+a+Randomized+12-week+Clinical+Trial&doi=10.1093%2Fntr%2Fntw301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial</span></div><div class="casAuthors">Shanahan, William R.; Rose, Jed E.; Glicklich, Alan; Stubbe, Scott; Sanchez-Kam, Matilde</div><div class="citationInfo"><span class="NLM_cas:title">Nicotine & Tobacco Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">944-951</span>CODEN:
                <span class="NLM_cas:coden">NTREF6</span>;
        ISSN:<span class="NLM_cas:issn">1469-994X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Introduction: Lorcaserin is a selective serotonin 2C receptor agonist approved by the Food and Drug Administration for chronic wt. management.  Preclin. data suggest that it may also be effective in smoking cessation through modulation of the dopaminergic reward system.  Methods: This was a 12-wk, randomized, double-blind, placebo-controlled trial conducted in 30 centers in the United States.  Six hundred three adult smokers with a Body Mass Index of 18.5-35 kg/m2 , averaging at least 10 cigarettes/day with no period of abstinence >3 mo for the past year were randomized to lorcaserin 10 mg once daily (QD), 10 mg twice daily (BID) or placebo; all received standardized smoking cessation counseling weekly.  The target quit date was day 15.  The primary endpoint was the exhaled carbon monoxide confirmed Continuous Abstinence Rate for weeks 9-12 (month 3).  Results: Continuous Abstinence Rates for month 3 were 5.6%, 8.7%, and 15.3% for the placebo, QD and BID groups, resp. (BID vs. placebo odds ratio 3.02, 95% confidence interval 1.47, 6.22, p = .0027).  Change in wt. at week 12 (randomized population) was -0.01, -0.35 and -0.98 kg, resp. (p = .0004, BID vs. placebo), and +0.73, +0.76, and -0.41 kg in participants achieving month 3 continuous abstinence.  The most frequent adverse events were headache, nausea, constipation, and fatigue.  Conclusions: Lorcaserin with counseling was assocd. with dose-related increases in smoking cessation and prevention of assocd. wt. gain over a 3-mo period.  Further investigation of lorcaserin in smoking cessation is warranted.  Trial Registration: ClinicalTrials.gov.  Identifier: NCT02044874 Implications: This randomized, controlled trial demonstrated that lorcaserin used in conjunction with std. cessation counseling was assocd. with dose-related increases in smoking cessation and prevention of assocd. wt. gain.  To our knowledge, this is the first demonstration in humans of a potential role of 5-HT2C agonism in the modulation of central neurol. circuits involved with reward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoerITmglXHkbVg90H21EOLACvtfcHk0ljkR6d0xDVMYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsVyntrs%253D&md5=c35a3194032c2533e4eae0235802dd90</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fntr%2Fntw301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fntr%252Fntw301%26sid%3Dliteratum%253Aachs%26aulast%3DShanahan%26aufirst%3DW.%2BR.%26aulast%3DRose%26aufirst%3DJ.%2BE.%26aulast%3DGlicklich%26aufirst%3DA.%26aulast%3DStubbe%26aufirst%3DS.%26aulast%3DSanchez-Kam%26aufirst%3DM.%26atitle%3DLorcaserin%2520for%2520Smoking%2520Cessation%2520and%2520Associated%2520Weight%2520Gain%253A%2520a%2520Randomized%252012-week%2520Clinical%2520Trial%26jtitle%3DNicotine%2520Tob.%2520Res.%26date%3D2017%26volume%3D19%26spage%3D944%26epage%3D951%26doi%3D10.1093%2Fntr%2Fntw301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farr, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrieli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyrou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koniaris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srnka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migdal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantzoros, C. S.</span></span> <span> </span><span class="NLM_article-title">Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-related Changes Correlate with Weight Loss Effects: a 4-Week-long Randomized, Placebo-controlled, Double-blind Clinical Trial</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">2943</span>â <span class="NLM_lpage">2953</span>, <span class="refDoi">Â DOI: 10.2337/db16-0635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.2337%2Fdb16-0635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=27385157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOrtL7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=2943-2953&author=O.+M.+Farrauthor=J.+Upadhyayauthor=A.+Gavrieliauthor=M.+Campauthor=N.+Spyrouauthor=H.+Kayeauthor=H.+Mathewauthor=M.+Vamviniauthor=A.+Koniarisauthor=H.+Kilimauthor=A.+Srnkaauthor=A.+Migdalauthor=C.+S.+Mantzoros&title=Lorcaserin+Administration+Decreases+Activation+of+Brain+Centers+in+Response+to+Food+Cues+and+These+Emotion-+and+Salience-related+Changes+Correlate+with+Weight+Loss+Effects%3A+a+4-Week-long+Randomized%2C+Placebo-controlled%2C+Double-blind+Clinical+Trial&doi=10.2337%2Fdb16-0635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin administration decreases activation of brain centers in response to food cues, these emotion-, salience-related changes correlate with weight loss effects: a 4-week-long randomized, placebo-controlled, double-blind clinical trial</span></div><div class="casAuthors">Farr, Olivia M.; Upadhyay, Jagriti; Gavrieli, Anna; Camp, Michelle; Spyrou, Nikolaos; Kaye, Harper; Mathew, Hannah; Vamvini, Maria; Koniaris, Anastasia; Kilim, Holly; Srnka, Alexandra; Migdal, Alexandra; Mantzoros, Christos S.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2943-2953</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Lorcaserin is a serotonin 5-hydroxytryptamine 2c receptor agonist effective in treating obesity.  Studies in rodents have shown that lorcaserin acts in the brain to exert its wt.-reducing effects, but this has not yet been studied in humans.  We performed a randomized, placebo-controlled, double-blind trial with 48 obese participants and used functional MRI to study the effects of lorcaserin on the brain.  Subjects taking lorcaserin had decreased brain activations in the attention-related parietal and visual cortices in response to highly palatable food cues at 1 wk in the fasting state and in the parietal cortex in response to any food cues at 4 wk in the fed state.  Decreases in emotion- and salience-related limbic activity, including the insula and amygdala, were attenuated at 4 wk.  Decreases in caloric intake, wt., and BMI correlated with activations in the amygdala, parietal, and visual cortices at baseline.  These data suggest that lorcaserin exerts its wt.-reducing effects by decreasing attention-related brain activations to food cues (parietal and visual cortices) and emotional and limbic activity (insula, amygdala).  Results indicating that baseline activation of the amygdala relates to increased efficacy suggest that lorcaserin would be of particular benefit to emotional eaters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLA0TdIp1TKLVg90H21EOLACvtfcHk0lgPb1PhFFlzcw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOrtL7J&md5=e2f7f3842a6c75dc45d064376398256b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2337%2Fdb16-0635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb16-0635%26sid%3Dliteratum%253Aachs%26aulast%3DFarr%26aufirst%3DO.%2BM.%26aulast%3DUpadhyay%26aufirst%3DJ.%26aulast%3DGavrieli%26aufirst%3DA.%26aulast%3DCamp%26aufirst%3DM.%26aulast%3DSpyrou%26aufirst%3DN.%26aulast%3DKaye%26aufirst%3DH.%26aulast%3DMathew%26aufirst%3DH.%26aulast%3DVamvini%26aufirst%3DM.%26aulast%3DKoniaris%26aufirst%3DA.%26aulast%3DKilim%26aufirst%3DH.%26aulast%3DSrnka%26aufirst%3DA.%26aulast%3DMigdal%26aufirst%3DA.%26aulast%3DMantzoros%26aufirst%3DC.%2BS.%26atitle%3DLorcaserin%2520Administration%2520Decreases%2520Activation%2520of%2520Brain%2520Centers%2520in%2520Response%2520to%2520Food%2520Cues%2520and%2520These%2520Emotion-%2520and%2520Salience-related%2520Changes%2520Correlate%2520with%2520Weight%2520Loss%2520Effects%253A%2520a%25204-Week-long%2520Randomized%252C%2520Placebo-controlled%252C%2520Double-blind%2520Clinical%2520Trial%26jtitle%3DDiabetes%26date%3D2016%26volume%3D65%26spage%3D2943%26epage%3D2953%26doi%3D10.2337%2Fdb16-0635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maili, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swinford, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, F. G.</span></span> <span> </span><span class="NLM_article-title">Variation within the serotonin (5-HT) 5-HT2C receptor system aligns with vulnerability to cocaine cue reactivity</span>. <i>Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e369</span> <span class="refDoi">Â DOI: 10.1038/tp.2013.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1038%2Ftp.2013.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVCnsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&author=N.+C.+Anastasioauthor=S.+Liuauthor=L.+Mailiauthor=S.+E.+Swinfordauthor=S.+D.+Laneauthor=R.+G.+Foxauthor=S.+C.+Hamonauthor=D.+A.+Nielsenauthor=K.+A.+Cunninghamauthor=F.+G.+Moeller&title=Variation+within+the+serotonin+%285-HT%29+5-HT2C+receptor+system+aligns+with+vulnerability+to+cocaine+cue+reactivity&doi=10.1038%2Ftp.2013.131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Variation within the serotonin (5-HT) 5-HT2C receptor system aligns with vulnerability to cocaine cue reactivity</span></div><div class="casAuthors">Anastasio, N. C.; Liu, S.; Maili, L.; Swinford, S. E.; Lane, S. D.; Fox, R. G.; Hamon, S. C.; Nielsen, D. A.; Cunningham, K. A.; Moeller, F. G.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e369</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cocaine dependence remains a challenging public health problem with relapse cited as a major determinant in its chronicity and severity.  Environmental contexts and stimuli become reliably assocd. with its use leading to durable conditioned responses ('cue reactivity') that can predict relapse as well as treatment success.  Individual variation in the magnitude and influence of cue reactivity over behavior in humans and animals suggest that cue-reactive individuals may be at greater risk for the progression to addiction and/or relapse.  In the present translational study, we investigated the contribution of variation in the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) system in individual differences in cocaine cue reactivity in humans and rodents.  We found that cocaine-dependent subjects carrying a single nucleotide polymorphism (SNP) in the HTR2C gene that encodes for the conversion of cysteine to serine at codon 23 (Ser23 variant) exhibited significantly higher attentional bias to cocaine cues in the cocaine-word Stroop task than those carrying the Cys23 variant.  In a model of individual differences in cocaine cue reactivity in rats, we identified that high cocaine cue reactivity measured as appetitive approach behavior (lever presses reinforced by the discrete cue complex) correlated with lower 5-HT2CR protein expression in the medial prefrontal cortex and blunted sensitivity to the suppressive effects of the selective 5-HT2CR agonist WAY163909.  Our translational findings suggest that the functional status of the 5-HT2CR system is a mechanistic factor in the generation of vulnerability to cocaine-assocd. cues, an observation that opens new avenues for future development of biomarker and therapeutic approaches to suppress relapse in cocaine dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4-6Q9fk9SyLVg90H21EOLACvtfcHk0lg-jChqK1eF8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVCnsrk%253D&md5=9372b11e4f3479212fda09b936713bfc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Ftp.2013.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2013.131%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMaili%26aufirst%3DL.%26aulast%3DSwinford%26aufirst%3DS.%2BE.%26aulast%3DLane%26aufirst%3DS.%2BD.%26aulast%3DFox%26aufirst%3DR.%2BG.%26aulast%3DHamon%26aufirst%3DS.%2BC.%26aulast%3DNielsen%26aufirst%3DD.%2BA.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DMoeller%26aufirst%3DF.%2BG.%26atitle%3DVariation%2520within%2520the%2520serotonin%2520%25285-HT%2529%25205-HT2C%2520receptor%2520system%2520aligns%2520with%2520vulnerability%2520to%2520cocaine%2520cue%2520reactivity%26jtitle%3DPsychiatry%26date%3D2014%26volume%3D4%26doi%3D10.1038%2Ftp.2013.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, T. W.</span></span> <span> </span><span class="NLM_article-title">Drug Addiction: Updating Actions to Habits to Compulsions Ten Years On</span>. <i>Annu. Rev. Psychol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">50</span>, <span class="refDoi">Â DOI: 10.1146/annurev-psych-122414-033457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1146%2Fannurev-psych-122414-033457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=26253543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A280%3ADC%252BC287gvFSrtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=23-50&author=B.+J.+Everittauthor=T.+W.+Robbins&title=Drug+Addiction%3A+Updating+Actions+to+Habits+to+Compulsions+Ten+Years+On&doi=10.1146%2Fannurev-psych-122414-033457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Addiction: Updating Actions to Habits to Compulsions Ten Years On</span></div><div class="casAuthors">Everitt Barry J; Robbins Trevor W</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of psychology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A decade ago, we hypothesized that drug addiction can be viewed as a transition from voluntary, recreational drug use to compulsive drug-seeking habits, neurally underpinned by a transition from prefrontal cortical to striatal control over drug seeking and taking as well as a progression from the ventral to the dorsal striatum.  Here, in the light of burgeoning, supportive evidence, we reconsider and elaborate this hypothesis, in particular the refinements in our understanding of ventral and dorsal striatal mechanisms underlying goal-directed and habitual drug seeking, the influence of drug-associated Pavlovian-conditioned stimuli on drug seeking and relapse, and evidence for impairments in top-down prefrontal cortical inhibitory control over this behavior.  We further review animal and human studies that have begun to define etiological factors and individual differences in the propensity to become addicted to drugs, leading to the description of addiction endophenotypes, especially for cocaine addiction.  We consider the prospect of novel treatments for addiction that promote abstinence from and relapse to drug use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-E8ITY507OQ5nADWVYHg1fW6udTcc2eYfvaKQPYFI97ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287gvFSrtQ%253D%253D&md5=ae5829b8685d3a5a7c4ec46243125154</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1146%2Fannurev-psych-122414-033457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-psych-122414-033457%26sid%3Dliteratum%253Aachs%26aulast%3DEveritt%26aufirst%3DB.%2BJ.%26aulast%3DRobbins%26aufirst%3DT.%2BW.%26atitle%3DDrug%2520Addiction%253A%2520Updating%2520Actions%2520to%2520Habits%2520to%2520Compulsions%2520Ten%2520Years%2520On%26jtitle%3DAnnu.%2520Rev.%2520Psychol.%26date%3D2016%26volume%3D67%26spage%3D23%26epage%3D50%26doi%3D10.1146%2Fannurev-psych-122414-033457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span> <span> </span><span class="NLM_article-title">Hallucinogens</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">131</span>â <span class="NLM_lpage">181</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2003.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2Fj.pharmthera.2003.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=14761703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=131-181&author=D.+E.+Nichols&title=Hallucinogens&doi=10.1016%2Fj.pharmthera.2003.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Hallucinogens</span></div><div class="casAuthors">Nichols, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes.  They are considered physiol. safe and do not produce dependence or addiction.  Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts.  In the 1950s, after the virtually contemporaneous discovery of both serotonin (5-HT) and lysergic acid diethylamide (LSD-25), early brain research focused intensely on the possibility that LSD or other hallucinogens had a serotonergic basis of action and reinforced the idea that 5-HT was an important neurotransmitter in brain.  These ideas were eventually proven, and today it is believed that hallucinogens stimulate 5-HT2A receptors, esp. those expressed on neocortical pyramidal cells.  Activation of 5-HT2A receptors also leads to increased cortical glutamate levels presumably by a presynaptic receptor-mediated release from thalamic afferents.  These findings have led to comparisons of the effects of classical hallucinogens with certain aspects of acute psychosis and to a focus on thalamocortical interactions as key to understanding both the action of these substances and the neuroanatomical sites involved in altered states of consciousness (ASC).  In vivo brain imaging in humans using [18F]fluorodeoxyglucose has shown that hallucinogens increase prefrontal cortical metab., and correlations have been developed between activity in specific brain areas and psychol. elements of the ASC produced by hallucinogens.  The 5-HT2A receptor clearly plays an essential role in cognitive processing, including working memory, and ligands for this receptor may be extremely useful tools for future cognitive neuroscience research.  In addn., it appears entirely possible that utility may still emerge for the use of hallucinogens in treating alcoholism, substance abuse, and certain psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRl6lKmZ_4Y7Vg90H21EOLACvtfcHk0lgebmgtN7QWpw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D&md5=7b5246f6479d76736c5a7223c60a9e99</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2003.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2003.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DD.%2BE.%26atitle%3DHallucinogens%26jtitle%3DPharmacol.%2520Ther.%26date%3D2004%26volume%3D101%26spage%3D131%26epage%3D181%26doi%3D10.1016%2Fj.pharmthera.2003.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corjay, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbaszade, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largent, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartig, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, D. W.</span></span> <span> </span><span class="NLM_article-title">Possible Role of Valvular Serotonin 5-HT(2B) Receptors in the Cardiopathy Associated with Fenfluramine</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">75</span>â <span class="NLM_lpage">81</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10617681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslCltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2000&pages=75-81&author=L.+W.+Fitzgeraldauthor=T.+C.+Burnauthor=B.+S.+Brownauthor=J.+P.+Pattersonauthor=M.+H.+Corjayauthor=P.+A.+Valentineauthor=J.+H.+Sunauthor=J.+R.+Linkauthor=I.+Abbaszadeauthor=J.+M.+Hollisauthor=B.+L.+Largentauthor=P.+R.+Hartigauthor=G.+F.+Hollisauthor=P.+C.+Meunierauthor=A.+J.+Robichaudauthor=D.+W.+Robertson&title=Possible+Role+of+Valvular+Serotonin+5-HT%282B%29+Receptors+in+the+Cardiopathy+Associated+with+Fenfluramine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine</span></div><div class="casAuthors">Fitzgerald, Lawrence W.; Burn, Timothy C.; Brown, Barry S.; Patterson, John P.; Corjay, Martha H.; Valentine, Patricia A.; Sun, Jung-Hui; Link, John R.; Abbaszade, Ilgar; Hollis, Jeannine M.; Largent, Brian L.; Hartig, Paul R.; Hollis, Gregory F.; Meunier, Paul C.; Robichaud, Albert J.; Robertson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dexfenfluramine was approved in the United States for longterm use as an appetite suppressant until it was reported to be assocd. with valvular heart disease.  The valvular changes (myofibroblast proliferation) are histopathol. indistinguishable from those obsd. in carcinoid disease or after long-term exposure to 5-hydroxytryptamine (5-HT)2-preferring ergot drugs (ergotamine, methysergide).  5-HT2 receptor stimulation is known to cause fibroblast mitogenesis, which could contribute to this lesion.  To elucidate the mechanism of "fenphen"-assocd. valvular lesions, we examd. the interaction of fenfluramine and its metabolite norfenfluramine with 5-HT2 receptor subtypes and examd. the expression of these receptors in human and porcine heart valves.  Fenfluramine binds weakly to 5-HT2A, 5-HT2B, and 5-HT2C receptors.  In contrast, norfenfluramine exhibited high affinity for 5-HT2B and 5-HT2C receptors and more moderate affinity for 5-HT2A receptors.  In cells expressing recombinant 5-HT2B receptors, norfenfluramine potently stimulated the hydrolysis of inositol phosphates, increased intracellular Ca2+, and activated the mitogen-activated protein kinase cascade, the latter of which has been linked to mitogenic actions of the 5-HT2B receptor.  The level of 5-HT2B and 5-HT2A receptor transcripts in heart valves was at least 300-fold higher than the levels of 5-HT2C receptor transcript, which were barely detectable.  We propose that preferential stimulation of valvular 5-HT2B receptors by norfenfluramine, ergot drugs, or 5-HT released from carcinoid tumors (with or without accompanying 5-HT2A receptor activation) may contribute to valvular fibroplasia in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmkbFOXGVxcLVg90H21EOLACvtfcHk0lirkJA1mu1cNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslCltA%253D%253D&md5=b99b778d0de695d377aa4f0006b6dc47</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DL.%2BW.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DBrown%26aufirst%3DB.%2BS.%26aulast%3DPatterson%26aufirst%3DJ.%2BP.%26aulast%3DCorjay%26aufirst%3DM.%2BH.%26aulast%3DValentine%26aufirst%3DP.%2BA.%26aulast%3DSun%26aufirst%3DJ.%2BH.%26aulast%3DLink%26aufirst%3DJ.%2BR.%26aulast%3DAbbaszade%26aufirst%3DI.%26aulast%3DHollis%26aufirst%3DJ.%2BM.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DHartig%26aufirst%3DP.%2BR.%26aulast%3DHollis%26aufirst%3DG.%2BF.%26aulast%3DMeunier%26aufirst%3DP.%2BC.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DRobertson%26aufirst%3DD.%2BW.%26atitle%3DPossible%2520Role%2520of%2520Valvular%2520Serotonin%25205-HT%25282B%2529%2520Receptors%2520in%2520the%2520Cardiopathy%2520Associated%2520with%2520Fenfluramine%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D57%26spage%3D75%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of G Protein-Coupled Receptors: An Emerging Approach of Drug Discovery</span>. <i>Austin J. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">3</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=3&author=C.+Wildauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+Modulation+of+G+Protein-Coupled+Receptors%3A+An+Emerging+Approach+of+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWild%26aufirst%3DC.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520Modulation%2520of%2520G%2520Protein-Coupled%2520Receptors%253A%2520An%2520Emerging%2520Approach%2520of%2520Drug%2520Discovery%26jtitle%3DAustin%2520J.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D2%26spage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">GPCR Allosteric Modulators: Mechanistic Advantages and Therapeutic Applications</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2002</span>â <span class="NLM_lpage">2006</span>, <span class="refDoi">Â DOI: 10.2174/1568026619999190101151837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.2174%2F1568026619999190101151837" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=2002-2006&author=E.+A.+Woldauthor=J.+Zhou&title=GPCR+Allosteric+Modulators%3A+Mechanistic+Advantages+and+Therapeutic+Applications&doi=10.2174%2F1568026619999190101151837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1568026619999190101151837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619999190101151837%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DGPCR%2520Allosteric%2520Modulators%253A%2520Mechanistic%2520Advantages%2520and%2520Therapeutic%2520Applications%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D18%26spage%3D2002%26epage%3D2006%26doi%3D10.2174%2F1568026619999190101151837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">88</span>â <span class="NLM_lpage">127</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=88-127&author=E.+A.+Woldauthor=J.+Chenauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+Modulation+of+Class+A+GPCRs%3A+Targets%2C+Agents%2C+and+Emerging+Concepts&doi=10.1021%2Facs.jmedchem.8b00875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span></div><div class="casAuthors">Wold, Eric A.; Chen, Jianping; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs.  Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases.  GPCR allosteric modulation is an innovative targeting approach that broadens the available small mol. toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clin. trials.  Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development.  This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chem. approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zBEGIhRgD7Vg90H21EOLACvtfcHk0lgYVhRJ8xN6UQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK&md5=c724b7cb534a9eb52c371961bb9c9b42</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00875%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520Modulation%2520of%2520Class%2520A%2520GPCRs%253A%2520Targets%252C%2520Agents%252C%2520and%2520Emerging%2520Concepts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D88%26epage%3D127%26doi%3D10.1021%2Facs.jmedchem.8b00875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Im, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chio, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span> <span> </span><span class="NLM_article-title">Positive Allosteric Modulator of the Human 5-HT<sub>2C</sub> Receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">78</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1124/mol.64.1.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1124%2Fmol.64.1.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=12815163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvV2qtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2003&pages=78-84&author=W.+B.+Imauthor=C.+L.+Chioauthor=G.+L.+Albertsauthor=D.+M.+Dinh&title=Positive+Allosteric+Modulator+of+the+Human+5-HT2C+Receptor&doi=10.1124%2Fmol.64.1.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulator of the human 5-HT2C receptor</span></div><div class="casAuthors">Im, Wha Bin; Chio, Christopher L.; Alberts, Glen L.; Dinh, Dac M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-84</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The human 5-hydroxytryptamine-2C (5-HT2C) receptor has been the target of potential anxiolytics and antiobesity drugs, and its pos. allosteric modulator was discovered to be L-threo-Î±-D-galacto-octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[(4-undecyl-2-piperidinyl)carbonyl]amino]-1-thiomonohydrochloride (2S-cis) (PNU-69176E).  The drug at low micromolar concns. (<25 Î¼M) markedly enhanced [3H]5-HT binding (more than 300%) by increasing its affinity for low-affinity sites but with no appreciable effect on antagonist ([3H]mesulergine) binding.  Functionally, PNU-69176E alone rendered receptors constitutively active, producing the phenotypes of 5-HT-activated receptors, as measured with mesulergine-sensitive guanosine 5'-O-(3-[35S]thio)triphosphate binding, transient inositol 1,4,5-triphosphate release, and [3H]inositol phosphate accumulation.  These actions of PNU-69176E were obsd. with the human 5-HT2C receptor expressed in several mammalian cell lines (human embryonic kidney 293, NIH3T3, and SH-EP) at variable receptor densities (6 to 45 pmol/mg of protein), but not with analogous 5-HT and dopamine receptors (human 5-HT2A, 5-HT2B, 5-HT6, 5-HT7, and dopamine D2-long and D3 receptors).  Structurally, PNU-69176E consists of a long alkyl chain and a polar moiety, including the Î±-D-galactopyranoside.  Its analogs with shorter alkyl chains (Me to n-hexyl instead of n-undecyl group) failed to enhance [3H]5-HT binding, and also long alkyl amides are without allosteric modulation.  We propose that PNU-69176E may represent a new class of membrane receptor modulators, which probably need a long alkyl chain as a membrane anchor and target a selective polar head group to receptor modulatory sites near the membrane surface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMdPZHNbAJJbVg90H21EOLACvtfcHk0lj9Bozao7RaXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvV2qtrs%253D&md5=26c9f18b3097e2a8921b7803bc836489</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fmol.64.1.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.64.1.78%26sid%3Dliteratum%253Aachs%26aulast%3DIm%26aufirst%3DW.%2BB.%26aulast%3DChio%26aufirst%3DC.%2BL.%26aulast%3DAlberts%26aufirst%3DG.%2BL.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26atitle%3DPositive%2520Allosteric%2520Modulator%2520of%2520the%2520Human%25205-HT2C%2520Receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D64%26spage%3D78%26epage%3D84%26doi%3D10.1124%2Fmol.64.1.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Exploration of Synthetic Approaches and Pharmacological Evaluation of PNU-69176E and its Stereoisomer as 5-HT<sub>2C</sub> Receptor Allosteric Modulators</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">538</span>â <span class="NLM_lpage">545</span>, <span class="refDoi">Â DOI: 10.1021/cn300020x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300020x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOqsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=538-545&author=C.+Dingauthor=N.+M.+Bremerauthor=T.+D.+Smithauthor=P.+K.+Seitzauthor=N.+C.+Anastasioauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Exploration+of+Synthetic+Approaches+and+Pharmacological+Evaluation+of+PNU-69176E+and+its+Stereoisomer+as+5-HT2C+Receptor+Allosteric+Modulators&doi=10.1021%2Fcn300020x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Synthetic Approaches and Pharmacological Evaluation of PNU-69176E and Its Stereoisomer as 5-HT2C Receptor Allosteric Modulators</span></div><div class="casAuthors">Ding, Chunyong; Bremer, Nicole M.; Smith, Thressa D.; Seitz, Patricia K.; Anastasio, Noelle C.; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">538-545</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric modulators of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) present a unique drug design strategy to augment the response to endogenous 5-HT in a site- and event-specific manner with great potential as novel central nervous system probes and therapeutics.  To date, PNU-69176E is the only reported selective pos. allosteric modulator for the 5-HT2CR.  For the first time, an optimized synthetic route to readily access PNU-69176E (1) and its diastereomer 2 has been established in moderate to good overall yields over 10 steps starting from com. available picolinic acid.  This synthetic approach not only enables a feasible prepn. of a sufficient amt. of 1 for use as a ref. compd. for secondary pharmacol. studies, but also provides an efficient synthesis of key intermediates to develop novel and simplified 5-HT2CR allosteric modulators.  Compd. 1 and its diastereomer 2 were functionally characterized in Chinese hamster ovary (CHO) cells stably transfected with the 5-HT2CR using an intracellular calcium (Cai2+) release assay.  Compd. 1 demonstrated efficacy and potency as an allosteric modulator for the 5-HT2CR with no intrinsic agonist activity.  Compd. 1 did not alter 5-HT-evoked Cai2+ in CHO cells stably transfected with the highly homologous 5-HT2AR.  In contrast, the diastereomer 2 did not alter 5-HT-evoked Cai2+ release in 5-HT2AR-CHO or 5-HT2CR-CHO cells or exhibit intrinsic agonist activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-ZC-7cVkBGrVg90H21EOLACvtfcHk0lhpoI6WfRzJNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOqsb0%253D&md5=1f635dd7796d2663f1ab08b92c7d7cb9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fcn300020x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300020x%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DBremer%26aufirst%3DN.%2BM.%26aulast%3DSmith%26aufirst%3DT.%2BD.%26aulast%3DSeitz%26aufirst%3DP.%2BK.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DExploration%2520of%2520Synthetic%2520Approaches%2520and%2520Pharmacological%2520Evaluation%2520of%2520PNU-69176E%2520and%2520its%2520Stereoisomer%2520as%25205-HT2C%2520Receptor%2520Allosteric%2520Modulators%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D538%26epage%3D545%26doi%3D10.1021%2Fcn300020x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miszkiel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">288</span>â <span class="NLM_lpage">305</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00401</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00401" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntFWit7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=288-305&author=C.+T.+Wildauthor=J.+M.+Miszkielauthor=E.+A.+Woldauthor=C.+A.+Sotoauthor=C.+Dingauthor=R.+M.+Hartleyauthor=M.+A.+Whiteauthor=N.+C.+Anastasioauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Design%2C+Synthesis%2C+and+Characterization+of+4-Undecylpiperidine-2-carboxamides+as+Positive+Allosteric+Modulators+of+the+Serotonin+%285-HT%29+5-HT2C+Receptor&doi=10.1021%2Facs.jmedchem.8b00401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor</span></div><div class="casAuthors">Wild, Christopher T.; Miszkiel, Joanna M.; Wold, Eric A.; Soto, Claudia A.; Ding, Chunyong; Hartley, Rachel M.; White, Mark A.; Anastasio, Noelle C.; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">288-305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cis-alkylpiperidinecarboxamides such as I were prepd. as pos. allosteric modulators of the 5-HT2c receptor for potential use in the prevention of cocaine addiction relapse.  I potentiated 5-HT-evoked intracellular calcium release in cells stably expressing the human 5-HT2c receptor but not cells expressing human 5-HT2a receptors.  Mol. docking calcns. of I at the 5-HT2c receptor identified a topog. distinct allosteric site.  The pharmacokinetics of I upon i.v. administration, its toxicity, and its selectivity for the 5-HT2c receptor over a variety of other competing receptors was detd.  I modulated 5-HT2c receptor-mediated spontaneous ambulation, partially substituted for the training dose of the 5-HT2c receptor agonist WAY163909, synergized with a low dose of WAY163909 to substitute fully for the stimulus effects of WAY163909, and attenuated relapse vulnerability as assessed in a rodent self-administration model, indicating its therapeutic promise for cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyQPhHrzQH-LVg90H21EOLACvtfcHk0lhmrew5ESnSNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntFWit7o%253D&md5=a783f4d24d6e8fb3af595d7948e4952d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00401%26sid%3Dliteratum%253Aachs%26aulast%3DWild%26aufirst%3DC.%2BT.%26aulast%3DMiszkiel%26aufirst%3DJ.%2BM.%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DSoto%26aufirst%3DC.%2BA.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DHartley%26aufirst%3DR.%2BM.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Characterization%2520of%25204-Undecylpiperidine-2-carboxamides%2520as%2520Positive%2520Allosteric%2520Modulators%2520of%2520the%2520Serotonin%2520%25285-HT%2529%25205-HT2C%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D288%26epage%3D305%26doi%3D10.1021%2Facs.jmedchem.8b00401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-CÃ¡rceles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VÃ¡zquez-Villa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RodrÃ­guez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codesido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruces, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loza, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlÃ©n, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BenhamÃº, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RodrÃ­guez de Fonseca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez-RodrÃ­guez, M. L.</span></span> <span> </span><span class="NLM_article-title">A Positive Allosteric Modulator of the Serotonin 5-HT2CReceptor for Obesity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9575</span>â <span class="NLM_lpage">9584</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00994</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00994" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslyrsL7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9575-9584&author=J.+Garc%C3%ADa-C%C3%A1rcelesauthor=J.+M.+Decaraauthor=H.+V%C3%A1zquez-Villaauthor=R.+Rodr%C3%ADguezauthor=E.+Codesidoauthor=J.+Crucesauthor=J.+Breaauthor=M.+I.+Lozaauthor=F.+Al%C3%A9nauthor=J.+Bottaauthor=P.+J.+McCormickauthor=J.+A.+Ballesterosauthor=B.+Benham%C3%BAauthor=F.+Rodr%C3%ADguez+de+Fonsecaauthor=M.+L.+L%C3%B3pez-Rodr%C3%ADguez&title=A+Positive+Allosteric+Modulator+of+the+Serotonin+5-HT2CReceptor+for+Obesity&doi=10.1021%2Facs.jmedchem.7b00994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A Positive Allosteric Modulator of the Serotonin 5-HT2C Receptor for Obesity</span></div><div class="casAuthors">Garcia-Carceles, Javier; Decara, Juan M.; Vazquez-Villa, Henar; Rodriguez, Ramon; Codesido, Eva; Cruces, Jacobo; Brea, Jose; Loza, Maria I.; Alen, Francisco; Botta, Joaquin; McCormick, Peter J.; Ballesteros, Juan A.; Benhamu, Bellinda; Rodriguez de Fonseca, Fernando; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9575-9584</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 5-HT2CR agonist lorcaserin, clin. approved for the treatment of obesity, causes important side effects mainly related to subtype selectivity.  In the search for 5-HT2CR allosteric modulators as safer antiobesity drugs, a chem. library from Vivia Biotech was screened using ExviTech platform.  Structural modifications of identified hit VA240 in synthesized analogs 6-41 afforded compd. 11 (N-[(1-benzyl-1H-indol-3-yl)methyl]pyridin-3-amine, VA012), which exhibited dose-dependent enhancement of serotonin efficacy, no significant off-target activities, and low binding competition with serotonin or other orthosteric ligands.  PAM 11 was very active in feeding inhibition in rodents, an effect that was not related to the activation of 5-HT2AR.  A combination of 11 with the SSRI sertraline increased the anorectic effect.  Subchronic administration of 11 reduced food intake and body wt. gain without causing CNS-related malaise.  The behavior of compd. 11 identified in this work supports the interest of a serotonin 5-HT2CR PAM as a promising therapeutic approach for obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXljb401CzwLVg90H21EOLACvtfcHk0lhb0BxfhBoNVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslyrsL7K&md5=e5c1d03f3e25fa49072265c9ab77ea21</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00994%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-C%25C3%25A1rceles%26aufirst%3DJ.%26aulast%3DDecara%26aufirst%3DJ.%2BM.%26aulast%3DV%25C3%25A1zquez-Villa%26aufirst%3DH.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DR.%26aulast%3DCodesido%26aufirst%3DE.%26aulast%3DCruces%26aufirst%3DJ.%26aulast%3DBrea%26aufirst%3DJ.%26aulast%3DLoza%26aufirst%3DM.%2BI.%26aulast%3DAl%25C3%25A9n%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DJ.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26aulast%3DBallesteros%26aufirst%3DJ.%2BA.%26aulast%3DBenham%25C3%25BA%26aufirst%3DB.%26aulast%3DRodr%25C3%25ADguez%2Bde%2BFonseca%26aufirst%3DF.%26aulast%3DL%25C3%25B3pez-Rodr%25C3%25ADguez%26aufirst%3DM.%2BL.%26atitle%3DA%2520Positive%2520Allosteric%2520Modulator%2520of%2520the%2520Serotonin%25205-HT2CReceptor%2520for%2520Obesity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9575%26epage%3D9584%26doi%3D10.1021%2Facs.jmedchem.7b00994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqi, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, P. N.</span></span> <span> </span><span class="NLM_article-title">Identification of Dual Role of Piperazine-linked Phenyl Cyclopropyl Methanone as Positive Allosteric Modulator of 5-HT2C and Negative Allosteric Modulator of 5-HT2B Receptors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">499</span>â <span class="NLM_lpage">516</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.12.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2Fj.ejmech.2018.12.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=30622024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslaluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=499-516&author=K.+Singhauthor=C.+Sonaauthor=V.+Ojhaauthor=M.+Singhauthor=A.+Mishraauthor=A.+Kumarauthor=M.+I.+Siddiqiauthor=R.+P.+Tripathiauthor=P.+N.+Yadav&title=Identification+of+Dual+Role+of+Piperazine-linked+Phenyl+Cyclopropyl+Methanone+as+Positive+Allosteric+Modulator+of+5-HT2C+and+Negative+Allosteric+Modulator+of+5-HT2B+Receptors&doi=10.1016%2Fj.ejmech.2018.12.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT2C and negative allosteric modulator of 5-HT2B receptors</span></div><div class="casAuthors">Singh, Kartikey; Sona, Chandan; Ojha, Vikash; Singh, Maninder; Mishra, Ankita; Kumar, Ajeet; Siddiqi, Mohammad Imran; Tripathi, Rama P.; Yadav, Prem N.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">499-516</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Allosteric modulators of G-protein-coupled receptors have lately gained significant traction in drug discovery.  Recent studies have shown that allosteric modulation of serotonin 2C receptor (5-HT2C) as a viable strategy for the treatment of various central nervous system (CNS) disorders.  Considering the crit. role of 5-HT2C in the modulation of appetite, a selective pos. allosteric modulator (PAM) of 5-HT2C offers a new opportunity for anti-obesity therapeutic development.  In this study, Ph cyclopropyl-linked N-heterocycles were synthesized and evaluated at 5-HT2C for agonist and PAM activity.  Our study shows that imidazole linked Ph cyclopropyl methanones has PAM activity on both 5-HT2C and serotonin 2B receptor (5-HT2B).  Interestingly, piperazine linked Ph cyclopropyl methanones was active as PAM of 5-HT2C (increased the Emax of 5-HT to 139%), and as neg. allosteric modulator (NAM) of 5-HT2B (decreases EC50 of 5-HT 10 times without affecting Emax).  Similar effect of compd. I was obsd. with synthetic orthosteric agonist lorcaserin on 5-HT2B.  Mol. docking study revealed that all active compds. were binding to the predicted allosteric site on 5-HT2C and shared a common interacting residues.  Finally, compd. I suppressed food intake in Sprague Dawley (SD) rats similar to lorcaserin after i.c.v. administration.  Therefore, these results suggest that piperazine moiety is essential for dual activity (PAM & NAM) of compds. I, and supports the hypothesis of 5-HT2C PAM for the treatment of obesity similar to the full agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIZVtcltP7JLVg90H21EOLACvtfcHk0lgJg7pbIwxwHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslaluw%253D%253D&md5=e115d454720ac5755168af7045cb0e51</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.070%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DSona%26aufirst%3DC.%26aulast%3DOjha%26aufirst%3DV.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DMishra%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSiddiqi%26aufirst%3DM.%2BI.%26aulast%3DTripathi%26aufirst%3DR.%2BP.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26atitle%3DIdentification%2520of%2520Dual%2520Role%2520of%2520Piperazine-linked%2520Phenyl%2520Cyclopropyl%2520Methanone%2520as%2520Positive%2520Allosteric%2520Modulator%2520of%25205-HT2C%2520and%2520Negative%2520Allosteric%2520Modulator%2520of%25205-HT2B%2520Receptors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D499%26epage%3D516%26doi%3D10.1016%2Fj.ejmech.2018.12.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. S.</span></span> <span> </span><span class="NLM_article-title">Quantitative Changes in Intracellular Calcium and Extracellular-regulated Kinase Activation Measured in Parallel in CHO Cells Stably Expressing Serotonin (5-HT) 5-HT2A or 5-HT2C Receptors</span>. <i>BMC Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi">Â DOI: 10.1186/1471-2202-13-25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1186%2F1471-2202-13-25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=22397586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCgu7nL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=25&author=P.+K.+Seitzauthor=N.+M.+Bremerauthor=A.+G.+McGinnisauthor=K.+A.+Cunninghamauthor=C.+S.+Watson&title=Quantitative+Changes+in+Intracellular+Calcium+and+Extracellular-regulated+Kinase+Activation+Measured+in+Parallel+in+CHO+Cells+Stably+Expressing+Serotonin+%285-HT%29+5-HT2A+or+5-HT2C+Receptors&doi=10.1186%2F1471-2202-13-25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative changes in intracellular calcium and extracellular-regulated kinase activation measured in parallel in CHO cells stably expressing serotonin (5-HT) 5-HT2A or 5-HT2C receptors</span></div><div class="casAuthors">Seitz, Patricia K.; Bremer, Nicole M.; McGinnis, Andrew G.; Cunningham, Kathryn A.; Watson, Cheryl S.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25</span>CODEN:
                <span class="NLM_cas:coden">BNMEA6</span>;
        ISSN:<span class="NLM_cas:issn">1471-2202</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The serotonin (5-HT) 2A and 2C receptors (5-HT2AR and 5-HT2CR) are involved in a wide range of physiol. and behavioral processes in the mammalian central and peripheral nervous systems.  These receptors share a high degree of homol., have overlapping pharmacol. profiles, and utilize many of the same and richly diverse second messenger signaling systems.  We have developed quant. assays for cells stably expressing these two receptors involving minimal cell sample manipulations that dramatically improve parallel assessments of two signaling responses: intracellular calcium (Cai++) changes and activation (phosphorylation) of downstream kinases.  Such profiles are needed to begin to understand the simultaneous contributions from the multiplicity of signaling cascades likely to be initiated by serotonergic ligands.  Results: We optimized the Cai++ assay for stable cell lines expressing either 5-HT2AR or 5-HT2CR (including dye use and measurement parameters; cell d. and serum requirements).  We adapted a quant. 96-well plate immunoassay for pERK in the same cell lines.  Similar cell d. optima and time courses were obsd. for 5-HT2AR- and 5-HT2CR-expressing cells in generating both types of signaling.  Both cell lines also require serum-free preincubation for maximal agonist responses in the pERK assay.  However, 5-HT2AR-expressing cells showed significant release of Cai++ in response to 5-HT stimulation even when preincubated in serum-replete medium, while the response was completely eliminated by serum in 5-HT2CR-expressing cells.  Response to another serotonergic ligand (DOI) was eliminated by serum-replete preincubation in both cells lines.  Conclusions: These data expand our knowledge of differences in ligand-stimulated signaling cascades between 5-HT2AR and 5-HT2CR.  Our parallel assays can be applied to other cell and receptor systems for monitoring and dissecting concurrent signaling responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6M4u7LVn5PbVg90H21EOLACvtfcHk0lgxg4zBsXV1Ww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCgu7nL&md5=6b1b3b3c45590bda79f49f89d8e7fdbb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1186%2F1471-2202-13-25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2202-13-25%26sid%3Dliteratum%253Aachs%26aulast%3DSeitz%26aufirst%3DP.%2BK.%26aulast%3DBremer%26aufirst%3DN.%2BM.%26aulast%3DMcGinnis%26aufirst%3DA.%2BG.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DWatson%26aufirst%3DC.%2BS.%26atitle%3DQuantitative%2520Changes%2520in%2520Intracellular%2520Calcium%2520and%2520Extracellular-regulated%2520Kinase%2520Activation%2520Measured%2520in%2520Parallel%2520in%2520CHO%2520Cells%2520Stably%2520Expressing%2520Serotonin%2520%25285-HT%2529%25205-HT2A%2520or%25205-HT2C%2520Receptors%26jtitle%3DBMC%2520Neurosci.%26date%3D2012%26volume%3D13%26spage%3D25%26doi%3D10.1186%2F1471-2202-13-25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1381</span>â <span class="NLM_lpage">1398</span>, <span class="refDoi">Â DOI: 10.2174/1568026619666190709101449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.2174%2F1568026619666190709101449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=31288724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvV2is7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=1381-1398&author=E.+A.+Woldauthor=C.+T.+Wildauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Targeting+the+5-HT2C+Receptor+in+Biological+Context+and+the+Current+State+of+5-HT2C+Receptor+Ligand+Development&doi=10.2174%2F1568026619666190709101449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development</span></div><div class="casAuthors">Wold, Eric A.; Wild, Christopher T.; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1381-1398</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Serotonin (5-HT) 5-HT2C receptor (5-HT2CR) is recognized as a crit. mediator of diseaserelated pathways and behaviors based upon actions in the central nervous system (CNS).  Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia.  The most significant agonist discovery to date is the FDA approved anti-obesity medication lorcaserin.  In recent years, efforts towards developing other mechanisms to enhance receptor function have resulted in the discovery of Pos. Allosteric Modulators (PAMs) for the 5-HT2CR, with several mol. series now reported.  The biol. significance and context for signaling and function of the 5-HT2CR, and the current status of 5-HT2CR agonists and PAMs are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7Nb18Hq98iLVg90H21EOLACvtfcHk0lioTzEFOI7Www"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvV2is7fE&md5=e4f90bb137775feb1d6a601192e7c9a7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190709101449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190709101449%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DWild%26aufirst%3DC.%2BT.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DTargeting%2520the%25205-HT2C%2520Receptor%2520in%2520Biological%2520Context%2520and%2520the%2520Current%2520State%2520of%25205-HT2C%2520Receptor%2520Ligand%2520Development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D1381%26epage%3D1398%26doi%3D10.2174%2F1568026619666190709101449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HarpsÃ¸e, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolajsen, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BjÃ¸rn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span> <span> </span><span class="NLM_article-title">5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">719</span>â <span class="NLM_lpage">730</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2018.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2Fj.cell.2018.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=29398112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=719-730&author=Y.+Pengauthor=J.+D.+McCorvyauthor=K.+Harps%C3%B8eauthor=K.+Lansuauthor=S.+Yuanauthor=P.+Popovauthor=L.+Quauthor=M.+Puauthor=T.+Cheauthor=L.+F.+Nikolajsenauthor=X.-P.+Huangauthor=Y.+Wuauthor=L.+Shenauthor=W.+E.+Bj%C3%B8rn-Yoshimotoauthor=K.+Dingauthor=D.+Wackerauthor=G.+W.+Hanauthor=J.+Chengauthor=V.+Katritchauthor=A.+A.+Jensenauthor=M.+A.+Hansonauthor=S.+Zhaoauthor=D.+E.+Gloriamauthor=B.+L.+Rothauthor=R.+C.+Stevensauthor=Z.-J.+Liu&title=5-HT2C+Receptor+Structures+Reveal+the+Structural+Basis+of+GPCR+Polypharmacology&doi=10.1016%2Fj.cell.2018.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology</span></div><div class="casAuthors">Peng, Yao; McCorvy, John D.; Harpsoee, Kasper; Lansu, Katherine; Yuan, Shuguang; Popov, Petr; Qu, Lu; Pu, Mengchen; Che, Tao; Nikolajsen, Louise F.; Huang, Xi-Ping; Wu, Yiran; Shen, Ling; Bjoern-Yoshimoto, Walden E.; Ding, Kang; Wacker, Daniel; Han, Gye Won; Cheng, Jianjun; Katritch, Vsevolod; Jensen, Anders A.; Hanson, Michael A.; Zhao, Suwen; Gloriam, David E.; Roth, Bryan L.; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">719-730.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drugs frequently require interactions with multiple targets-via a process known as polypharmacol.-to achieve their therapeutic actions.  Currently, drugs targeting several serotonin receptors, including the 5-HT2C receptor, are useful for treating obesity, drug abuse, and schizophrenia.  The competing challenges of developing selective 5-HT2C receptor ligands or creating drugs with a defined polypharmacol. profile, esp. aimed at G protein-coupled receptors (GPCRs), remain extremely difficult.  Here, we solved two structures of the 5-HT2C receptor in complex with the highly promiscuous agonist ergotamine and the 5-HT2A-C receptor-selective inverse agonist ritanserin at resolns. of 3.0 Ã and 2.7 Ã, resp.  We analyzed their resp. binding poses to provide mechanistic insights into their receptor recognition and opposing pharmacol. actions.  This study investigates the structural basis of polypharmacol. at canonical GPCRs and illustrates how understanding characteristic patterns of ligand-receptor interaction and activation may ultimately facilitate drug design at multiple GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooMwdaPWz7FLVg90H21EOLACvtfcHk0ljsY__9Yyo0hQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSitrs%253D&md5=b6c7f55568544a8c363794fa12f18175</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DHarps%25C3%25B8e%26aufirst%3DK.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DPopov%26aufirst%3DP.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DNikolajsen%26aufirst%3DL.%2BF.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DBj%25C3%25B8rn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.-J.%26atitle%3D5-HT2C%2520Receptor%2520Structures%2520Reveal%2520the%2520Structural%2520Basis%2520of%2520GPCR%2520Polypharmacology%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D719%26epage%3D730%26doi%3D10.1016%2Fj.cell.2018.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manivet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, D.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maroteaux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellermann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Launay, J.-M.</span></span> <span> </span><span class="NLM_article-title">The Serotonin Binding Site of Human and Murine 5-HT<sub>2B</sub> Receptors: Molecular Modeling and Site-Directed Mutagenesis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">17170</span>â <span class="NLM_lpage">17178</span>, <span class="refDoi">Â DOI: 10.1074/jbc.m200195200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1074%2Fjbc.M200195200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=11859080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD38XjslWgs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=17170-17178&author=P.+Manivetauthor=B.+Schneiderauthor=J.+C.+Smithauthor=D.-S.+Choiauthor=L.+Maroteauxauthor=O.+Kellermannauthor=J.-M.+Launay&title=The+Serotonin+Binding+Site+of+Human+and+Murine+5-HT2B+Receptors%3A+Molecular+Modeling+and+Site-Directed+Mutagenesis&doi=10.1074%2Fjbc.m200195200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis</span></div><div class="casAuthors">Manivet, Philippe; Schneider, Benoit; Smith, Jeremy Christopher; Choi, Doo-Sup; Maroteaux, Luc; Kellermann, Odile; Launay, Jean-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">17170-17178</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Bacteriorhodopsin and rhodopsin crystal structures were used as templates to build structural models of the mouse and human serotonin (5-HT)-2B receptors (5-HT2BRs).  Serotonin was docked to the receptors, and the amino acids predicted to participate to its binding were subjected to mutagenesis.  5-HT binding affinity and 5-HT-induced inositol triphosphate prodn. were measured in LMTK- cells transfected with either wild-type or mutated receptor genes.  According to these measurements, the bacteriorhodopsin-based models of the 5-HT2BRs appear more confident than the rhodopsin-based ones.  Residues belonging to the transmembrane domains 3 and 6, i.e. Asp3.32, Ser3.36, Phe6.52, and Asn6.55, make direct contacts with 5-HT.  In addn., Trp3.28, Phe3.35, Phe6.52, and Phe7.38 form an arom. box surrounding 5-HT.  The specificity of human and mouse 5-HT2BRs may be reflected by different rearrangements of the arom. network upon 5-HT binding.  Two amino acids close to Pro5.50 in the human transmembrane domain 5 sequence were permuted to introduce a "mouse-like" sequence.  This change was enough to confer the human 5-HT2BR properties similar to those of the mouse.  Taken together, the computed models and the site-directed mutagenesis expts. give a structural explanation to (i) the different 5-HT pKD values measured with the human and mouse 5-HT2BRs (7.9 and 5.8, resp.) and (ii) the specificity of 5-HT binding to 5-HT2BRs as compared with other serotonergic G-protein coupled receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr51vp_1vjTJbVg90H21EOLACvtfcHk0lgGxMiFzRX6-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjslWgs74%253D&md5=31a2c6e7a5a6551d46693e76bbb32b5f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M200195200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M200195200%26sid%3Dliteratum%253Aachs%26aulast%3DManivet%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DJ.%2BC.%26aulast%3DChoi%26aufirst%3DD.-S.%26aulast%3DMaroteaux%26aufirst%3DL.%26aulast%3DKellermann%26aufirst%3DO.%26aulast%3DLaunay%26aufirst%3DJ.-M.%26atitle%3DThe%2520Serotonin%2520Binding%2520Site%2520of%2520Human%2520and%2520Murine%25205-HT2B%2520Receptors%253A%2520Molecular%2520Modeling%2520and%2520Site-Directed%2520Mutagenesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D17170%26epage%3D17178%26doi%3D10.1074%2Fjbc.m200195200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Improved Method for the Identification and Validation of Allosteric Sites</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2358</span>â <span class="NLM_lpage">2363</span>, <span class="refDoi">Â DOI: 10.1021/acs.jcim.7b00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.7b00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlGlu7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=2358-2363&author=K.+Songauthor=X.+Liuauthor=W.+Huangauthor=S.+Luauthor=Q.+Shenauthor=L.+Zhangauthor=J.+Zhang&title=Improved+Method+for+the+Identification+and+Validation+of+Allosteric+Sites&doi=10.1021%2Facs.jcim.7b00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Improved Method for the Identification and Validation of Allosteric Sites</span></div><div class="casAuthors">Song, Kun; Liu, Xinyi; Huang, Wenkang; Lu, Shaoyong; Shen, Qiancheng; Zhang, Lu; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2358-2363</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric regulation induced by modulators binding to different, often distant, allosteric sites allows for exquisite control of protein functional activity.  The structural diversity of allosteric sites endows allosteric modulators with high selectivity and low toxicity.  Targeting allosteric sites, a novel tactic in drug discovery, has garnered much attention in the scientific community, and the identification of allosteric sites has become an important component of the development of allosteric drugs.  Here we present AllositePro, a method which predicts allosteric sites in proteins by combining pocket features with perturbation anal.  The performance of AllositePro is superior to that of the other currently available methods.  Using AllositePro, we predicted a novel allosteric site in cyclin-dependent kinase 2 (CDK2) and validated it by site-directed mutagenesis assay.  Thus, the AllositePro method provides an effective way to identify allosteric sites and could be a useful strategy for allosteric drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq23d-Zg0_4G7Vg90H21EOLACvtfcHk0lgxbAOodyDtcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlGlu7vL&md5=fbc362245d0bfb34686e0bc2fb38203b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.7b00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.7b00014%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DImproved%2520Method%2520for%2520the%2520Identification%2520and%2520Validation%2520of%2520Allosteric%2520Sites%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26spage%3D2358%26epage%3D2363%26doi%3D10.1021%2Facs.jcim.7b00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrey, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preissner, R.</span></span> <span> </span><span class="NLM_article-title">ProTox-II: A Webserver for the Prediction of Toxicity of Chemicals</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">W257</span>â <span class="NLM_lpage">W263</span>, <span class="refDoi">Â DOI: 10.1093/nar/gky318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1093%2Fnar%2Fgky318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=29718510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVyrt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=W257-W263&author=P.+Banerjeeauthor=A.+O.+Eckertauthor=A.+K.+Schreyauthor=R.+Preissner&title=ProTox-II%3A+A+Webserver+for+the+Prediction+of+Toxicity+of+Chemicals&doi=10.1093%2Fnar%2Fgky318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">ProTox-II: a webserver for the prediction of toxicity of chemicals</span></div><div class="casAuthors">Banerjee, Priyanka; Eckert, Andreas O.; Schrey, Anna K.; Preissner, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">W1</span>),
    <span class="NLM_cas:pages">W257-W263</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Advancement in the field of computational research has made it possible for the in silico methods to offer significant benefits to both regulatory needs and requirements for risk assessments, and pharmaceutical industry to assess the safety profile of a chem.  Here, we present ProTox-II that incorporates mol. similarity, pharmacophores, fragment propensities and machine-learning models for the prediction of various toxicity endpoints; such as acute toxicity, hepatotoxicity, cytotoxicity, carcinogenicity, mutagenicity, immunotoxicity, adverse outcomes pathways (Tox21) and toxicity targets.  The predictive models are built on data from both in vitro assays (e.g.Tox21 assays, Ames bacterial mutation assays, hepG2 cytotoxicity assays, Immunotoxicity assays) and in vivo cases (e.g. carcinogenicity, hepatotoxicity).  The models have been validated on independent external sets and have shown strong performance.  ProTox-II provides a freely available webserver for in silico toxicity prediction for toxicologists, regulatory agencies, computational and medicinal chemists.  The webserver takes a two-dimensional chem. structure as an input and reports the possible toxicity profile of the chem. for 33 models with confidence scores, and an overall toxicity radar chart along with three most similar compds. with known acute toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0iLlkldrW27Vg90H21EOLACvtfcHk0liSrBMjNgV9CQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVyrt7Y%253D&md5=c39b880461f53ae84341843feafe3e1c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky318%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DP.%26aulast%3DEckert%26aufirst%3DA.%2BO.%26aulast%3DSchrey%26aufirst%3DA.%2BK.%26aulast%3DPreissner%26aufirst%3DR.%26atitle%3DProTox-II%253A%2520A%2520Webserver%2520for%2520the%2520Prediction%2520of%2520Toxicity%2520of%2520Chemicals%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26spage%3DW257%26epage%3DW263%26doi%3D10.1093%2Fnar%2Fgky318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Moving Beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach to Enable Alignment of Druglike Properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>â <span class="NLM_lpage">449</span>, <span class="refDoi">Â DOI: 10.1021/cn100008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+Beyond+Rules%3A+The+Development+of+a+Central+Nervous+System+Multiparameter+Optimization+%28CNS+MPO%29+Approach+to+Enable+Alignment+of+Druglike+Properties&doi=10.1021%2Fcn100008c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-449</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The interplay among commonly used physicochem. properties in drug design was examd. and utilized to create a prospective design tool focused on the alignment of key druglike attributes.  Using a set of six physicochem. parameters ((a) lipophilicity, calcd. partition coeff. (ClogP); (b) calcd. distribution coeff. at pH = 7.4 (ClogD); (c) mol. wt. (MW); (d) topol. polar surface area (TPSA); (e) no. of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compds. (N = 11 303).  The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score â¥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates.  This anal. suggests that this algorithm could potentially be used to identify compds. with a higher probability of successfully testing hypotheses in the clinic.  In addn., a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set.  The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chem. design space through a holistic assessment approach.  Based on six physicochem. properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compds. with increased probability of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3Mvkgm_X5bVg90H21EOLACvtfcHk0lihSyEdzpETyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D&md5=e94998f65a420be6ee4dec4a987cb983</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520Beyond%2520Rules%253A%2520The%2520Development%2520of%2520a%2520Central%2520Nervous%2520System%2520Multiparameter%2520Optimization%2520%2528CNS%2520MPO%2529%2520Approach%2520to%2520Enable%2520Alignment%2520of%2520Druglike%2520Properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449%26doi%3D10.1021%2Fcn100008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, C. L.</span></span> <span> </span><span class="NLM_article-title">Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-Species Pharmacologic ExposureâResponse Relationships</span>. In  <i>Annual Reports in Medicinal Chemistry</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">2010</span>; Vol.  <span class="NLM_volume">45</span>, pp  <span class="NLM_fpage">55</span>â <span class="NLM_lpage">70</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2FS0065-7743%2810%2945004-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+L.+Shafferauthor=J.+E.+Macor&title=Defining+Neuropharmacokinetic+Parameters+in+CNS+Drug+Discovery+to+Determine+Cross-Species+Pharmacologic+Exposure%E2%80%93Response+Relationships"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2810%2945004-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26id%3Ddoi%3A10.1016%252FS0065-7743%252810%252945004-6%26sid%3Dliteratum%253Aachs%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26atitle%3DDefining%2520Neuropharmacokinetic%2520Parameters%2520in%2520CNS%2520Drug%2520Discovery%2520to%2520Determine%2520Cross-Species%2520Pharmacologic%2520Exposure%25E2%2580%2593Response%2520Relationships%26jtitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26pub%3DAcademic%2520Press%26date%3D2010%26volume%3D45%26spage%3D55%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soto, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbertson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">In Vivo and In Vitro Analyses of Novel Peptidomimetic Disruptors for the Serotonin 5-HT2C Receptor Interaction With Phosphatase and Tensin Homolog</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">907</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2019.00907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.3389%2Ffphar.2019.00907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=31507411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFShtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=907&author=C.+A.+Sotoauthor=H.+C.+Duauthor=R.+G.+Foxauthor=T.+Yangauthor=J.+Hoosonauthor=N.+C.+Anastasioauthor=S.+R.+Gilbertsonauthor=K.+A.+Cunningham&title=In+Vivo+and+In+Vitro+Analyses+of+Novel+Peptidomimetic+Disruptors+for+the+Serotonin+5-HT2C+Receptor+Interaction+With+Phosphatase+and+Tensin+Homolog&doi=10.3389%2Ffphar.2019.00907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo and in vitro analyses of novel peptidomimetic disruptors for the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog</span></div><div class="casAuthors">Soto, Claudia A.; Du, Huang-Chi; Fox, Robert G.; Yang, Taegyun; Hooson, James; Anastasio, Noelle C.; Gilbertson, Scott R.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">907</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Hypofunction of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in a variety of disorders including substance use disorders.  As such, approaches to enhance 5-HT2CR signaling display therapeutic potential.  In the present study, we show that disruption of the 5-HT2CR interaction with the protein phosphatase and tensin homolog (PTEN) via peptidomimetics enhances 5-HT2CR-mediating signaling in vitro and potentiates selective 5-HT2CR agonists in behavioral rodent models.  Overall, the present study provides further evidence that 5-HT2CR activity can be modulated through an allosteric protein-protein interaction.  This work provides the groundwork for the continued exploration of protein-protein interactions that can allosterically modulate this crit. receptor and other important G protein-coupled receptors (GPCRs) for new therapeutic development through mechanisms that may display clin. utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxgSjgfgTkfLVg90H21EOLACvtfcHk0ljm95_INQRCOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFShtrw%253D&md5=c57f6c61b8e096f3b03db9930569c5f3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00907%26sid%3Dliteratum%253Aachs%26aulast%3DSoto%26aufirst%3DC.%2BA.%26aulast%3DDu%26aufirst%3DH.%2BC.%26aulast%3DFox%26aufirst%3DR.%2BG.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DHooson%26aufirst%3DJ.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DGilbertson%26aufirst%3DS.%2BR.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DIn%2520Vivo%2520and%2520In%2520Vitro%2520Analyses%2520of%2520Novel%2520Peptidomimetic%2520Disruptors%2520for%2520the%2520Serotonin%25205-HT2C%2520Receptor%2520Interaction%2520With%2520Phosphatase%2520and%2520Tensin%2520Homolog%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D907%26doi%3D10.3389%2Ffphar.2019.00907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F. C.</span></span> <span> </span><span class="NLM_article-title">Drug Discrimination in Neurobiology</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">337</span>â <span class="NLM_lpage">345</span>, <span class="refDoi">Â DOI: 10.1016/s0091-3057(99)00047-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2FS0091-3057%2899%2900047-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10515310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaK1MXmt1eksbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=337-345&author=F.+C.+Colpaert&title=Drug+Discrimination+in+Neurobiology&doi=10.1016%2Fs0091-3057%2899%2900047-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discrimination in Neurobiology</span></div><div class="casAuthors">Colpaert, F. C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-345</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 166 refs.  Areas of neurobiol. interest are identified towards which drug discrimination (DD) studies have made important contributions.  DD allows ligand actions to be analyzed at the whole organism level, with a neurobiol. specificity that is exquisite and often unrivalled.  DD analyses have thus been made of a vast array of CNS agents acting on receptors, enzymes, or ion channels, including most drugs of abuse.  DD uniquely offers access to the study of subjective drug effects in animals, using a methodol. that also is transposable to humans and has generated unprecedented models of pathol. (e.g., chronic pain, opiate addiction).  Parametric studies of such independent variables as training dose and reinforcement provide refined insights into the dynamic psychophysiol. mechanisms of both drug effects and behavior.  Three different mechanisms have been identified by which discriminative, and perhaps other behaviors, can come about.  DD also is superbly sensitive to small, partial activation of mol. substrates; this has enabled DD analyses to pioneer the unravelling of mol. mechanisms of drug action (attributing, f.ex., LSD's particular subjective effects to an unusual, partial activation of 5-HT, and perhaps other receptors).  DD has both oriented and served as a tool to conduct drug discovery research (e.g., pirenperone-risperidone, loperamide).  The DD response arguably constitutes a quantal, rather than graded, variable, and as such allows a comprehension of mol., pharmacol., and behavioral mechanisms that would have been otherwise inaccessible.  Perhaps most important are the following further contributions.  One is the notion that particular, different levels of receptor activation are assocd. with qualities of neurobiol. actions that also differ and are unique, this notion arguably constituting the most significant addn. to affinity and intrinsic activity since the earliest theor. conceptions of mol. pharmacol.  Another contribution consists of studies that render redundant the notion of tolerance and identify fundamental mechanisms of signal transduction; these mechanisms account for apparent tolerance, dependence, addiction, and sensitization, and appear to operate ubiquitously in a bewildering array of biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQOkeVux09GLVg90H21EOLACvtfcHk0linVzZz5WbJ0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt1eksbk%253D&md5=67afd32d4245a597953605b545bf1c61</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2899%2900047-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252899%252900047-7%26sid%3Dliteratum%253Aachs%26aulast%3DColpaert%26aufirst%3DF.%2BC.%26atitle%3DDrug%2520Discrimination%2520in%2520Neurobiology%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1999%26volume%3D64%26spage%3D337%26epage%3D345%26doi%3D10.1016%2Fs0091-3057%2899%2900047-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F. C.</span></span> <span> </span><span class="NLM_article-title">Drug Discrimination: Methods of Manipulation, Measurement, and Analysis</span>. In  <i>Methods of Assessing the Reinforcing Properties of Abused Drugs</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozarth, M. A.</span></span>, Ed.; <span class="NLM_publisher-name">Springer New York</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">1987</span>; pp  <span class="NLM_fpage">341</span>â <span class="NLM_lpage">372</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1007%2F978-1-4612-4812-5_17" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&pages=341-372&author=F.+C.+Colpaertauthor=M.+A.+Bozarth&title=Methods+of+Assessing+the+Reinforcing+Properties+of+Abused+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2F978-1-4612-4812-5_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4612-4812-5_17%26sid%3Dliteratum%253Aachs%26aulast%3DColpaert%26aufirst%3DF.%2BC.%26atitle%3DDrug%2520Discrimination%253A%2520Methods%2520of%2520Manipulation%252C%2520Measurement%252C%2520and%2520Analysis%26btitle%3DMethods%2520of%2520Assessing%2520the%2520Reinforcing%2520Properties%2520of%2520Abused%2520Drugs%26aulast%3DBozarth%26aufirst%3DM.%2BA.%26pub%3DSpringer%2520New%2520York%26date%3D1987%26spage%3D341%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colpaert, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span> <span> </span><span class="NLM_article-title">Agonist and Antagonist Effects of Prototype Opiate Drugs in Rats Discriminating Fentanyl from Saline: Characteristics of Partial Generalization</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>230</i></span>,  <span class="NLM_fpage">193</span>â <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=6747824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaL2cXltVeqt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=1984&pages=193-199&author=F.+C.+Colpaertauthor=P.+A.+Janssen&title=Agonist+and+Antagonist+Effects+of+Prototype+Opiate+Drugs+in+Rats+Discriminating+Fentanyl+from+Saline%3A+Characteristics+of+Partial+Generalization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist and antagonist effects of prototype opiate drugs in rats discriminating fentanyl from saline:  characteristics of partial generalization</span></div><div class="casAuthors">Colpaert, Francis C.; Janssen, Paul A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">193-9</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The partial generalizations that prototype opiate drugs may produce in rats that are trained to discriminate 0.04 mg/kg of fentanyl citrate  [990-73-8] from saline were characterized.  Cyclazocine  [3572-80-3], nalorphine  [62-67-9], ketocyclazocine  [36292-69-0], and N-allylnormetazocine  [14198-28-8] produced partial generalization with fentanyl; the same compds. also partially antagonized fentanyl.  The fentanyl-like and the fentanyl-antagonist effects of these compds. occurred within similar ranges of dose.  An orderly incompatibility was apparent between the agonist and antagonist effects produced by each drug; cyclazocine, for example, was unlikely to antagonize fentanyl in animals in which it produced generalization, whereas it did antagonize fentanyl in animals in which it produced no generalization.  Cyclazocine, nalorphine, N-allylnormetazocine, and naloxone  [465-65-6] produced either fentanyl-like or fentanyl-antagonist effects in all animals tested.  A reliable relation was apparent among the agonist and antagonist effects of different opiate drugs; rats that generalized cyclazocine also were likely to generalize nalorphine and ketocyclazocine and were relatively less responsive to cyclazocine, nalorphine, N-allylnormetazocine, and naloxone as antagonists of fentanyl.  The results point to the importance of a no. of new methods in the anal. of drug discrimination data, which are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHZd6ZtPQWzrVg90H21EOLACvtfcHk0lifzyaDKHnTuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXltVeqt7Y%253D&md5=7464e71aae4a0969689e4df3f38b107f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColpaert%26aufirst%3DF.%2BC.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26atitle%3DAgonist%2520and%2520Antagonist%2520Effects%2520of%2520Prototype%2520Opiate%2520Drugs%2520in%2520Rats%2520Discriminating%2520Fentanyl%2520from%2520Saline%253A%2520Characteristics%2520of%2520Partial%2520Generalization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1984%26volume%3D230%26spage%3D193%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stevens
Negus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, M. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination</span>. <i>Curr. Top. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">245</span>â <span class="NLM_lpage">259</span>, <span class="refDoi">Â DOI: 10.1007/7854_2016_36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1007%2F7854_2016_36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=27571746" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=245-259&author=S.+Stevens%0ANegusauthor=M.+L.+Banks&title=Pharmacokinetic-Pharmacodynamic+%28PKPD%29+Analysis+with+Drug+Discrimination&doi=10.1007%2F7854_2016_36"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2F7854_2016_36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7854_2016_36%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%2BNegus%26aufirst%3DS.%26aulast%3DBanks%26aufirst%3DM.%2BL.%26atitle%3DPharmacokinetic-Pharmacodynamic%2520%2528PKPD%2529%2520Analysis%2520with%2520Drug%2520Discrimination%26jtitle%3DCurr.%2520Top.%2520Behav.%2520Neurosci.%26date%3D2018%26volume%3D39%26spage%3D245%26epage%3D259%26doi%3D10.1007%2F7854_2016_36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCreary, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filip, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Discriminative Stimulus Properties of (Â±)-Fenfluramine: the Role of 5-HT<sub>2</sub> Receptor Subtypes</span>. <i>Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">212</span>â <span class="NLM_lpage">221</span>, <span class="refDoi">Â DOI: 10.1037/0735-7044.117.2.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1037%2F0735-7044.117.2.212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=12708517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivFehsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2003&pages=212-221&author=A.+C.+McCrearyauthor=M.+Filipauthor=K.+A.+Cunningham&title=Discriminative+Stimulus+Properties+of+%28%C2%B1%29-Fenfluramine%3A+the+Role+of+5-HT2+Receptor+Subtypes&doi=10.1037%2F0735-7044.117.2.212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discriminative stimulus properties of (Â±)-fenfluramine: the role of 5-HT2 receptor subtypes</span></div><div class="casAuthors">McCreary, Andrew C.; Filip, Malgorzata; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioral Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-221</span>CODEN:
                <span class="NLM_cas:coden">BENEDJ</span>;
        ISSN:<span class="NLM_cas:issn">0735-7044</span>.
    
            (<span class="NLM_cas:orgname">American Psychological Association</span>)
        </div><div class="casAbstract">The role of serotonin 5-HT2 receptors (5-HT2R) in the discriminative stimulus effects of fenfluramine was investigated.  Male Sprague-Dawley rats were trained to discriminate (Â±)-fenfluramine (2 mg/kg i.p.) from saline using a 2-lever, water-reinforced paradigm.  Drug-lever responding after fenfluramine was dose-dependent.  The 5-HT2C/1BR agonist mCPP and the 5-HT2CR agonist MK 212 fully substituted, whereas the 5-HT2A/2CR agonist DOI partially substituted, for the training drug.  The 5-HT2BR agonist BW 723C86 engendered saline-lever responding.  The 5-HT2C/2BR antagonist SB 206553 completely antagonized the fenfluramine discrimination as well as the full substitutions of mCPP and MK 212 and the partial substitution of DOI.  The selective 5-HT2AR antagonist M100907 partially suppressed the stimulus effects of fenfluramine, mCPP, and MK 212 and almost fully attenuated the partial substitution of DOI.  RS 102221, a selective 5-HT2CR antagonist that does not cross the blood-brain barrier, did not alter the fenfluramine cue.  Results demonstrate that the discriminative stimulus effects of fenfluramine are centrally mediated by 5-HT2CR and to some extent by 5-HT2AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq3wP3zWbZSbVg90H21EOLACvtfcHk0liBIfMWiTQ65A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivFehsbg%253D&md5=0b2669064bf27454e16ee63cfb8130df</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1037%2F0735-7044.117.2.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F0735-7044.117.2.212%26sid%3Dliteratum%253Aachs%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DFilip%26aufirst%3DM.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DDiscriminative%2520Stimulus%2520Properties%2520of%2520%2528%25C2%25B1%2529-Fenfluramine%253A%2520the%2520Role%2520of%25205-HT2%2520Receptor%2520Subtypes%26jtitle%3DBehav.%2520Neurosci.%26date%3D2003%26volume%3D117%26spage%3D212%26epage%3D221%26doi%3D10.1037%2F0735-7044.117.2.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Involvement of 5-HT2C Receptors in Mediating the Discriminative Stimulus Properties of m-Chlorophenylpiperazine (mCPP)</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">38</span>, <span class="refDoi">Â DOI: 10.1016/0014-2999(94)90690-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2F0014-2999%2894%2990690-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=8082704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaK2cXkt1Kktrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1994&pages=27-38&author=P.+M.+Callahanauthor=K.+A.+Cunningham&title=Involvement+of+5-HT2C+Receptors+in+Mediating+the+Discriminative+Stimulus+Properties+of+m-Chlorophenylpiperazine+%28mCPP%29&doi=10.1016%2F0014-2999%2894%2990690-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP)</span></div><div class="casAuthors">Callahan, Patrick M.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">27-38</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Rats were trained to discriminate the 5-HT receptor agonist m-chlorophenylpiperazine (mCPP; 1 mg/kg) from saline using a two-lever, water-reinforced drug discrimination task.  The antidepressant trazodone (1-8 mg/kg), the 5-HT1B/2C receptor agonists 1-(m-trifluoromethylphenyl)piperazine (TFMPP; 0.25-1 mg/kg) and MK 212 (0.125-1 mg/kg), and the mixed 5-HT1A/B receptor agonist RU 24969 (0.25-2 mg/kg) substituted fully for mCPP.  The 5-HT2A/2C receptor agonists 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 0.25-1 mg/kg) and d-lysergic acid diethylamide (LSD; 0.02-0.08 mg/kg) and the 5-HT releaser fenfluramine (0.5-2 mg/kg) also mimicked mCPP.  Agonists selective for the 5-HT1A or 5-HT3 receptor or the 5-HT reuptake site produced saline-lever responding.  The ergoline deriv. mesulergine (0.5-4 mg/kg) produced a partial agonist/antagonist profile.  The 5-HT1/2 receptor antagonist metergoline (0.125-1 mg/kg) completely blocked the mCPP cue whereas the 5-HT2A/2C receptor antagonists ketanserin and LY 53857 as well as all other 5-HT receptor antagonists failed to block the mCPP cue.  The dopamine receptor antagonists SCH 23390 and haloperidol were also ineffective mCPP antagonists.  Following pretreatment with the 5-HT synthesis inhibitor p-chlorophenylalanine (pCPA; 100 mg/kg/day) for 3 consecutive days, the discriminability of low doses of mCPP increased, whereas the effects of fenfluramine decreased.  The present results suggest that the discriminative stimulus effects of mCPP in rats are mediated primarily by postsynaptic 5-HT2C receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrebmnBj2zsK7Vg90H21EOLACvtfcHk0lg4LFMeIBe7QA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkt1Kktrk%253D&md5=98623ad672842986facfc5cf3fa0a345</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2894%2990690-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252894%252990690-4%26sid%3Dliteratum%253Aachs%26aulast%3DCallahan%26aufirst%3DP.%2BM.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DInvolvement%2520of%25205-HT2C%2520Receptors%2520in%2520Mediating%2520the%2520Discriminative%2520Stimulus%2520Properties%2520of%2520m-Chlorophenylpiperazine%2520%2528mCPP%2529%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1994%26volume%3D257%26spage%3D27%26epage%3D38%26doi%3D10.1016%2F0014-2999%2894%2990690-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">m-Chlorophenylpiperazine (mCPP) Modulates the Discriminative Stimulus Effects of Cocaine Through Actions at the 5-HT<sub>2</sub>C Receptor</span>. <i>Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">157</span>â <span class="NLM_lpage">162</span>, <span class="refDoi">Â DOI: 10.1037/0735-7044.118.1.157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1037%2F0735-7044.118.1.157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=14979792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitVyqtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2004&pages=157-162&author=P.+S.+Frankelauthor=K.+A.+Cunningham&title=m-Chlorophenylpiperazine+%28mCPP%29+Modulates+the+Discriminative+Stimulus+Effects+of+Cocaine+Through+Actions+at+the+5-HT2C+Receptor&doi=10.1037%2F0735-7044.118.1.157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">m-Chlorophenylpiperazine (mCPP) modulates the discriminative stimulus effects of cocaine through actions at the 5-HT2C receptor</span></div><div class="casAuthors">Frankel, Paul S.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioral Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">157-162</span>CODEN:
                <span class="NLM_cas:coden">BENEDJ</span>;
        ISSN:<span class="NLM_cas:issn">0735-7044</span>.
    
            (<span class="NLM_cas:orgname">American Psychological Association</span>)
        </div><div class="casAbstract">Agonists acting at the serotonin-1B receptor (5-HT1BR) and 5-HT2CR have been reported to potentiate and block, resp., the discriminative stimulus effects of cocaine.  The present investigation reassessed the antagonistic effects of the mixed 5-HT2C/1BR agonist m-chlorophenylpiperazine (mCPP) on the discriminative stimulus effects of cocaine in the presence or absence of selective antagonism of the 5-HT1BR or 5-HT2CR.  The stimulus effects of cocaine were attenuated by mCPP at doses that reduced response rates.  The selective 5-HT2CR antagonist SB 242084, but not the selective 5-HT1BR antagonist GR 127935, reversed the mCPP-evoked attenuation of the cocaine cue and the suppression of response rates.  These results demonstrate that the suppressive effects of mCPP on cocaine discrimination are related to stimulation of the 5-HT2CR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq822S6caSBpLVg90H21EOLACvtfcHk0li9Eet_ZJ-gOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitVyqtb0%253D&md5=6c61e7a449610957fc9c819edec93d4c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1037%2F0735-7044.118.1.157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F0735-7044.118.1.157%26sid%3Dliteratum%253Aachs%26aulast%3DFrankel%26aufirst%3DP.%2BS.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3Dm-Chlorophenylpiperazine%2520%2528mCPP%2529%2520Modulates%2520the%2520Discriminative%2520Stimulus%2520Effects%2520of%2520Cocaine%2520Through%2520Actions%2520at%2520the%25205-HT2C%2520Receptor%26jtitle%3DBehav.%2520Neurosci.%26date%3D2004%26volume%3D118%26spage%3D157%26epage%3D162%26doi%3D10.1037%2F0735-7044.118.1.157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span>; <span class="NLM_string-name">Young, R.</span></span> <span> </span><span class="NLM_article-title">Drug Discrimination and Development of Novel Agents and Pharmacological Tools</span>. In  <i>Drug Discrimination: Applications to Medicinal Chemistry and Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span>, <span class="NLM_string-name">Young, R.</span></span>, Eds.; <span class="NLM_publisher-name">John Wiley and Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">217</span>â <span class="NLM_lpage">238</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1002%2F9781118023150.ch7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=217-238&author=R.+A.+Glennon&author=R.+Youngauthor=R.+A.+Glennon&author=R.+Young&title=Drug+Discrimination%3A+Applications+to+Medicinal+Chemistry+and+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2F9781118023150.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118023150.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DDrug%2520Discrimination%2520and%2520Development%2520of%2520Novel%2520Agents%2520and%2520Pharmacological%2520Tools%26btitle%3DDrug%2520Discrimination%253A%2520Applications%2520to%2520Medicinal%2520Chemistry%2520and%2520Drug%2520Discovery%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26pub%3DJohn%2520Wiley%2520and%2520Sons%26date%3D2011%26spage%3D217%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathis, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmett-Oglesby, M. W.</span></span> <span> </span><span class="NLM_article-title">Quantal vs. Graded Generalization in Drug Discrimination: Measuring a Graded Response</span>. <i>J. Neurosci. Methods</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.1016/0165-0270(90)90005-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2F0165-0270%2890%2990005-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=2407907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A280%3ADyaK3c7ntlektw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1990&pages=23-33&author=D.+A.+Mathisauthor=M.+W.+Emmett-Oglesby&title=Quantal+vs.+Graded+Generalization+in+Drug+Discrimination%3A+Measuring+a+Graded+Response&doi=10.1016%2F0165-0270%2890%2990005-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Quantal vs. graded generalization in drug discrimination: measuring a graded response</span></div><div class="casAuthors">Mathis D A; Emmett-Oglesby M W</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroscience methods</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-33</span>
        ISSN:<span class="NLM_cas:issn">0165-0270</span>.
    </div><div class="casAbstract">In drug discrimination research, detection of drug stimuli by animals is used for investigating various properties of psychoactive drugs.  The major issue addressed by this paper is whether detection of drug stimuli by animals is a quantal or graded event.  Some data suggest that detection of a drug stimulus by animals is quantal in nature.  Thus, variations in drug stimulus substitution may only reflect variations in threshold for detecting the training stimulus rather than the current concept of these data reflecting graded responding to stimulus intensity.  Therefore, drug discrimination procedures may have limited utility for detecting quantitative differences in the subjective effects of varying drug doses.  In order to examine this problem, a method for measuring continuous response gradients in individual animals is needed.  Tests for quantal responding generally use the distribution of responses on two manipulanda as the dependent measure.  However, this variable may be inadequate for detecting a graded response, and may actually reflect loss of stimulus control or a deterioration in performance, rather than changes in response magnitude.  Most alternative measures utilize response rate.  Unfortunately, these measures are influenced by the direct rate-altering properties of some drugs.  One possible alternative method is conditioned taste aversion as the discriminative task.  This paradigm provides a means for not only ascertaining if graded discriminative responses occur in individual animals, but also more rapidly training a drug discrimination.  Thus, using conditioned taste aversion techniques for measuring a drug discrimination may provide better indices for detecting response gradations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKo3Q2_Hi_y0loaUqgkFHkfW6udTcc2eZ6GXafWeE6cLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c7ntlektw%253D%253D&md5=216a85969e0fc540ce7d92ee1af44947</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2F0165-0270%2890%2990005-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-0270%252890%252990005-Z%26sid%3Dliteratum%253Aachs%26aulast%3DMathis%26aufirst%3DD.%2BA.%26aulast%3DEmmett-Oglesby%26aufirst%3DM.%2BW.%26atitle%3DQuantal%2520vs.%2520Graded%2520Generalization%2520in%2520Drug%2520Discrimination%253A%2520Measuring%2520a%2520Graded%2520Response%26jtitle%3DJ.%2520Neurosci.%2520Methods%26date%3D1990%26volume%3D31%26spage%3D23%26epage%3D33%26doi%3D10.1016%2F0165-0270%2890%2990005-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennett, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bright, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avenell, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stean, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromidge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middlemiss, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, T. P.</span></span> <span> </span><span class="NLM_article-title">SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">609</span>â <span class="NLM_lpage">620</span>, <span class="refDoi">Â DOI: 10.1016/s0028-3908(97)00038-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1016%2FS0028-3908%2897%2900038-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=9225286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADyaK2sXktlSmu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=609-620&author=G.+A.+Kennettauthor=M.+D.+Woodauthor=F.+Brightauthor=B.+Trailauthor=G.+Rileyauthor=V.+Hollandauthor=K.+Y.+Avenellauthor=T.+Steanauthor=N.+Uptonauthor=S.+Bromidgeauthor=I.+T.+Forbesauthor=A.+M.+Brownauthor=D.+N.+Middlemissauthor=T.+P.+Blackburn&title=SB+242084%2C+a+Selective+and+Brain+Penetrant+5-HT+2C+Receptor+Antagonist&doi=10.1016%2Fs0028-3908%2897%2900038-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist</span></div><div class="casAuthors">Kennett, G. A.; Wood, M. D.; Bright, F.; Trail, B.; Riley, G.; Holland, V.; Avenell, K. Y.; Stean, T.; Upton, N.; Bromidge, S.; Forbes, I. T.; Brown, A. M.; Middlemiss, D. N.; Blackburn, T. P.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4/5</span>),
    <span class="NLM_cas:pages">609-620</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">SB 242084 has a high affinity (pKi 9.0) for the cloned human 5-HT2C receptor and 100- and 158-fold selectivity over the closely related cloned human 5-HT2B and 5-HT2A subtypes, resp.  SB 242084 had over 100-fold selectivity over a range of other 5-HT, dopamine and adrenergic receptors.  In studies of 5-HT-stimulated phosphatidylinositol hydrolysis using SH-SY5Y cells stably expressing the cloned human 5-HT2C receptor, SB 242084 acted as an antagonist with a pKb of 9.3, which closely resembled its corresponding receptor binding affinity.  SB 242084 potently inhibited m-chlorophenylpiperazine (mCPP, 7 mg/kg i.p. 20 min pre-test)-induced hypolocomotion in rats, a model of in vivo central 5-HT2C receptor function, with an ID50 of 0.11 mg/kg i.p., and 2.0 mg/kg p.o.  SB 242084 (0.1-1 mg/kg i.p.) exhibited an anxiolytic-like profile in the rat social interaction test, increasing time spent in social interaction, but having no effect on locomotion.  SB 242084 (0.1-1 mg/kg i.p.) also markedly increased punished responding in a rat Geller-Seifter conflict test of anxiety, but had no consistent effect on unpunished responding.  A large acute dose of SB 242084 (30 mg/kg p.o.) had no effect on seizure susceptibility in the rat maximal electroshock seizure threshold test.  Also, while SB 242084 (2 and 6 mg/kg p.o. 1 h pre-test) antagonized the hypophagic response to mCPP, neither acute nor subchronic administration of the drug, for 5 days at 2 or 6 mg/kg p.o. twice daily, affected food intake or wt. gain.  The results suggest that SB 242084 is the first reported selective potent and brain penetrant 5-HT2C receptor antagonist and has anxiolytic-like activity, but does not possess either proconvulsant or hyperphagic properties which are characteristic of mutant mice lacking the 5-HT2C receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosMHDoDrRiabVg90H21EOLACvtfcHk0lhUhCfkV5S06Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlSmu7Y%253D&md5=75f9afeb2a2bb89e2303b64bbb0afbb5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2897%2900038-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252897%252900038-5%26sid%3Dliteratum%253Aachs%26aulast%3DKennett%26aufirst%3DG.%2BA.%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DBright%26aufirst%3DF.%26aulast%3DTrail%26aufirst%3DB.%26aulast%3DRiley%26aufirst%3DG.%26aulast%3DHolland%26aufirst%3DV.%26aulast%3DAvenell%26aufirst%3DK.%2BY.%26aulast%3DStean%26aufirst%3DT.%26aulast%3DUpton%26aufirst%3DN.%26aulast%3DBromidge%26aufirst%3DS.%26aulast%3DForbes%26aufirst%3DI.%2BT.%26aulast%3DBrown%26aufirst%3DA.%2BM.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26aulast%3DBlackburn%26aufirst%3DT.%2BP.%26atitle%3DSB%2520242084%252C%2520a%2520Selective%2520and%2520Brain%2520Penetrant%25205-HT%25202C%2520Receptor%2520Antagonist%26jtitle%3DNeuropharmacology%26date%3D1997%26volume%3D36%26spage%3D609%26epage%3D620%26doi%3D10.1016%2Fs0028-3908%2897%2900038-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fronik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaiser, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sejer
Pedersen, D.</span></span> <span> </span><span class="NLM_article-title">Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4126</span>â <span class="NLM_lpage">4134</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01601</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01601" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVyktbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4126-4134&author=P.+Fronikauthor=B.+I.+Gaiserauthor=D.+Sejer%0APedersen&title=Bitopic+Ligands+and+Metastable+Binding+Sites%3A+Opportunities+for+G+Protein-Coupled+Receptor+%28GPCR%29+Medicinal+Chemistry&doi=10.1021%2Facs.jmedchem.6b01601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry</span></div><div class="casAuthors">Fronik, Philipp; Gaiser, Birgit I.; Sejer Pedersen, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4126-4134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) belong to a large superfamily of membrane receptors mediating a variety of physiol. functions.  As such they are attractive targets for drug therapy.  However, it remains a challenge to develop subtype selective GPCR ligands, due to the high conservation of orthosteric binding sites.  Bitopic ligands have been employed to address the selectivity problem by combining (linking) an orthosteric ligand with an allosteric modulator, theor. leading to high-affinity subtype selective ligands.  However, it remains a challenge to identify suitable allosteric binding sites.  Computational studies on ligand binding to GPCRs have revealed transient, low-affinity binding sites, termed metastable binding sites.  Metastable binding sites may provide a new source of allosteric binding sites that could be exploited in the design of bitopic ligands.  Unlike the bitopic ligands that have been reported to date this type of bitopic ligands would be composed of two identical pharmacophores.  Herein, the authors outline the concept of bitopic ligands, review metastable binding sites and discuss their potential as a new source of allosteric binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpihAXt959S37Vg90H21EOLACvtfcHk0ljbBSRf8xz9_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVyktbw%253D&md5=a20875145b65a948c772e988ff1217bc</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01601%26sid%3Dliteratum%253Aachs%26aulast%3DFronik%26aufirst%3DP.%26aulast%3DGaiser%26aufirst%3DB.%2BI.%26aulast%3DSejer%2BPedersen%26aufirst%3DD.%26atitle%3DBitopic%2520Ligands%2520and%2520Metastable%2520Binding%2520Sites%253A%2520Opportunities%2520for%2520G%2520Protein-Coupled%2520Receptor%2520%2528GPCR%2529%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4126%26epage%3D4134%26doi%3D10.1021%2Facs.jmedchem.6b01601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaiser, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcher-RÃ¸rsted, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RÃ¸pke
JÃ¸rgensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WrÃ³bel, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frykman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BrÃ¤uner-Osborne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiesen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sejer Pedersen, D.</span></span> <span> </span><span class="NLM_article-title">Probing the Existence of a Metastable Binding Site at the Î²2-Adrenergic Receptor with Homobivalent Bitopic Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7806</span>â <span class="NLM_lpage">7839</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00595</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00595" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7806-7839&author=B.+I.+Gaiserauthor=M.+Danielsenauthor=E.+Marcher-R%C3%B8rstedauthor=K.+R%C3%B8pke%0AJ%C3%B8rgensenauthor=T.+M.+Wr%C3%B3belauthor=M.+Frykmanauthor=H.+Johanssonauthor=H.+Br%C3%A4uner-Osborneauthor=D.+E.+Gloriamauthor=J.+M.+Mathiesenauthor=D.+Sejer+Pedersen&title=Probing+the+Existence+of+a+Metastable+Binding+Site+at+the+%CE%B22-Adrenergic+Receptor+with+Homobivalent+Bitopic+Ligands&doi=10.1021%2Facs.jmedchem.9b00595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the Existence of a Metastable Binding Site at the Î²2-Adrenergic Receptor with Homobivalent Bitopic Ligands</span></div><div class="casAuthors">Gaiser, Birgit I.; Danielsen, Mia; Marcher-Roersted, Emil; Roepke Joergensen, Kira; Wrobel, Tomasz M.; Frykman, Mikael; Johansson, Henrik; Brauner-Osborne, Hans; Gloriam, David E.; Mathiesen, Jesper Mosolff; Sejer Pedersen, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7806-7839</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we report the development of bitopic ligands aimed at targeting the orthosteric binding site (OBS) and a metastable binding site (MBS) within the same receptor unit.  Previous mol. dynamics studies on ligand binding to the Î²2-adrenergic receptor (Î²2AR) suggested that ligands pause at transient, less-conserved MBSs.  We envisioned that MBSs can be regarded as allosteric binding sites and targeted by homobivalent bitopic ligands linking two identical pharmacophores.  Such ligands were designed based on docking of the antagonist (S)-alprenolol into the OBS and an MBS and synthesized.  Pharmacol. characterization revealed ligands with similar potency and affinity, slightly increased Î²2/Î²1AR-selectivity, and/or substantially slower Î²2AR off-rates compared to (S)-alprenolol.  Truncated bitopic ligands suggested the major contribution of the metastable pharmacophore to be a hydrophobic interaction with the Î²2AR, while the linkers alone decreased the potency of the orthosteric fragment.  Altogether, the study underlines the potential of targeting MBSs for improving the pharmacol. profiles of ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt_nqROQHIBrVg90H21EOLACvtfcHk0liiTnua2LD2FA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7%252FI&md5=411f11f6df72b940f3919b21510adf0b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00595%26sid%3Dliteratum%253Aachs%26aulast%3DGaiser%26aufirst%3DB.%2BI.%26aulast%3DDanielsen%26aufirst%3DM.%26aulast%3DMarcher-R%25C3%25B8rsted%26aufirst%3DE.%26aulast%3DR%25C3%25B8pke%2BJ%25C3%25B8rgensen%26aufirst%3DK.%26aulast%3DWr%25C3%25B3bel%26aufirst%3DT.%2BM.%26aulast%3DFrykman%26aufirst%3DM.%26aulast%3DJohansson%26aufirst%3DH.%26aulast%3DBr%25C3%25A4uner-Osborne%26aufirst%3DH.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26aulast%3DMathiesen%26aufirst%3DJ.%2BM.%26aulast%3DSejer%2BPedersen%26aufirst%3DD.%26atitle%3DProbing%2520the%2520Existence%2520of%2520a%2520Metastable%2520Binding%2520Site%2520at%2520the%2520%25CE%25B22-Adrenergic%2520Receptor%2520with%2520Homobivalent%2520Bitopic%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7806%26epage%3D7839%26doi%3D10.1021%2Facs.jmedchem.9b00595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlow, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhani, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Pathway and Mechanism of Drug Binding to G-Protein-Coupled Receptors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">13118</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1104614108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1073%2Fpnas.1104614108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=21778406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKit7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=13118&author=R.+O.+Drorauthor=A.+C.+Panauthor=D.+H.+Arlowauthor=D.+W.+Borhaniauthor=P.+Maragakisauthor=Y.+Shanauthor=H.+Xuauthor=D.+E.+Shaw&title=Pathway+and+Mechanism+of+Drug+Binding+to+G-Protein-Coupled+Receptors&doi=10.1073%2Fpnas.1104614108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pathway and mechanism of drug binding to G-protein-coupled receptors</span></div><div class="casAuthors">Dror, Ron O.; Pan, Albert C.; Arlow, Daniel H.; Borhani, David W.; Maragakis, Paul; Shan, Yibing; Xu, Huafeng; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">13118-13123, S13118/1-S13118/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">How drugs bind to their receptors-from initial assocn., through drug entry into the binding pocket, to adoption of the final bound conformation, or "pose"-has remained unknown, even for G-protein-coupled receptor modulators, which constitute 1/3 of all marketed drugs.  Here, the authors captured this pharmaceutically crit. process in at. detail using the 1st unbiased mol. dynamics simulations in which drug mols. spontaneously assoc. with G-protein-coupled receptors to achieve final poses matching those detd. crystallog.  The authors found that several beta blockers and a beta agonist all traversed the same well-defined, dominant pathway as they bound to the Î²1- and Î²2-adrenergic receptors, initially making contact with a vestibule on each receptor's extracellular surface.  Surprisingly, assocn. with this vestibule, at a distance of 15 Ã from the binding pocket, often presented the largest energetic barrier to binding, despite the fact that subsequent entry into the binding pocket required the receptor to deform and the drug to squeeze through a narrow passage.  The early barrier appeared to reflect the substantial dehydration that takes place as the drug assocs. with the vestibule.  The at.-level description of the binding process suggests opportunities for allosteric modulation and provides a structural foundation for future optimization of drug-receptor binding and unbinding rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKUYFtkTGwf7Vg90H21EOLACvtfcHk0ljEQebxQqXE8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKit7bE&md5=9cfa8673217931cacd586321309fa72e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104614108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104614108%26sid%3Dliteratum%253Aachs%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DPan%26aufirst%3DA.%2BC.%26aulast%3DArlow%26aufirst%3DD.%2BH.%26aulast%3DBorhani%26aufirst%3DD.%2BW.%26aulast%3DMaragakis%26aufirst%3DP.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DPathway%2520and%2520Mechanism%2520of%2520Drug%2520Binding%2520to%2520G-Protein-Coupled%2520Receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D13118%26doi%3D10.1073%2Fpnas.1104614108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Ding, C.</span>; <span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulators of 5-Hydroxytryptamine 2C Receptor (5-HT2CR)</span>. U.S. Patent <span class="NLM_patent">9,533,973 B2</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+Zhou&author=C.+Ding&author=K.+A.+Cunningham&title=Allosteric+Modulators+of+5-Hydroxytryptamine+2C+Receptor+%285-HT2CR%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520Modulators%2520of%25205-Hydroxytryptamine%25202C%2520Receptor%2520%25285-HT2CR%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filip, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span> <span> </span><span class="NLM_article-title">Contribution of Serotonin (5-HT) 5-HT2 Receptor Subtypes to the Discriminative Stimulus Effects of Cocaine in Rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">482</span>â <span class="NLM_lpage">489</span>, <span class="refDoi">Â DOI: 10.1007/s00213-005-0197-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=10.1007%2Fs00213-005-0197-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=16261316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Knt7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2006&pages=482-489&author=M.+Filipauthor=M.+J.+Bubarauthor=K.+A.+Cunningham&title=Contribution+of+Serotonin+%285-HT%29+5-HT2+Receptor+Subtypes+to+the+Discriminative+Stimulus+Effects+of+Cocaine+in+Rats&doi=10.1007%2Fs00213-005-0197-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats</span></div><div class="casAuthors">Filip, Malgorzata; Bubar, Marcy J.; Cunningham, Kathryn A.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">482-489</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">The serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor (5-HT2R) family is an important regulator of the behavioral responsiveness to cocaine.  The present study is an anal. of the role of the 5-HT2R subtypes (5-HT2AR, 5-HT2BR, and 5-HT2CR) in the discriminative stimulus effects of cocaine.  Male Wistar rats were trained to discriminate cocaine (10 mg/kg) from saline in a 2-lever, water-reinforced FR 20 task, and the authors investigated the ability of the 5-HT2AR antagonist 1(Z)-[2-(dimethylamino)ethoxyimino]-1(2-fluorophenyl)-3-(4-hydroxyphenyl)-2(E)-propene (SR 46349B), the 5-HT2BR antagonist N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl) urea (SB 204741), and the 5-HT2CR antagonist [(+)-cis-4,5,7a,8,9,10,11,11a-octahydro-7H-10-methylindolo(1,7-bC)(2,6)naphthyridine] (SDZ SER-082) to substitute for or to modulate the stimulus effects of cocaine.  Pretreatment with SR 46349B (0.5-1 mg/kg) resulted in a rightward shift of the cocaine dose-response curve, while SDZ SER-082 (1 mg/kg) shifted the dose-response for cocaine to the left; SB 204741 (1-3 mg/kg) was inactive.  Our pharmacol. analyses of selective antagonists of 5-HT2AR, 5-HT2BR, and 5-HT2CR indicate oppositional influence of 5-HT2AR and 5-HT2CR on the stimulus effects of cocaine and exclude a role for the 5-HT2BR.  These data suggest that 5-HT2AR and 5-HT2CR may be important in modulating the subjective effects of cocaine in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYQE4xqM8ubVg90H21EOLACvtfcHk0ljuGS17Z4nexA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Knt7vE&md5=1371e379951f683e82ed8bbd31ef7a4b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs00213-005-0197-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-005-0197-y%26sid%3Dliteratum%253Aachs%26aulast%3DFilip%26aufirst%3DM.%26aulast%3DBubar%26aufirst%3DM.%2BJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26atitle%3DContribution%2520of%2520Serotonin%2520%25285-HT%2529%25205-HT2%2520Receptor%2520Subtypes%2520to%2520the%2520Discriminative%2520Stimulus%2520Effects%2520of%2520Cocaine%2520in%2520Rats%26jtitle%3DPsychopharmacology%26date%3D2006%26volume%3D183%26spage%3D482%26epage%3D489%26doi%3D10.1007%2Fs00213-005-0197-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG','PDB','6BQG'); return false;">PDB: 6BQG</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i49"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01953">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_17807"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01953?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01953</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Calculated physicochemical properties, radioligand binding data, cytotoxicity data, additional cellular assay data, docking protocol, and <sup>1</sup>H and <sup>13</sup>C NMR spectra for the compounds described in this paper (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Atomic coordinates of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6BQG">6BQG</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings of PAM2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_001.pdf">jm9b01953_si_001.pdf (3.82 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_002.pdb">jm9b01953_si_002.pdb (283.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01953/suppl_file/jm9b01953_si_003.csv">jm9b01953_si_003.csv (2.42 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01953&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-14%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01953%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01953" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679946557ea01243","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
